University of Wollongong

Research Online
University of Wollongong Thesis Collection
1954-2016

University of Wollongong Thesis Collections

2016

The interaction of small heat shock molecular chaperone proteins with asynuclein
Dezerae Cox
University of Wollongong
Follow this and additional works at: https://ro.uow.edu.au/theses
University of Wollongong
Copyright Warning
You may print or download ONE copy of this document for the purpose of your own research or study. The University
does not authorise you to copy, communicate or otherwise make available electronically to any other person any
copyright material contained on this site.
You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act
1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised,
without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe
their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court
may impose penalties and award damages in relation to offences and infringements relating to copyright material.
Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the
conversion of material into digital or electronic form.
Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily
represent the views of the University of Wollongong.

Recommended Citation
Cox, Dezerae, The interaction of small heat shock molecular chaperone proteins with a-synuclein, Doctor
of Philosophy thesis, School of Biological Sciences, University of Wollongong, 2016.
https://ro.uow.edu.au/theses/4823

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

The interaction of small heat shock
molecular chaperone proteins with
α-synuclein

Dezerae Cox

A thesis submitted in fulfilment of the requirements for the award of the degree
Doctor of Philosophy

from

Illawarra Health and Medical Research Institute
School of Biological Sciences, University of Wollongong

September, 2016

DECLARATION
This thesis is submitted in accordance with the University of Wollongong guidelines in
fulfilment of the requirements for the award of Doctor of Philosophy. This thesis does not
contain material that has been previously published by another person except where
referenced or acknowledged, and has not been submitted for the award of any degree at any
other academic institution.
______________
Dezerae M. Cox
September, 2016

ii

ACKNOWLEDGEMENTS
First and foremost, I would like to thank my supervisor, Associate Professor Heath Ecroyd,
for his unwavering encouragement, guidance and support. I could not have asked for a more
patient, caring and accommodating mentor. Your infectious enthusiasm and passion have
been a constant source of inspiration and motivation, and without you none of this work
would have been possible. I feel deeply privileged to have worked for, and alongside, you,
and I cannot express how grateful I am for the opportunities you have afforded me
throughout my time at UOW.
Thank you to the Ecroyd lab, in all its various incarnations, but especially Tracey, Megan, BJ,
Amelia, Bec, Anthea, Caitlin, Shannon and Nick. Thank you for being my daily dose of
realism, for celebrating the science wins and commiserating the many, many days in between,
and, of course, for always having cake spoons at the ready. You are some of the funniest,
most intelligent and most helpful people I have met. My time at IHMRI would not have been
the same without you.
Thanks also to Professor David Klenerman FRS, for welcoming me into your lab. My visiting
studentship at the University of Cambridge was a truly life-altering experience. To the
Klenerfolk, especially Mathew, Laura, Nadia, Fran, Chris, Rebecca and Joe, thank you for
your patience and unwavering support. Your willingness to impart advice and expertise
assisted my research and broadened my understanding of what is achievable with scientific
research. To my partner-in-crime, Daniel, thank you for all your patience, ideas and
encouragement, and for being my home-away-from-home. Thanks to you, I experienced the
best of what Cambridge has to offer, and it was truly unforgettable.
To those who began this journey with me, you have made this experience unlike any other. I
hope that the friendships forged will endure across the globe for many years to come.
Finally, to my family and friends. Thank you for reminding me that there is a big wide world
out there, and that it is our responsibility to make the most of what life has to offer. Although
most of you still wonder exactly what I do at University, your belief in me has made this
possible. The last four years have been some of the most challenging, frustrating and
exhausting in memory, however they have also been the most wholly rewarding of my life.
Thank you for giving me the strength and freedom to accomplish anything.

iii

ABSTRACT
Protein homeostasis, or proteostasis, is the process of maintaining the conformational and
functional integrity of the proteome. Proteostasis is preserved in the face of stress by a
complex network of cellular machinery which acts to maintain proteins in their native state,
enabling them to perform their biological function. Failure of the proteostasis network can
result in the accumulation of non-native (misfolded) proteins, leading to their aggregation and
deposition. For example, the amyloid fibrillar aggregation of the protein α-synuclein (α-syn)
into Lewy bodies and Lewy neurites is associated with neurodegenerative diseases, classified
as α-synucleinopathies, which include Parkinson's disease and dementia with Lewy bodies.
The small heat shock proteins (sHsps) are a family of molecular chaperones that are one of
the cell's first lines of defence against protein aggregation. They act to stabilise partiallyfolded protein intermediates, in an ATP-independent manner, to maintain cellular proteostasis
under stress conditions. Thus, the sHsps are ideally suited to protect against α-syn
aggregation, however, they fail to do so in the context of the α-synucleinopathies. Therefore,
this project aimed to characterise the ability of the canonical sHsps, αB-crystallin (αB-c) and
Hsp27, to prevent α-syn aggregation, both in vitro and in a neuronal cell model.
Experiments investigating the mechanism of interaction between the sHsps and monomeric,
aggregation-prone α-syn are described in Chapter 3. Analytical size exclusion
chromatography and ultracentrifugation were used to demonstrate that the interaction
between αB-c or Hsp27 and monomeric α-syn is transient, yet sufficient to prevent α-syn
aggregation. This work also sought to address potential mechanisms by which aggregating αsyn may evade sHsp chaperone action. By using two methods (monomeric concentration and
disease-related mutations) to alter the kinetics of α-syn aggregation, it was demonstrated that
the rate of aggregation (and in particular the length of the lag phase) had a significant effect

iv

on the chaperone efficacy of αB-c and Hsp27. The more rapid the rate of α-syn aggregation,
the less effective these sHsps were in terms of their ability to prevent aggregation.
Given the ability of αB-c to bind mature α-syn fibrils, the interaction of the sHsps with other
α-syn aggregation intermediates was also examined. Single molecule techniques were
employed in Chapter 4 to study the interaction between Hsp27 and oligomeric α-syn species
formed early during its aggregation. It was found that Hsp27 inhibits the growth and
structural conversion of α-syn oligomers into amyloid fibrils. In addition, Hsp27 binds to
mature α-syn fibrils with micromolar affinity. Using super resolution microscopy, the
interaction of Hsp27 with α-syn fibrils was found to reduce the surface hydrophobicity of the
fibrils. Furthermore, by measuring the production of reactive oxygen species generated by a
murine neuronal cell line (Neuro-2a) in response to fibrillar α-syn, this work shows that by
binding to α-syn fibrils, both αB-c and Hsp27 inhibit fibril-associated toxicity. Taken
together, these data suggest that binding to fibrils is a generic property of sHsps and, by doing
so, the sHsps prevent the toxicity associated with amyloid aggregates.
Finally, the ability of the sHsps, αB-c and Hsp27, to prevent α-syn aggregation in cells was
examined. As part of the work presented in Chapter 5, a robust cellular model of α-syn
aggregation was established using Neuro-2a cells. Overexpression of αB-c and Hsp27 was
shown to significantly reduce the formation of intracellular α-syn inclusions in this model.
This suggests that over-expressing or boosting the activity of sHsps may be a valid way to
prevent amyloid fibrillar aggregation of α-syn in cells. In contrast, the sHsps were ineffective
at preventing the accumulation of another disease-associated amyloidogenic protein,
huntingtin, highlighting the substrate specificity of the sHsp-target protein interaction.
The work presented in this thesis highlights the multi-faceted nature of the chaperone
mechanisms used by sHsps to prevent protein aggregation. It also reveals, for the first time, a
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specific factor (i.e. the rate of aggregation) which may contribute to the failure of the sHsps
to prevent α-syn aggregation in the context of the α-synucleinopathies. Elucidating the
mechanistic details of interactions between the sHsps and disease-relevant proteins such as αsyn provides essential insight into sHsp chaperone action. Future work establishing the
physiological relevance of these interactions in the cellular environment, and in the context of
the α-synucleinopathies, will be crucial in pursuing potential avenues for therapeutic
intervention that target the sHsp molecular chaperones.
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Chapter 1:
Introduction

Portions of this chapter have been previously published in the following work:
Cox, D., J. A. Carver and H. Ecroyd (2014). "Preventing α-synuclein aggregation: The role of
the small heat shock molecular chaperone proteins." Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease 1842(9): 1830-1843.
Author Contributions: DC wrote the manuscript, composed the figures and generated the
table; HE and JAC edited the manuscript for submission.
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Chapter 1: Introduction
1.1 Proteostasis
Proteostasis, or the maintenance of protein homeostasis, operates both inside and outside the
cell (for recent comprehensive reviews see Gidalevitz et al. (2011) and Wyatt et al. (2013))
and is dependent on numerous integrated pathways that control the lifecycle and fate of a
protein (Figure 1.1). These pathways include those involved in gene transcription, mRNA
translation and protein synthesis on the ribosome, through to protein folding, trafficking and
compartmentalisation in cellular organelles, and finally to protein degradation by autophagy
or the proteasome (Yerbury et al. 2005). As such, the macromolecular elements comprising
the cellular proteostasis network include transcription factors, RNA processing and
translocation factors, folding enzymes, trafficking components, molecular chaperones and
degradation components. The capacity to maintain proteostasis varies between cell types
(Chen and Brown 2007), and is thought to be reflective of the composition and concentration
of components of the proteostasis network that arise as a result of differences during cellular
differentiation and development (Powers et al. 2009). Whilst this capacity is finite at any
point in time, it can be spatially and temporally altered through varying the amount and/or
activity of individual components. Thus, an appropriate analogy for proteostasis is a see-saw;
there is an intricate balance required in the use of energy and resources to maintain the
functional integrity of the proteome and thus avoid protein aggregation and disease.
1.1.1 Protein folding
The biological function of most proteins is inextricably linked to them obtaining the correct
(native) conformation. Whilst some proteins are intrinsically disordered, remaining unfolded
throughout their life span or acquiring structure upon binding to other proteins (Wright and
Dyson 1999, Dunker et al. 2001, Uversky 2002), most exhibit defined secondary and tertiary
structures which require ‘folding’ of the polypeptide chain. Protein folding is defined as the
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Figure 1.1: Cellular proteostasis mechanisms. In the endoplasmic reticulum (ER), molecular
chaperones assist newly synthesised protein intermediates to fold into their native conformation for
transport into the cytosol. Persistent or misfolded protein intermediates can be proteolytically
degraded within the ER or transported to the cytosol. Once in the cytosol, protein intermediates are
recognised by molecular chaperones and targeted for refolding or degradation via lysosomal or
proteasomal pathways. When these mechanisms fail to clear protein intermediates, insoluble
aggregates can accumulate within the ER or cytosol as aggresomes. Adapted from Yerbury et al.
(2005).

process by which the three-dimensional conformation of a functional protein results from the
linear sequence of information contained in the amino acid chain (Anfinsen et al. 1961, Hartl
1996). In a cellular context, folding may be co-translational (i.e. initiated during completion
of protein synthesis whilst the nascent chain is still associated with the ribosome) or occur
post-translationally, either in the cytoplasm or in specific compartments, such as the
endoplasmic reticulum (ER), following trafficking and translocation through membranes
(Dobson 2003). Unfolding is also important in the life cycle of many proteins; it is required
in various biological processes including protein trafficking, secretion and translocation
across membranes, as well as regulation of the cell cycle (Radford and Dobson 1999). In all
cases, attaining the correct native state, whether folded or disordered, is essential for protein
function and often relies on the presence of molecular chaperones.
3
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Folding reactions are highly complex given the sheer number of potential conformations
available to a protein chain following synthesis. The current model posits a funnel-shaped
energy landscape in which polypeptide chains explore a range of energy states whilst
progressing along downhill routes in search of the native structure (Figure 1.2). Soluble
proteins rely on hydrophobic forces, which encourage chain collapse thereby facilitating
burial of non-polar residues (Hartl et al. 2011). The potential conformations populating the
folding landscape are rapidly restricted by this chain collapse, and an increasing number of
native interactions. However, there are often substantial energetic barriers that must be
overcome in the search toward a native conformation, resulting in partially-folded
intermediate states which can become kinetically trapped (Figure 1.2). An important function
of molecular chaperones in the folding process is assisting a protein to overcome these
energetic barriers and preventing non-native, but energetically favourable, interactions. In
particular, for larger proteins, hydrophobic collapse often results in the formation of
kinetically trapped, partially-folded intermediates which may be stabilised by non-native
interactions (Hartl et al. 2011). In this case, these conformations are now considered
‘misfolded’.
1.1.2 Protein misfolding and aggregation
The persistence of partially-folded or misfolded protein states becomes problematic in the
cellular context, as they expose hydrophobic and unstructured regions which would otherwise
be buried in the native conformation (Dobson 2001, Hartl et al. 2011). These features often
lead to the association of non-native proteins, resulting in them leaving the ‘on-folding’
pathway and entering ‘off-folding’ pathways, eventually leading to amorphous (disordered)
or amyloid fibrillar (ordered) aggregates (Figure 1.2). These aggregated protein forms are
generally defined by the presence of non-native secondary structures which are stable under
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Figure 1.2: Schematic representation of the funnel-shaped energy landscape explored by
proteins during folding and aggregation. Unfolded proteins on the folding pathway (green) move
toward their native state, by exploring intermediate conformations; however, the energy contours of
this landscape result in kinetically trapped, partially-folded intermediates. These conformations are
able to traverse energy barriers, with the assistance of chaperones, in order to attain the native state.
Alternatively, proteins unable to transition to the native state, either during de novo synthesis or as a
result of unfolding, enter off-folding pathways (red) and are prone to aggregation. Proteins may then
form amorphous or fibrillar aggregates. Chaperones are also crucial in preventing the formation of
these non-native, but energetically favourable, interactions. Adapted from Hartl et al. (2011).

physiological conditions, have poor solubility and aberrant subcellular or extracellular
localisation (Kopito 2000). The propensity of any given protein to aggregate is a function of
its chemical properties, governed by the amino acid sequence, the conformational stability of
its folded states, and its relative cellular concentration (Hipp et al. 2014). For example,
although some proteins are expressed at levels exceeding their solubility (referred to as
supersaturated), they may not be at risk of becoming insoluble unless their intrinsic
aggregation propensity is high (Ciryam et al. 2015). In addition, the total cellular
concentration of proteins is commonly in excess of 300 g/L, resulting in macromolecular
crowding, and this significantly increases the propensity of non-native proteins to aggregate
(Hipp et al. 2014).
Whether a protein undergoes amorphous or fibrillar aggregation is similarly governed by the
structure and stability of the precursor partially-folded intermediate. Native-like folding
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intermediates that have a relatively high degree of exposed hydrophobicity, while retaining
elements of secondary structure, are observed to preferentially lead to the rapid formation of
amorphous aggregates (Khurana et al. 2001). Conversely, intermediates which are relatively
unfolded, display little secondary structure and have a relatively low degree of exposed
hydrophobicity, commonly form fibrils via ordered self-assembly (Khurana et al. 2001).
Importantly, the formation of fibrillar aggregates is characterised by the initial formation of
soluble, oligomeric species which must undergo rearrangement to form amyloid fibrils. In
this way, oligomeric states may be comparable to kinetically trapped monomeric
intermediates, as their conversion to fibrils requires overcoming energetic barriers, making
this a key process for chaperones in order to prevent protein aggregation and deposition
(Figure 1.2).
1.1.3 In vitro versus in vivo: considering the cellular context
Many studies examine protein aggregation in isolation, often using reactions containing only
the protein(s) of interest (an aggregation-prone target protein) and inducers or inhibitors of
aggregation. These experiments provide useful mechanistic details of a protein’s aggregation
pathway, allowing researchers to consider the evolution of aggregating species and their
relationship with a range of aggregation modulators. These approaches have allowed the
characterisation of amyloid as a generic conformation accessible by most, if not all, proteins
(Chiti and Dobson 2006). It is now routine to investigate the kinetics of amyloid formation
using amyloidophillic dyes such as Thioflavin-T (ThT) or Congo red, characterise aggregate
morphology via Transmission Electron Microscopy (TEM) or Atomic Force Microscopy
(AFM), determine the secondary structure of aggregates using Circular Dichroism (CD) and
Fourier-transform infrared (FTIR) spectroscopy, and identify the protease-resistant core via
limited protease digestion (Gregoire and Kwon 2012). In addition, the advent of confocal and
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total internal reflection fluorescence (TIRF) microscopy-based single-molecule techniques,
such as single molecule Förster Resonance Energy Transfer (smFRET), two-colour
coincidence detection (TCCD), Stochastic Optical Reconstruction Microscopy (STORM),
single aggregate visualisation by enhancement (SAVE) and spectrally-resolved Point
Accumulation for Imaging in Nanoscale Topography (sPAINT), now enable examination of
rare species present during aggregation that are otherwise undetectable using traditional
‘bulk’ methods. These techniques can therefore provide both qualitative and quantitative
information regarding the formation of oligomers and fibrils, their surface properties and
potential interactions with other proteins of interest.
By combining each of the techniques discussed above, it is possible to build a comprehensive
understanding of the aggregation of a given protein, including pathway intermediates,
morphology, structure and kinetics. However, these studies fail to replicate the complex
factors present in the intra- or extracellular environments in which aggregation takes place.
As such, extending the characterisation of aggregating proteins from the ‘test tube’ to the
cellular context is crucial. Studying protein aggregation in situ helps develop our
understanding of the interplay between intracellular components, such as chaperones and
proteases, and processes including protein expression, deposition and degradation, in the
crowded cellular environment (Ami et al. 2013).
The aggregation of intracellular proteins is most commonly monitored in situ using
fluorescence techniques. Methods of covalently attaching fluorescent molecules through
genetically encoding specific tag sequences at the N- or C-terminals of the protein of interest
form the basis of many cellular aggregation studies (Crivat and Taraska 2012). Tracking
cellular proteins was initially made routine through the in-frame genetic fusion of inherently
fluorescent proteins such as green fluorescent protein (GFP), enhancedGFP (EGFP), yellow
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fluorescent protein (YFP) or red fluorescent protein (RFP), to the protein of interest (Crivat
and Taraska 2012). Extensive customisation of these fluorescent proteins has resulted in a
suite of potential protein tags, covering a range of excitation and emission wavelengths,
brightnesses, pH sensitivities and photophysical properties (Day and Davidson 2009).
Fluorescently tagged proteins are especially useful when characterising the real-time
distribution, trafficking and aggregation of proteins within a cell. Alternatively, cellular
proteins may be detected via immunohistochemistry, in which antibodies specific for the
protein and conformation of interest are introduced to the cell following fixation and
permeabilisation of the cell membrane. Together, these techniques enable protein
aggregation, and factors that regulate this process, to be studied and measured in cells.
1.1.4 The role of molecular chaperones
Molecular chaperones protect and stabilise non-native regions of proteins, or assist in
proteins acquiring their native state, without contributing conformational information or
forming part of the final native structure (Hartl 1996, Hartl et al. 2011). Chaperones achieve
this by interacting with (and stabilizing) partially-folded protein intermediates in order to
prevent improper associations that could otherwise lead to misfolding and aggregation (Ellis
1997). In addition, chaperones can also facilitate the folding of multi-domain proteins,
through transient sequestration of the folding intermediates (Powers et al. 2009).
Due to their role in assisting proteins to acquire and maintain their native conformation,
molecular chaperones are key components of the proteostasis network. They participate in
protein folding, complex assembly, protein trafficking, protein stabilisation and protein
degradation. As their name implies, the class of molecular chaperones referred to as heat
shock proteins (Hsps) are most commonly expressed as part of the cellular response to stress,
although some members are constitutively expressed and play important roles under non-
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stress conditions (Feder and Hofmann 1999). The Hsps have been classified into families
based on the mass of their monomeric subunits; these include Hsp100, Hsp90, Hsp70, Hsp60
and the small Heat shock proteins (sHsps; HSPB) (Sarkar et al. 2011). In addition,
chaperones have also been classified as having either a ‘foldase’ or ‘holdase’ type action. For
example, Hsp70 and Hsp60 are classified as ‘foldase’ type chaperones as they actively
facilitate the folding of protein intermediates to their native folded state, often acting in
tandem. Their mechanism of action is dependent on ATP hydrolysis, which results in cycles
of high- to low-affinity target protein binding, to promote folding of the target protein
(Beissinger and Buchner 1998, Hoffmann et al. 2004). Foldase chaperones also encompass
the so-called ‘unfoldase’ action attributed to some chaperones, including Hsp100 and Hsp70,
in which ATP hydrolysis is used to unfold or disaggregate misfolded or aggregated proteins
to provide folding-competent intermediates (Hubbard and Sander 1991, Slepenkov and Witt
2002). In contrast, ‘holdase’ chaperones, which includes the sHsps, interact with partiallyfolded intermediate states of proteins to stabilise them and prevent their mutual association.
The mechanism of action of holdase chaperones is ATP-independent since they do not have
an active role in folding proteins; their association with target proteins is driven primarily
through hydrophobic interactions. This enables holdases to function in the ATP-depleted
environment that occurs in the cell when it is under stress, ensuring their function is not
compromised at the time cell viability is threatened. When energy levels permit, holdase
chaperones can deliver target proteins to foldases for refolding, or to the proteasome or
autophagy for degradation (Beissinger and Buchner 1998, Hoffmann et al. 2004, Rikhvanov
et al. 2007).
When a protein can no longer maintain its correct conformation, the cell utilises degradation
pathways such as the ubiquitin-proteasome machinery and autophagic-lysosomal trafficking
systems to remove it. Misfolded proteins are recognised by the ubiquitin-proteasome system,
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which labels and degrades them through a highly regulated pathway. Using a series of
ubiquitin ligase enzymes, ubiquitin polypeptide chains are covalently linked to misfolded
proteins, marking them as substrates for selective degradation within the proteasome
(Schwartz and Ciechanover 1999, Cook et al. 2012). Lysosomal mechanisms, such as
macroautophagy and microautophagy, are less selective; membrane-bound vesicles capture a
selection of the cytosol, which is then targeted for degradation. By contrast, chaperonemediated autophagy provides a level of targeted degradation as it relies on the recognition of
a target motif in cytosolic proteins by specific chaperones, which then deliver the proteins to
the membrane of the lysosome for internalisation and degradation (Kaushik and Cuervo
2012). The sHsps may play a role in all of these degradation pathways; for instance, αBcrystallin (αB-c; HSPB5) stimulates ubiquitination of insoluble proteins which marks them
for ubiquitin-dependent degradation (Engelsman et al. 2003), Hsp22 (HSPB8) in cooperation
with Bag3, promotes degradation of mutant Huntingtin (Htt) protein through induction of
macroautophagy (Carra et al. 2008) and Hsp27 (HSPB1) targets misfolded cystic fibrosis
transmembrane conductance regulator protein for degradation in the proteasome (Ahner et al.
2013). Whether these activities are specific to individual sHsps or represent more generic
mechanisms of action of sHsp family members is yet to be determined, however it is clear
from this work that as a chaperone class, sHsps function not only to maintain proteins in their
biologically active conformation, but also to facilitate their degradation when misfolded
(Parcellier et al. 2003).
1.2 Proteostasis and disease
A number of factors can influence the ability of a cell, tissue or organism to maintain
proteostasis. Changes in cellular ATP levels, amino acid pools, metabolites, lipid homeostasis
and ion balance can all disrupt the protein folding and degradation capabilities of the cell
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(Powers et al. 2009). Signalling pathways can be exploited to control transcriptional,
translational and post-translational mechanisms in the cell in order to regulate protein
synthesis, folding, trafficking and degradation (Powers et al. 2009). However, disruption of
any element within this integrated network can result in proteostasis dysfunction. Aberrant
protein folding and protein aggregation are now recognised as key factors in many diseases,
collectively termed protein misfolding or conformational diseases (Chiti and Dobson 2006).
These diseases, which include type II diabetes, cataract, and neurological disorders such as
Alzheimer’s disease and Parkinson’s disease (PD) (Barral et al. 2004), are associated with the
aggregation and precipitation of misfolded protein into either amorphous or fibrillar
aggregates. Those associated with amyloid aggregation represent the largest group of
misfolding disorders (Chiti and Dobson 2006). Their prevalence, and the prediction that this
will increase dramatically over the next decade as a consequence of the ageing population in
many countries (de Lau and Breteler 2006), underlies the importance of understanding the
network of pathways that maintain proteostasis.
1.2.1 The α-synucleinopathies: a collection of aggregation disorders
Despite the common pathway of pathogenic protein aggregation and deposition which leads
to disease, in many cases the underlying proteins associated with individual disorders are
unique (Chiti and Dobson 2006). In some circumstances, however, several disorders may be
linked by the aggregation of a single protein. The α-synucleinopathies are a group of
neurodegenerative diseases characterised by the amyloid fibrillar aggregation and
intracellular deposition of α-synuclein (α-syn) (Martí et al. 2003). Deposition of α-syn occurs
in selected populations of neurons or glia, and may be localised to the cytoplasm or neurite
processes, giving rise to clinically distinct disorders with a common underlying pathology
(Goedert 2001). These diseases include multiple system atrophy, dementia with Lewy bodies
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and PD (Hashimoto and Masliah 1999, Spillantini and Goedert 2000, Campbell et al. 2001,
Goedert 2001, Pountney et al. 2005).
The most well recognised α-synucleinopathy is PD. It is the second most prevalent
neurological disorder, after Alzheimer’s disease, with its world-wide incidence projected to
reach at least 8.7 million individuals over 50 years of age by 2030 (de Lau and Breteler 2006,
Dorsey et al. 2007, Massano and Bhatia 2012). Typically, PD is characterised by motor
manifestations including tremor, rigidity, bradykinesia and postural instability, which can
also be accompanied by non-motor symptoms such as sleep impairment, neuropsychiatric
disorders and olfactory deficits (Braak et al. 2004, Chaudhuri et al. 2006). All of these
symptoms are linked to a gradual reduction in dopamine content associated with the
progressive loss of dopaminergic neurons in the substantia nigra pars compacta, a region
located in the midbrain.
The histological hallmark of PD is the presence of protein inclusions, known as Lewy bodies
or Lewy neurites, localised to the cell body or cell processes, respectively (Wakabayashi et
al. 2007). These distinctive spherical protein inclusions, of which the principal protein is αsyn (Spillantini et al. 1997), are found in the cytoplasm of nigral neurons and are
characterised by a dense protein core surrounded by a halo of fibrils and auxiliary proteins
(Fink 2006).
1.2.2 α-Syn in disease
α-Syn, a 140 amino acid protein, was initially identified as a neuron-specific protein localised
within the nucleus and presynaptic terminals (Maroteaux et al. 1988). From a functional
perspective, there is still no definitive evidence for the role α-syn plays in cells. It has been
implicated in modulating synaptic activity through membrane processes, including
neurotransmitter release, trafficking and biogenesis (Davidson et al. 1998, Jenco et al. 1998).
12
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In addition to the full-length form of the protein, there are two shorter isoforms, which are
126 and 112 amino acids in length, and result from in-frame deletions of exon 3 and 5,
respectively (Ueda et al. 1994, Campion et al. 1995). However, the full length isoform is by
far the most abundant in the brain (Ueda et al. 1994, Campion et al. 1995, Halliday and
McCann 2008). Truncated versions, derived from proteolytic cleavage, have been identified
as significant components of Lewy body inclusions (Baba et al. 1998, Campbell et al. 2001,
Halliday and McCann 2008). Truncation fragments of α-syn also have a higher aggregation
propensity than the full length form, both in vitro and in vivo (Crowther et al. 1998, Tofaris et
al. 2003, Tofaris et al. 2006, Bellucci et al. 2011).
As well as the association of α-syn with Lewy body pathology, there is a strong genetic
association of α-syn with PD (Polymeropoulos et al. 1997) which has further piqued interest
into the role of this protein in disease. Parkinson’s disease may be either early onset (before
40 years of age) or late onset (after 40 years of age). Although most commonly presenting as
a late onset, sporadic disease of unknown aetiology, a familial form with an autosomal
dominant pattern of inheritance among early onset patients was initially identified in two
small kindreds (Golbe 1990, Golbe et al. 1990). This led to the identification of missense
mutations in the α-syn gene which correlate to early-onset and aggressive PD: A53T, A30P,
G51D, H50Q and E46K (Polymeropoulos et al. 1997, Kruger et al. 1998, Zarranz et al. 2004,
Kiely et al. 2013, Proukakis et al. 2013). Multiplication of the α-syn gene has also been
associated with the development of α-syn inclusions and PD (Baba et al. 1998, Campbell et
al. 2001). Gene copy number is strongly correlated with the age of disease onset; duplication
results in an average age of onset of 48.4 years while triplication results in an average age of
onset of 33.4 years (Farrer 2006).
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1.2.3 Aggregation of α-syn
Due to the presence of large amounts of aggregated α-syn in Lewy bodies and Lewy neurites,
and the correlation between α-syn genetic abnormalities and early onset PD, the mechanism
and kinetics by which α-syn aggregates to form amyloid fibrils in vitro have been examined
in detail (Figure 1.3). It has been generally accepted that α-syn exists as an unstructured
monomeric protein in its native state in solution. However, when the N-terminus of
monomeric α-syn interacts with lipids it attains an α-helical structure and recent evidence has
suggested it may form a tetramer in some cell types (Eliezer et al. 2001, Bartels et al. 2011,
Wang et al. 2011, Fauvet et al. 2012, Dettmer et al. 2013). Within inclusions, α-syn is
assembled into highly-ordered, β-sheet rich amyloid fibrils (Polymeropoulos et al. 1997).
Similarly, under conditions of physiological pH and temperature in vitro, purified α-syn
assembles into fibrils resembling those found in diseased brains (Rochet et al. 2000, Serpell
et al. 2000, Uversky 2007). Amyloid fibril formation occurs via a nucleation-dependent
mechanism in which the formation of oligomeric nuclei is the rate-limiting step, followed by
rapid elongation and assembly into mature fibrils (Wood et al. 1999, Bhak et al. 2009, Li et
al. 2009). All three α-syn mutations associated with PD have been found to influence the
early stages of aggregation, either nuclei formation or fibril growth, when their aggregation
propensities have been assessed in vitro (Ono et al. 2011). Each α-syn mutant exhibits
distinct fibrillation kinetics and/or aggregate morphologies: α-syn A53T and E46K form
fibrils more rapidly than the wild-type (WT) protein, and α-synA30P forms mature fibrils
more slowly, although smaller oligomeric species are formed more rapidly by this mutant
(Conway et al. 1998, Conway et al. 2000, Bruinsma et al. 2011). The difference in fibrillation
kinetics is generally attributed to variations in the rate of nucleation, as opposed to the rate of
elongation (Conway et al. 2000, Conway et al. 2000). As with gene multiplication, the
aggregation propensity of each α-syn variant correlates well with disease onset and the
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severity of familial PD, with the A53T variant aggregating the fastest and being associated
with the earliest and most aggressive disease phenotype (Sellbach et al. 2006).
In addition to the inherent aggregation propensity of α-syn, a number of factors have been
shown to influence the rate at which the protein forms fibrils. For example, aggregation is
promoted by the presence of metals, pesticides, lipids, membranes, and under conditions of
low pH or molecular crowding (Shtilerman et al. 2002, Uversky et al. 2002, Munishkina et al.
2004). In general, these factors increase the concentration of the prefibrillar intermediates
crucial for the formation of nuclei during the rate-limiting step (Shtilerman et al. 2002,
Uversky et al. 2002, Munishkina et al. 2004, Fink 2006). Conversely, aggregation is hindered
by the presence of β- and -synucleins (Hashimoto et al. 2001, Uversky et al. 2002), as well
as molecular chaperones such as sHsps (Bruinsma et al. 2011, Breydo et al. 2012). Changes
in the rate at which aggregation occurs (e.g. through the influence of the above mentioned
factors), may therefore contribute to the failure of proteostasis elements to prevent α-syn
aggregation in a disease context.

Figure 1.3: Amyloid fibrillar aggregation of α-syn. Unfolded α-syn exists as a monomer that can
interact with lipids, to form an α-helical structure (Eliezer et al. 2001). There is some evidence that a
tetrameric α-helical form of α-syn also exists in cells (Dettmer et al. 2013) and monomeric unfolded
forms of α-syn may be in equilibrium with this tetramer. Unfolded α-syn aggregates through a
nucleation-dependent mechanism, in which aggregation-prone α-syn monomers associate to form
soluble prefibrillar oligomeric nuclei. This is followed by the elongation of these nuclei into mature
amyloid fibrils. Fibrillar aggregates may then be sequestered into Lewy bodies or Lewy neurites.
Alternatively, fragmentation of mature fibrils can generate additional oligomeric nuclei which seed
secondary aggregation events.
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1.2.4 α-Syn pathogenicity
Although the exact physiological function of α-syn is yet to be defined, based on knowledge
of its broad physiological role of modulating synaptic activity, some features of PD may be
ascribed to a toxic loss of function encountered when α-syn in the cell is sequestered and
deposited following aggregation. The reduced availability of α-syn would impact on its
ability to interact with cellular membranes (Rajagopalan and Andersen 2001). Failure of αsyn to complete its physiological role within the cell could potentially cause neuronal
damage, particularly in the synaptic terminal (Stefanis 2012). However, it is considered
unlikely that this is the primary pathological effect of α-syn aggregation since α-syn knockout
mice do not display any overt neuropathological or behavioural phenotypes, in contrast to
mice that overexpress α-syn (Abeliovich et al. 2000, Welchko et al. 2012). Instead, it is now
generally accepted that the accumulation of α-syn into Lewy bodies and Lewy neurites leads
to disease due to a toxic gain-of-function inherent in the protein when it exceeds a threshold
concentration and adopts a fibrillar-type conformation (Stefanis 2012). The aggregation of αsyn, exacerbated by a decrease in the ability of the cell to dispose of damaged proteins,
results in the accumulation of non-functional (potentially toxic) α-syn species, which may
interfere with normal metabolic processes.
1.2.5 Identifying the toxic species in disease
For some time, the toxic α-syn species responsible for neurodegeneration has been hotly
debated. Initially, cytoplasmic inclusions were thought to be a characteristic feature of dead
or dying neurons, with the deposition of mature amyloid fibrils into Lewy bodies identified as
the neurotoxic event. This was primarily based on findings suggesting that inclusions may
suppress organelle function, interfere with axonal transport, or induce energy failure via
hyperubiquitination (Iwai 2000, Kaplan et al. 2003). However, Lewy bodies are commonly
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found in living neurons, and are also present in up to 15% of healthy, aged individuals (Gibb
and Lees 1988, Hindle 2010).
In cell-based models and in vivo, neurotoxicity correlates best with the appearance of soluble
α-syn oligomers, as opposed to inclusions (Gosavi et al. 2002). Toxicity is usually observed
in the absence of mature α-syn fibrils or detectable deposition into inclusions in cell models
(Gosavi et al. 2002, Xu et al. 2002). Moreover, surviving dopaminergic neurons demonstrate
equivalent viability irrespective of the presence or absence of Lewy bodies (Gertz et al.
1994). Furthermore, transgenic mice exhibit neurodegeneration outside the substantia nigra
in the absence of fibrillary inclusions, and α-syn fibril-containing inclusions in Drosophila
are observed in the absence of neurodegeneration (van der Putten et al. 2000, Auluck and
Bonini 2002, Auluck et al. 2002).
A recent study utilised a rat lentivirus system to examine the cellular toxicity of α-syn E35K
and E37K, which were specifically designed to form small oligomers, compared to an α-syn
variant encompassing residues 30-110, which forms fibrils (Winner et al. 2011). Following
injection into the substantia nigra, cell loss was assessed based on a reduction in tyrosine
hydroxylase-positive neurons in this region. Higher toxicity was observed in dopaminergic
neurons of animals exposed to the oligomer-forming variants of α-syn compared to that
which formed fibrils (Winner et al. 2011). Finally, dopamine and its metabolites inhibit the
conversion of protofibrils to mature amyloid both in vitro and in vivo (Conway et al. 2001,
Mazzulli et al. 2006, Tsika et al. 2010), providing a potential rationalisation for the
vulnerability of dopaminergic neurons (since they would therefore promote protofibril
formation). Alternatively, dopamine may act as a source of reactive oxygen species (ROS) in
a process potentiated by α-syn, thereby promoting apoptosis (Xu et al. 2002).
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In light of this evidence, the predominant consensus is now that soluble prefibrillar
oligomeric species of α-syn are the most toxic entity, and fibrils are the less toxic end-product
of the aggregation process (Glabe 2008, Glabe 2009). Yet, mature fibrils can be a source of
cytotoxic oligomeric species due to their fragmentation and potential to act as sites of
secondary nucleation (Xue et al. 2009). Thus, it has been proposed that the formation of
protein inclusions may represent an additional protective mechanism employed by the cell
(Hashimoto and Masliah 1999, Goldberg and Lansbury Jr 2000, Glabe 2008). The formation
of inclusion bodies within cells may therefore represent a protection strategy to actively
sequester toxic oligomeric forms that may arise due to fibril fragmentation. In this way,
potentially toxic species can be isolated in specific compartments in the cell as a protection
mechanism (Tyedmers et al. 2010, Yerbury et al. 2016). However, the appearance of
inclusions is an indication of the cell’s inability to maintain proteostasis and prevent
aggregation. Thus, while it may provide short-term protection, the presence of inclusions is
likely to signify that the long-term outcome will be cell death should the cell be unable to
restore proteostasis.
The generic toxicity of prefibrillar (i.e. small soluble oligomeric) species is also evident in
non-disease-associated proteins capable of forming amyloid. For example, using two
unrelated and non-disease-associated protein domains, the SH3 domain from bovine
phosphatidyl-inositol-3’-kinase and the amino terminal of HypF from E. coli, Bucciantini and
colleagues (2002) demonstrated that oligomeric forms of these proteins, generated during the
early stages of aggregation, were inherently cytotoxic when added to cells in culture. As well,
early prefibrillar aggregates of apomyoglobin are toxic to cultured fibroblasts via their ability
to alter membrane permeability (Sirangelo et al. 2004). Finally, soluble amyloidogenic
oligomers of equine lysozyme are toxic to both primary and cultured neuronal cells;
cytotoxicity is correlated with the size of the oligomers within the sample; larger species
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being less cytotoxic (Malisauskas et al. 2005). Thus, it is concluded that prefibrillar
aggregates are the most toxic entity formed during amyloid fibril formation.
The toxicity of aggregates formed from a variety of pathogenic and non-pathogenic proteins
correlates with the level of exposed hydrophobicity at the aggregate surface (Bolognesi et al.
2010). Initially, there is an abundance of soluble oligomeric aggregates with a high surfaceto-volume ratio and a high degree of exposed hydrophobicity (Cheon et al. 2007). As the
aggregate increases in size over time, there is a decrease in the surface-to-volume ratio and
amount of exposed hydrophobicity (Kremer et al. 2000, Cheon et al. 2007, Bolognesi et al.
2010). The higher proportion of hydrophobic residues exposed on the smaller oligomeric
species enables them to participate in inappropriate interactions that can ultimately lead to
cell death (Chiti and Dobson 2006). It is important to note, however, that although this
mechanism appears generally applicable to pathogenic and non-pathogenic proteins alike,
ultimately the amino acid sequence defines the kinetics by which a protein aggregates and the
specific properties of any aggregate formed. Thus, the specific toxicity of a protein is
influenced by its relative ability to form oligomers, the rate these oligomers are then
converted to mature fibrils, and the amount of hydrophobicity exposed throughout this
process (Bolognesi et al. 2010).
The relative hydrophobicity of prefibrillar aggregates appears to endow them with a large
potential to cause cellular damage. Many mechanisms have been proposed for the toxicity of
aggregated forms of α-syn (summarised in Figure 1.4). When considering the mechanism of
toxicity of these species, it is important to also take into account their physical properties. For
example, α-syn is capable of lipid-binding (Volles and Lansbury 2003, Zhu et al. 2003) and
early oligomers formed from α-syn can be small, flexible spheroids, characteristics which
favour their association with membranes and pore formation (Invernizzi et al. 2012). Pore
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Figure 1.4: A schematic model for the potential mechanisms by which α-syn aggregation is toxic
to neuronal cells. Aggregation-prone monomeric α-syn associates to form soluble oligomeric nuclei
leading to the formation of mature fibrils. (1) Inclusion body formation: Fibrillar α-syn is
sequestered into protein inclusions, which also contain various other cellular proteins, including
sHsps, potentially depleting the cell of these essential components (2) Initiation of the heat shock
response: An accumulation of toxic α-syn species within the cell activates the heat shock response
pathway, initiating changes in transcription of stress response genes. (3) Blocking protein trafficking
from the ER to Golgi: Aggregation of toxic forms of α-syn in the cell can block protein transport
from the ER to Golgi, inducing Golgi fragmentation. (4) Oxidative stress: Aggregation of α-syn
induces dopamine (DA)-dependent ROS production, resulting in oxidative stress. (5) Defects in
axonal transport: Aggregated α-syn induces hyperphosphorylation of tau in the axon, which causes
defects in axonal transport through restricting the ability of tau to modulate microtubule assembly.
This impairs essential cellular transport as well as resulting in the accumulation of aggregated
material in the cell body. (6) Altered synaptic terminal excitability and protein expression: The
presence of aggregated α-syn in the synaptic compartment alters the distribution of synaptic terminal
proteins, diminishing synaptic vesicle release and leading to changes in synaptic terminal protein
expression and excitability. (7) Impaired autophagy: Binding of α-syn to lysosomal membranes
impairs chaperone-mediated autophagic function, resulting in substrate accumulation and proteasomal
impairment in the cell body. (8) Release of toxic α-syn species into extracellular space: Aggregated
α-syn may be actively secreted (e.g. via exosomes) or passively released by dying neurons and be
subsequently taken up by neighbouring neurons, resulting in seeded aggregation and altered synaptic
terminal activity. Uptake by surrounding glia can induce proinflammatory activity including ROS
production, which is toxic to surrounding neurons. (9) Impaired energy production and increased
ROS production: Localisation of α-syn to mitochondrial membranes may impair energy production
or increase ROS formation. (10) Membrane pore formation: Ring-like oligomeric α-syn species
may infiltrate cellular membranes forming pores within the membrane and altering ion permeability.
Figure compiled using information from (Gosavi et al. 2002, Volles and Lansbury 2002, Xu et al.
2002, Maries et al. 2003, Volles and Lansbury 2003, Cookson 2009, Bellucci et al. 2012, Chu et al.
2012, Lundblad et al. 2012, Marques and Outeiro 2012).

formation may occur on any of the cellular membranes, both inter- and intra-cellular,
providing several targets for α-syn mediated toxicity (Cookson and van der Brug 2008). For
instance, pore formation within the plasma membrane may allow the abnormal flow of ions,
causing cellular dysfunction and leading to apoptosis (Volles and Lansbury 2002, Volles and
Lansbury 2003). This is indirectly supported by work showing that cells expressing α-syn
have increased cation permeability (Furukawa et al. 2006).

Through interaction with

lysosomal membranes, α-syn aggregates may inhibit chaperone-mediated autophagy, leading
to an accumulation of substrates and proteasome inhibition (Cookson 2009). Alternatively,
prefibrillar oligomers can impair axonal transport via hyperphosphorylation of Tau, a protein
normally responsible for stabilising and regulating microtubule assembly and interacting with
membranous cargo (Chu et al. 2012). By disrupting transport from the ER to Golgi, α-syn can
cause ER stress and Golgi fragmentation (Gosavi et al. 2002, Cookson 2009). Energy
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production can also be impaired due to effects of oligomeric α-syn on mitochondria (Maries
et al. 2003). In addition, α-syn is implicated in reducing dopamine release and its subsequent
reuptake in the synaptic terminal (Lundblad et al. 2012). The active secretion or passive
release (following death) of aggregated forms of α-syn can also result in cell-to-cell transfer
of toxic intermediates that alter synaptic protein expression and excitability (Bellucci et al.
2012). Moreover, these extracellular species of α-syn can activate surrounding astrocytes and
glia, resulting in the production of ROS and proinflammatory cytokines, which in turn can be
toxic to surrounding neurons (Marques and Outeiro 2012). Finally, although inclusion bodies
may sequester potentially harmful aggregation intermediates, this process may also result in
the depletion of proteins that become associated with the inclusions from the cytoplasm,
leading to a loss in their biological activity (Maries et al. 2003). Together these factors may
lead to compromised cell viability (and cell death), however, any one of these events (or
combination thereof) may be sufficient given the delicate balance required to maintain
proteostasis.
1.2.6 Current cell-based models of α-syn aggregation
Despite the lingering debate surrounding whether incorporation of proteins into inclusions is
in fact protective or detrimental for a cell, it is clear that protein aggregation and the
formation of these inclusions is closely associated with neurodegeneration and disease
(Yerbury et al. 2016). It is therefore critical to examine these processes, and the potential
impact of proteostasis elements, such as chaperones, in the cellular context. To date, this has
been achieved through the development of a range of cellular models targeting the
aggregation of disease-related target proteins. Most cell-based models of the toxicity
associated with α-syn aggregation are based on the exogenous application of aggregated αsyn to cells in culture. Whilst exogenous application of α-syn fibrils may have relevance in
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cell-to-cell propagation of aggregated α-syn (Desplats et al. 2009, Volpicelli-Daley et al.
2011, Freundt et al. 2012, Luk et al. 2012), the intracellular aggregation of α-syn into Lewy
body-like deposits most likely recapitulates the earliest events in disease and therefore is
considered especially relevant when considering the implications of proteostasis components
on aggregation.
Overexpression of α-syn (via transfection or viral induction) has been examined in both
primary and immortalised cell lines. Overexpression of both α-syn WT and A53T in primary
mesencephalic neuronal cultures not only results in significant cell death, which is specific to
dopaminergic neurons and does not impact the viability of the other cells in the culture, but
also renders surviving dopaminergic neurons more susceptible to neurotoxic insults (Zhou et
al. 2000, Zhou et al. 2002). Overexpression of α-syn WT, A53T and A30P in human
neuroblastoma cells (SH-SY5Y) is not sufficient to cause extensive inclusion formation.
However, co-treatment with various agents that generate ROS (e.g. rotenone, papaNONOate
and FeCl2) induces cytoplasmic protein inclusions in those cells which contain both α-syn
and ubiquitin, and are therefore typical of Lewy bodies isolated from diseased tissue
(Ostrerova-Golts et al. 2000, Matsuzaki et al. 2004). In these studies, the extent of α-syn
aggregation was dependent on both the level and isoform of α-syn expressed: α-synA53T
had an increased tendency to form inclusions, consistent with its increased propensity to form
fibrils in vitro and its genetic association with early onset PD (Ostrerova-Golts et al. 2000).
McLean et al (2001) expressed an α-syn isoform which was C-terminally tagged with EGFP
in H4 neuroglioma cells and demonstrated that overexpression of this protein results in
cytoplasmic inclusions in ~5% of transfected cells. Interestingly, co-transfection with
synphilin-1, a protein which binds α-syn in vivo, increased the percentage of cells containing
inclusions to ~55% (Engelender et al. 1999, McLean et al. 2001). Notably, although the α-syn
was expressed with an EGFP fluorescent tag, inclusions were not fluorescent or reactive to
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anti-GFP antibodies (McLean et al. 2001). This was found to be due to cleavage of part of the
C-terminal region of EGFP from the α-syn-EGFP expressed in these cells, generating a
truncated (and non-fluorescent) form of the protein which aggregated to form inclusions.
Thus, these findings highlight the potential problems with tagging α-syn (and indeed other
proteins) to monitor its aggregation in cells. Alternative methods for studying full length αsyn aggregation in cells have also been developed. For example, using a tetra-cysteine tagged
α-syn, that was either microinjected or transfected into cells and detected by labelling with a
fluorogenic biarsenical compound. Using this approach, Bertoncinni et al (2007)
demonstrated that the aggregation of α-syn into inclusions is significantly increased (up to
10%) by co-treating the cells with FeCl2 to induce oxidative stress. More recently, α-syn
aggregation in cells was modelled by the addition of a 16 amino acid peptide (termed CL1) to
the C-terminus of α-syn, and this was used to demonstrate a correlation between increasing
numbers of α-syn aggregates in cells and a reduction in cell viability (Wan and Chung 2012).
1.2.7 Lewy bodies and Lewy neurites: α-syn is not alone
Whilst α-syn is the main constituent of Lewy bodies and Lewy neurites, it is not the only
protein found in these insoluble inclusions: a range of other proteins has been identified
including synuclein-binding proteins, protein kinases, proteins implicated in the ubiquitinproteasome system and proteins associated with the cellular stress response (e.g. molecular
chaperones) (Wakabayashi et al. 2007). Immunostaining of post-mortem brain tissue from
PD patients indicates that Hsp90, Hsp70, Hsp40 and the sHsps are associated with Lewy
bodies and Lewy neurites (Auluck et al. 2002, McLean et al. 2002, Uryu et al. 2006). With
regard to the sHsps, diffuse Hsp27 was identified throughout Lewy bodies and Lewy neurites
in the substantia nigra (McLean et al. 2002, Outeiro et al. 2006) and αB-c also co-localises
with α-syn in Lewy bodies and Lewy neurites (Lowe et al. 1990, Iwaki et al. 1992, Mizutani
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et al. 1997, Outeiro et al. 2006). In addition, post-translationally modified forms of αB-c have
been found to be a major component of oligodendral cytoplasmic inclusions isolated from
clinically confirmed cases of multiple system atrophy (Pountney et al. 2005). Thus, it appears
that although these chaperone proteins are available to inhibit α-syn aggregation in cells,
under certain circumstances they are unable to prevent its deposition and instead become part
of the inclusions that are the hallmarks of the α-synucleinopathies.
1.3 Small heat shock proteins (sHsps) as molecular chaperones
1.3.1 Structure and function of the sHsps
There are ten sHsps in the human genome (HSPB1 – HSPB10), and of these the most well
characterised are Hsp27, αA-crystallin (αA-c), αB-c and Hsp22 (HSPB1, HSPB4, HSPB5
and HSPB8 respectively) (Kampinga et al. 2009, Carra et al. 2013). Whilst often described as
‘holdase’ chaperones, this term does not fully describe their chaperone activity (Kulig and
Ecroyd 2012) and not all sHsps have been shown to be capable of suppressing protein
aggregation (e.g. HSPB9 and HSPB10). Structural aspects of sHsps have been considered in
detail elsewhere (Haslbeck et al. 2005, Sun and MacRae 2005, Basha et al. 2012, Hilton et al.
2013) and therefore the salient features are only summarised here. The sHsps are defined by
their relatively small (compared to other Hsps) monomeric masses (12 – 43 kDa), and the
presence of a conserved central region referred to as the α-crystallin domain. The α-crystallin
domain is ~90 residues in length and contains eight anti-parallel β-strands organised into two
β-sheets in an immunoglobulin-like fold (van Montfort et al. 2001, Stamler et al. 2005). It is
flanked by N- and C-terminal regions of variable length and sequence that predominantly
lack structure (Kim et al. 1998). In mammalian sHsps, the extreme C-terminus is a short,
mobile and flexible extension which is typically polar in nature and contributes to
stabilisation of the protein (and complexes it forms with target proteins) during chaperone
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action (Carver et al. 1992, Lindner et al. 2000). The N-terminus contains regions of
significant hydrophobicity and has been suggested to mediate the interaction between the
chaperone and its target protein (Stromer et al. 2004, Giese et al. 2005, Aquilina and Watt
2007, Peschek et al. 2013), although recent work demonstrates that the N-terminus is not
essential for chaperone action (Feil et al. 2001, Jehle et al. 2010, Hochberg et al. 2014). The
formation of oligomeric assemblies is another defining feature of the sHsps. Whilst in some
species sHsps form well-defined homogenous multimers (e.g. wheat Hsp16.5), many
mammalian sHsps members (e.g. Hsp27, αB-c and αA-c (HSPB4)) form large polydisperse
oligomers which undergo rapid subunit exchange (Bova et al. 1997, Bova et al. 2000, Van
Montfort et al. 2002, Lelj-Garolla and Mauk 2006, Ahmad et al. 2008, Benesch et al. 2008,
Jehle et al. 2010, Jehle et al. 2011). The popular model of sHsp chaperone action is that
dissociated species (predominantly depicted as dimers) are the most chaperone-active form.
In this model, the rate of subunit exchange of sHsps dictates how fast chaperone active
subunits can be liberated from large oligomers, in order to interact with and prevent the
aggregation of target proteins. Previous work has shown that αB-c is most effective (on a
mole: mole basis) at preventing the aggregation of slowly aggregating target proteins
compared to those aggregating more quickly (Lindner et al. 2001) presumably because of the
requirement for active subunits to dissociate from larger oligomers as part of the chaperone
action of sHsps. Thus, when protein aggregation occurs very fast it may exceed the rate at
which active sHsp subunits can dissociate, therefore leading to a decrease in the chaperone
efficacy of the sHsp.
1.3.2 Modulators of sHsp activity
As a dimer is the smallest unit observed in all X-ray structures of sHsps obtained to date, it is
considered the smallest building block of sHsp oligomers and the primary species responsible
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for the dynamic subunit exchange observed between oligomeric units (Sobott et al. 2002, Van
Montfort et al. 2002). However, sHsps form large oligomeric assemblies with an odd number
of subunits and therefore a dimer cannot be the sole building block for all assemblies
(Aquilina et al. 2003, Aquilina et al. 2004). Dimers are generated through the formation of an
inter-subunit composite β-sheet structure via domain swapping between two α-crystallin
domains (Haslbeck et al. 2005, Baranova et al. 2011). The oligomeric state of a sHsp is
highly dependent on solution conditions, including temperature and pH, which can also affect
the rate of subunit exchange (Chernik et al. 2004, Lelj-Garolla and Mauk 2006). Although a
degree of chaperone activity has been demonstrated for the larger oligomeric assembly
(Augusteyn 2004, Franzmann et al. 2005), this remains contentious (Krushelnitsky et al.
2008). The consensus in most models of sHsp chaperone action is that dissociated species
(predominantly depicted as dimers) are the chaperone active form (or at least the most
chaperone active). This is based on the inference that they would have a higher degree of
exposed hydrophobicity compared to the larger oligomeric form, thereby facilitating their
interaction with partially-folded substrate proteins that also expose significant hydrophobicity
to solution (Haslbeck et al. 1999, Van Montfort et al. 2002). It is thought that chaperonebound substrate proteins then reassociate with the larger oligomers, to form a high molecular
weight chaperone-substrate protein complex. This complex maintains the solubility of the
partially-folded intermediates and, in doing so, sHsp oligomers acts as a reservoir of foldingcompetent intermediates (Leroux et al. 1997, Haslbeck 2002). This mechanism of action
explains their classification as ‘holdase’ chaperones; however, the ‘holdase’ name is a
misnomer since sHsps can prevent aggregation without ‘holding’ onto the substrate protein.
sHsps may instead transiently interact with the substrates to stabilise them and prevent their
aggregation (Ecroyd and Carver 2009, Kulig and Ecroyd 2012). As such, sHsps may be better
classified as ‘stabilisers’ rather than holdases as this would more fully describe their
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mechanism of action. Regardless of the mechanism of chaperone action used by sHsp to
interact with substrate proteins (weak, transient interactions versus the formation of a stable
complex), both are thought to be dependent on the dissociation of chaperone active species
from the larger oligomers, a process which occurs at a constant rate in a given environment,
but varies with temperature and solution conditions (Bova et al. 1997). Importantly, however,
the exchange rate is independent of the chaperone concentration for αB-c (Bova et al. 2000)
and thus, whilst cellular stress may act to up-regulate the rate of subunit exchange of sHsps in
the cell, this rate of exchange may be insufficient to cope with the concomitant increase in the
rate at which protein aggregation occurs. This may therefore be a significant factor that leads
to sHsp activity being overwhelmed in the context of protein aggregation diseases.
Post-translational modifications also modulate mammalian sHsp structure and function.
sHsps have been shown to undergo a range of post-translational modifications including
methylglycoxal modification (Sakamoto et al. 2002), S-thiolation (Eaton et al. 2002) and
truncation. However, the major modification identified to occur to sHsps is phosphorylation.
Some mammalian sHsps have serine residues within the N-terminal domain that can be
phosphorylated by various kinases (Vos et al. 2008). For example, Hsp27 is phosphorylated
by MAPKAP kinase-2 and MAPKAP kinase-3 at serine residues 15, 78 and 82 (Rogalla et al.
1999), and αB-c undergoes phosphorylation at residues45 and 59 by p44/p42 MAPK and
MAPKAP kinase-2 respectively, and at serine 19 by an as yet unknown kinase (Ito et al.
1997, Kato et al. 1998). Whilst phosphorylation of αB-c and Hsp27 has been studied in detail,
dephosphorylation and how this process is regulated has received much less attention.
Dephosphorylation of Hsp27 can occur in vitro via the action of the phosphatases PP2A, PP1
and PP2B (Cairns et al. 1994), however, it remains to be ascertained which phosphatases
fulfil this role in vivo.
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Phosphorylation of some sHsps occurs rapidly in response to cellular stress and acts to
modulate the oligomerisation of the sHsps (van den Ijssel et al. 1998). For example,
phosphorylation of Hsp27 results in its dissociation into smaller species, such that the form
phosphorylated on all three serine residues forms a monodisperse dimer in vitro (Kato et al.
1994, Lambert et al. 1999, Rogalla et al. 1999, Hayes et al. 2009, Jovcevski et al. 2015).
Similarly, phosphorylation of αB-c has been shown to disrupt the interaction between dimerforming αB-c subunits and is associated with an increase in oligomer polydispersity in vitro
and decrease in oligomer size (Ito et al. 2001, Aquilina et al. 2004, Ecroyd et al. 2007).
There remains some contention about the overall effect phosphorylation has on the chaperone
activity of sHsps; whether it is beneficial or deleterious is thought to depend on the context
and extent of phosphorylation (Bakthisaran et al. 2016). The effect of phosphorylation on
Hsp27 and αB-c chaperone activity and structure have been widely investigated using
phosphomimicking mutants, whereby the appropriate serine residues are replaced with either
aspartate or glutamate residues in order to mimic the negative charge of the phosphate group
(Panasenko et al. 2002, Ecroyd et al. 2007, Hayes et al. 2009). However, these mimics do
have their limitations: the substitution of aspartate or glutamate at the serine residues
introduces a -1 charge (as opposed to -2 that is introduced when a phosphate group is added
by a kinase) and the carboxylic acid group is smaller than the phosphate group introduced by
phosphorylation. The main advantage of using phosphomimics is that they enable a
homogenous isoform of the sHsp to be studied as opposed to the mixed isoform populations
that can occur when the protein is phosphorylated in vitro. Moreover, Hsp27 S15/78/82D has
been shown to have similar, albeit not identical, size and chaperone activity to the triply
phosphorylated form (Hayes et al. 2009).
Using a panel of related αB-c phosphomimics, Ecroyd and colleagues (2007) demonstrated
that the size and relative chaperone activity of αB-c is highly dependent on the solution
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conditions and substrate protein(s) used to assess the activity (Nicholl and Quinlan 1994,
Wang et al. 1995, Ito et al. 2001, Panasenko et al. 2002, Ecroyd et al. 2007). Moreover,
differences have been noted between recombinant forms of sHsps and those purified from
other sources (e.g. lenses), although those from the lens most likely contain other posttranslational modifications (Panasenko et al. 2002). In addition, it has also been postulated
that phosphorylation may modulate the proteins targeted by the sHsps, such that under
quiescent conditions the sHsps function with minimal phosphorylation and sufficient activity
to maintain proteostasis. Exposure to stress results in the rapid phosphorylation of the sHsps,
modifying their oligomeric structure and facilitating their interaction with destabilised
proteins in danger of aggregation (Treweek et al. 2015). Thus, the activity of the sHsps upon
phosphorylation may appear to increase or decrease according to the substrate tested. All
these factors no doubt help explain the variation between workers on the overall effect
phosphorylation has on sHsp chaperone activity and argue for a set of standard assays to be
used in the field in order to enable comparison between studies, and overall consensus to be
reached. In any case, intuitively it would be expected that phosphorylation of sHsps would
act to boost chaperone activity against aggregating proteins (rather than decrease it), since the
cell uses energy in an often energy poor environment to phosphorylate sHsps under stress
conditions. When overall energy levels in the cell are low, and cell viability is compromised,
the chaperone action of sHsps is crucial with regards to preventing the misfolding and
aggregation of cellular proteins destabilised by the stress.
1.3.3 Expression of the sHsps in the brain
Of the eleven identified human sHsps, some are ubiquitously expressed (e.g. Hsp27 and αBc), while others are found only within specific tissues (Stetler et al. 2010, Garrido et al.
2012). For example, αA-c (HSPB4) is only present at appreciable levels within the eye lens,
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where, together with αB-c, it forms α-crystallin, the hetero-oligomeric lens protein which is
responsible for maintaining lens transparency via its chaperone action and ordered
arrangement (Klemenz et al. 1991, Haley et al. 1998). Given the important role sHsps have in
proteostasis, it is surprising that there has not been a systematic study of sHsp expression and
localisation in the human brain. In relation to neurodegenerative conditions such as the αsynucleinopathies, five sHsps are expressed within the central nervous system. Myotonic
dystrophy protein kinase binding protein (HSPB2) is expressed in smooth muscle of vessel
walls of the brain (Wilhelmus et al. 2006), and compartment-specific expression of Hsp20
(HSPB6), Hsp22 , Hsp27 and αB-c has been demonstrated within other brain tissues of the
mouse (Quraishe et al. 2008). Hsp27 is expressed in motor and sensory neurons in the
brainstem and cranial nerve nuclei (Plumier et al. 1997), and is also constitutively expressed,
along with αB-c, in glial cells (Wilhelmus et al. 2006).
Although there is some evidence for the neuroprotective capabilities of Hsp20 and Hsp22
(Stetler et al. 2010), Hsp27 and αB-c have attracted the most attention in relation to
neurodegenerative disease. Both αB-c and Hsp27 expression are highly induced in response
to neurological stress (Iwaki et al. 1992, Kato et al. 1994). Hsp27 and αB-c are expressed in
reactive astrocytes adjacent to senile plaques in both normal aged brains and in
neurodegenerative conditions, such as Alzheimer’s disease (Wilhelmus et al. 2006), and their
expression is increased in reactive astrocytes in the hippocampus of PD patients with
dementia (Renkawek et al. 1999). Moreover, Hsp27 is one of the most strongly induced
proteins across several brain regions in PD patients (Zhang et al. 2005) and its levels are 2.5fold higher in pathologically confirmed cases of Dementia with Lewy bodies than agematched controls. Chen and Brown (2007) compared constitutive and inducible Hsp27
expression in several neuronal subtypes associated with neurodegenerative diseases,
including PD and amyotrophic lateral sclerosis (ALS). Constitutive Hsp27 expression was
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found within motor neurons of the spinal cord (the degeneration of which is associated with
ALS), but Hsp27 was not detected within dopaminergic neurons of the substantia nigra (the
degeneration of which is associated with PD). They speculated that one reason ALS is
approximately 33 times less frequent than PD is that motor neurons in the spinal cord are
better equipped to manage misfolded proteins than dopaminergic neurons due to the
protection provided by the levels of Hsp27 (Chen and Brown 2007). Thus, the low basal
expression of Hsp27 in dopaminergic neurons (Chen and Brown 2007, Carra et al. 2013) may
facilitate the onset of α-syn aggregation in these cells. The increased expression of sHsps in
the context of the α-synucleinopathies may be a consequence of the cellular stress conditions
that accompanies the onset and progression of these diseases.
1.3.4 sHsps interact with multiple species to inhibit aggregation
The design of most experiments testing the chaperone function of sHsps (and indeed
chaperones in general) to date has involved addition of the chaperone to a sample before
aggregation has commenced (Horwitz 1992, Rekas et al. 2004, Ecroyd et al. 2007, Bruinsma
et al. 2011). As such, these studies have focused on the interaction of the chaperones with
species formed early on during the aggregation process. More recently, some studies have
investigated the interaction of sHsps with preformed amyloid fibrils and shown that αB-c
binds along the length of amyloid fibrils, including those formed by α-syn (Waudby et al.
2010, Shammas et al. 2011). In doing so, it acts to inhibit further fibril growth. αB-c binds to
preformed amyloid-β (Aβ) and apolipoproteinC-II (apoC-II) fibrils with moderate (µM)
affinity (Shammas et al. 2011, Binger et al. 2013). By binding to fibrils, sHsps may act to
occlude the fibril ends, preventing the addition of further monomeric species and thus fibril
growth. They may also stabilise fibrils against fragmentation or conceal hydrophobic surfaces
that would otherwise be toxic. Fibril fragmentation (i.e. breaking) contributes to secondary

32

Chapter 1: Introduction
nucleation events, as the fragments act as nuclei for further fibril growth and are a source of
toxic oligomers (Knowles et al. 2009). Likewise, sites of exposed hydrophobicity along the
face of the fibril have also been identified as possible locations for secondary fibril
nucleation, again leading to rapid fibril growth and dominating the overall kinetics of fibril
growth (Ruschak and Miranker 2007, Knowles et al. 2009, Cohen et al. 2011). More recent
work has also shown that by binding to fibrils, sHsps can promote their clustering into larger
aggregates (Ojha et al. 2011, Mannini et al. 2012, Binger et al. 2013). Finally, using the
amyloidogenic protein β2-macroglobulin, αB-c has also been shown to reversibly dissociate
soluble oligomers to produce monomeric β2-macroglobulin, potentially providing another
protective mechanism against oligomer-induced toxicity (Esposito et al. 2013). Thus, it is
now apparent that rather than having a mechanism of action that is based solely on binding to
partially-folded monomeric states of proteins, sHsps can interact with multiple species
formed during protein aggregation, including the mature fibrils. In each case, it appears that
sHsps act to minimise the amount of toxic protein aggregates formed in the cell and thereby
its exposure to these harmful species. However, this is yet to be demonstrated experimentally
and is a key concept addressed in this work.
In addition, whilst the presence of sHsps within protein inclusions associated with disease has
been considered a by-product of their failed attempt to mitigate aggregation, the recent work
demonstrating the ability of sHsps to stabilise fibrils and mediate their tangling into larger
aggregates provides another rationale for their localisation in these deposits. However,
whether this is a beneficial effect in the cell remains to be established, since sequestering
chaperones within these deposits may in fact have a deleterious effect on the cell as it reduces
the ability of chaperones to participate in other physiological functions (Waudby et al. 2010,
Ebrahimi-Fakhari et al. 2012).
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1.4 sHsps interact with α-syn
The presence of the sHsps within Lewy bodies and their upregulation in the surrounding
neuronal tissues associated with a number of α-synucleinopathies has led to an examination
of potential interactions between α-syn and various sHsps. These findings are summarised in
Table 1.1 and are based on studies using a number of model systems, which can be grouped
into three distinct categories, in vitro α-syn aggregation assays, cell-based models and animal
models of α-syn aggregation.
Bruinsma et al (2011) assessed a panel of sHsps, including Hsp27, Hsp20, Hsp22, HspB2B3
and αB-c, for their ability to inhibit α-syn aggregation using both in vitro ThT assays and
atomic force microscopy. They reported that Hsp27 is the most efficacious of these sHsps
with regards to preventing fibril formation of α-synWT and it does so by inhibiting both the
lag and elongation phases of aggregation (Bruinsma et al. 2011). The interaction of Hsp27
with α-syn leads to an overall reduction in the number and size of α-syn fibrils. Comparable
effects were observed when Hsp27 was incubated with α-syn E46K and A30P, however, the
presence of Hsp27 increased the aggregation of α-synA53T compared to when no chaperone
was present (Bruinsma et al. 2011). αB-c also inhibits the aggregation of α-syn (and its
disease-related mutant forms) in vitro and does so at sub-stoichiometric levels (Rekas et al.
2004). In addition, the in vitro fibrillar aggregation of α-synA53T isolated from brain tissue
extracts of transgenic mice is significantly reduced by the presence of αB-c (Wang et al.
2008). As with Hsp27, the addition of αB-c not only increases the lag phase of α-syn
aggregation, slowing the formation of prefibrillar intermediates, but also inhibits the
elongation phase, indicating that it acts to stabilize monomeric and prefibrillar α-syn species
(Rekas et al. 2004, Rekas et al. 2007). Notably, the efficiency with which αB-c inhibits α-syn
fibril formation correlates with the aggregation-propensity of the α-syn isoform (Rekas et al.
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2004, Bruinsma et al. 2011). Thus, at a given molar ratio, αB-c is more effective at inhibiting
the aggregation of α-synWT (which aggregates the slowest) and is less effective against αsynA53T (which aggregates the fastest).
Much of what is known about the interaction between sHsps and α-syn in cells comes from
cell-based models of α-syn which rely on overexpression of α-syn alongside cofactors such as
synphillin-1, or treatment with inducers of cytotoxic stress (Engelender et al. 1999,
Ostrerova-Golts et al. 2000, McLean et al. 2001, Matsuzaki et al. 2004). However, in general
these cell models have only been used qualitatively to assess the effects of sHsps on α-syn
aggregation. For example, using an α-syn overexpression system coupled with viral-mediated
Hsp expression in ND7 cells, Zourlidou et al (2004) reported a reduction in α-syn-induced
cellular toxicity following Hsp27 expression. Although this study focused on the inherent
susceptibility of α-syn-expressing cells to external cell death stimuli, such as serum removal,
without directly considering α-syn aggregation, it was concluded that Hsp27 is
neuroprotective. Outeiro et al (2006) used overexpression of the truncated EGFP-tagged αsynWT in H4 cells to examine the effect of sHsps on α-syn aggregate formation, and reported
that co-transfection with Hsp27 significantly reduced the percentage of cells containing α-syn
inclusions. Both Hsp27 and αB-c reduced the inherent toxicity of α-syn expression to levels
similar to that seen when Hsp70 is expressed in these cells (Outeiro et al. 2006). This
reduction was reproduced when α-synA53T was overexpressed in primary midbrain cultures
(Klucken et al. 2004, Outeiro et al. 2006). Furthermore, a reduction in the endogenous levels
of Hsp27 (by siRNA knockdown) resulted in a concentration-dependent increase in α-syn
toxicity in the transfected H4 model (Outeiro et al. 2006). Together, cell culture studies such
as these have provided promising glimpses of the role of sHsps in preventing α-syn
aggregation in cells. However, they also serve to highlight the failure of sHsps to prevent this
aggregation in the context of the α-synucleinopathies.
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Table 1.1: A summary of studies that have investigated the interaction between sHsps and
α-syn. Key findings regarding this interaction are categorised according to the method used.
Method
used
α-Syn Isoform
sHsp
Key Findings
WT
Hsp27
In vitro
 sHsps bind α-syn variants in a weak,
A53T
αB-c
aggregation
transient but specific manner
A30P
Hsp20
assays, AFM
 sHsps reduce the amount of fibrillar
E46K
Hsp22
aggregation resulting in fibrils that are
HspB2B3
shorter, and have a clustered morphology.
WT
αB-c
In vitro
 αB-c inhibits α-syn fibril formation at
A53T
aggregation
substoichiometric ratios.
A30P
assays, EM
 The number of fibrils and generation of
amorphous-like aggregates are reduced.
WT
αB-c
In vitro
 The ability of αB-c to suppress α-syn
aggregation
aggregation increases with temperature.
assays
 αB-c inhibits further aggregation when
introduced during the elongation phase of
fibril growth.
A53T
αB-c
In vitro
 The interaction of αB-c with α-syn
assay, EM
monomers is weak and transient. αB-c
binds along the face and ends of mature αsyn fibrils.
 Fibril-bound αB-c inhibits further
elongation.
A53T
αB-c
In vitro
 αB-c significantly reduces the in vitro
aggregation
aggregation of α-syn extracted and purified
assays
from brain tissue of transgenic mice.
WT
Hsp27
Cell-based
 Hsp27 expression protects stably
A53T
model
transfected ND7 α-syn-expressing cells
A30P
from cell death stimuli including serum
withdrawal.
WT
Hsp27
Cell-based
 Both Hsp27 and αB-c co-localise with αA53T
αB-c
model
syn inclusions in co-transfected H4
neuroglioma cells.
 Hsp27 reduces inclusion formation,
although both αB-c and Hsp27 reduce αsyn toxicity.
 Hsp27 protects primary dopaminergic
neurons from α-syn toxicity.
WT
Hsp27
Cell-based
 Hsp27 does not co-localise with α-syn in
model
inclusions
A53T
Hsp25*
In vivo
 Hsp25 levels are significantly upregulated
αB-c
murine
in both the soluble and insoluble fractions
of spinal cord tissue of -synA53T overexpressing transgenic mice.
 αB-c levels are increased in the insoluble
fraction of spinal cord tissue from these
transgenic mice.
WT
αB-c
In vivo
 αB-c reduces the ‘rough eye’ phenotype
Drosophila
induced by α-syn expression and
aggregation in Drosophila

Reference
(Bruinsma
et al. 2011)

(Rekas et
al. 2004)

(Rekas et
al. 2007)

(Waudby et
al. 2010)

(Wang et
al. 2008)
(Zourlidou
et al. 2004)

(Outeiro et
al. 2006)

(McLean et
al. 2002)
(Wang et
al. 2008)

(Tue et al.
2012)

*Hsp25 is the murine ortholog of human Hsp27
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Despite these investigations, little is known about the molecular mechanism(s) by which the
sHsps, αB-c and Hsp27, interact with α-syn. As such, elucidating these details formed the
basis of this work.
1.5 Summary and aims
The aggregation of α-syn into protein inclusions underlies the onset and progression of the αsynucleinopathies and represents a failure of the proteostasis network in maintaining the
protein in a biologically active, non-toxic form. Key components of the proteostasis network
are molecular chaperones and the sHsps are the cell’s first line of defence against protein
aggregation; we need to better understand why they fail in the context of the αsynucleinopathies.
Whilst it has been generally considered that the role of sHsps in the chaperone network is to
stabilise partially-folded intermediate states of protein to prevent their aggregation, recent
work has demonstrated that their mechanism of chaperone action is multi-faceted. In the
context of α-syn aggregation, sHsps interact with multiple species formed during the
aggregation process, from monomeric partially-folded intermediate states through to the
mature fibrils themselves. However, the precise mechanism(s) of this interaction is yet to be
fully understood. Furthermore, the failure of sHsps to prevent α-syn aggregation in a disease
context is often attributed to their protective capacity being ‘overwhelmed’. However,
specific factors leading to this failure are yet to be determined.
In addition, whilst many studies have primarily considered the ability of the sHsps to inhibit
or prevent α-syn aggregation in vitro, there is limited evidence of the physiological relevance
of this interaction due to the limited number of cellular studies performed to date.
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As such, the specific aims of this work were to:
i.

Establish the mechanism by which the sHsps, αB-c and Hsp27, inhibit the initial
stages of monomeric α-syn aggregation and determine whether an increase in the rate
at which α-syn aggregates affects the ability of sHsps to prevent this process.

ii.

Characterise the ability of Hsp27 and αB-c to bind α-syn fibrils, and determine
whether this provides an alternate protective mechanism by which these chaperones
act to prevent the toxicity associated with α-syn fibrils.

iii.

Establish a robust cellular model of α-syn aggregation and use it to determine whether
sHsps can prevent the aggregation of α-syn into inclusions in cells.
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Common methods used in this work are outlined in this chapter. Methods specifically
pertaining to work presented in Chapters 3 – 5 are given in the relevant chapters.
2.1 Materials
All materials used in this work were purchased from Sigma-Aldrich (St. Louis, MO, USA) or
Amresco (Solon, OH, U.S.A.) unless otherwise indicated. Recombinant stocks of core
domain variants of the sHsps, consisting of residues 68 – 153 of αB-c (αB-ccore) and residues
84 – 176 of Hsp27 (Hsp27core), were kind gifts received from Prof. J. Benesch (University of
Oxford, United Kingdom), Prof. A. Laganoswsky (Texas A&M Health Science Center, USA)
and Assoc. Prof. Heath Ecroyd (University of Wollongong, Australia). Initial stocks of
recombinant α-synA90C, produced to enable site-specific labelling of the cysteine using
fluorescent dyes, were a kind gift from Dr. Laura Tosatto (University of Cambridge, UK).
Chemically competent DH5α or BL21(DE3) E. coli strains were kind gifts of Dr. Tracey
Berg (University of Wollongong, Australia). Mouse neuroblastoma (Neuro-2a; N2a) were
obtained from the American Type Culture Collection (Manassas, VA, U.S.A.). Human
embryonic kidney (HEK293) cells were gifts from Assoc. Prof. Ron Sluyter (University of
Wollongong, Australia). All cell lines were routinely tested for mycoplasma contamination
every 6 months, and the identity of the human-derived cell line was verified via short tandem
repeat (STR) profiling (Garvan Institute of Medical Research, Sydney, Australia).
Mouse monoclonal anti-B-c (clone 1B6.1-3G4) and anti-Hsp27 (clone G3.1), rabbit
polyclonal anti-B-c (ab13497) and anti-Hsp27 (ab5579), and anti-mouse (ab37355) and
anti-rabbit (ab171870) IgG control antibodies were all purchased from Abcam (Cambridge,
UK). Goat anti-mouse secondary antibodies conjugated to DyLight488 (ab96879) and
DyLight650 (ab96874), goat anti-rabbit secondary antibodies conjugated to DyLight488
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(ab96895), DyLight550 (ab96900) and DyLight650 (ab96902), and a rabbit anti-mouse
secondary conjugated to DyLight550 (ab98786) were also obtained from Abcam (Cambridge,
UK). Both the mouse monoclonal anti--syn antibody (clone Syn211) and the peroxidase
conjugated anti-mouse IgG secondary antibody were obtained from Sigma-Aldrich (St.
Louis, USA).
2.2 Bacterial and mammalian expression constructs
2.2.1 Plasmids
The pET24d(+) or pET24a(+) bacterial expression vectors, containing the human HSPB5
(αB-c), HSPB1 (Hsp27) and SNCA (α-syn) genes, were kind gifts of Assoc. Prof. Heath
Ecroyd, and were used for expression of recombinant WT proteins. Disease-related mutants
of α-syn (A30P, A53T and E46K) and sHsp variants used in this work were produced via
site-directed mutagenesis of the WT gene by GenScript( Piscataway, USA). In particular,
variants of the sHsps designed to mimic phosphorylation were generated by mutation of the
phosphorylatable serine residues to aspartic acid (Ser15, Ser45 and Ser59 to produce αB-c3D,
and Ser15, Ser78 and Ser82 to produce Hsp273D). Plasmids for the expression of the core
domains of the sHsps, i.e. residues 68 – 153 of αB-c (αB-ccore) and residues 84 – 176 of
Hsp27 (Hsp27core), were kind gifts from Prof A. Laganowsky (Texas A&M Health Science
Center, USA). The pT7-7 vector harbouring the SCNA gene containing an A90C mutation
was a kind gift from Dr. Laura Tosatto (University of Cambridge, UK) and was used for the
expression of α-syn suitable for site-specific fluorescent labelling (α-synA90C).
The pEGFP-N3 mammalian expression vector, containing the human SNCA (α-syn) gene
with or without the disease-related mutation (A53T), was a gift from Dr. Dean Poutney
(Griffith University, Australia) and was used to induce cellular expression of α-syn variants
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C-terminally tagged with EGFP. The pCMV6-AC-GFP mammalian expression vector,
containing M337V TDP-43 cDNA C-terminally tagged with TurboGFP (tGFP), was a kind
gift from Dr. Daniel Whiten (University of Wollongong, Australia). Constructs encoding pTRex-Htt46Q-Tc1-mCherry and pT-Rex-Htt25Q-Tc1-mCherry, were gifts from Assoc. Prof.
Danny Hatters (University of Melbourne, Australia). The bicistronic pIRES2-EGFP
constructs containing WT αB-c, Hsp27, Hsp40, Hsp70, Hsp90, or the non-chaperone controls
LacZ or invisibile EGFP (EGFPinv; i.e. a non-fluorescent derivative of EGFP, Y66L EGFP
(Olshina et al. 2010, Ramdzan et al. 2012)), were gifts from Dr. Tracey Berg (University of
Wollongong, Australia).
2.2.2

Transformation of chemically competent E. coli

One aliquot (200 µL) of chemically competent cells (DH5α for plasmid storage or
BL21(DE3) for recombinant protein expression) were thawed on ice before the addition of
100 ng of plasmid DNA (or 30 µL of ligation reaction) with gentle mixing. Cells were
incubated on ice for 30 min, then heat shocked at 42oC for 30 s using an Accublock digital
dry bath (Labnet International, Edison, USA). Cells were immediately transferred to ice, and
diluted 1:4 into Luria-Bertani broth (LB; 1% (w/v) tryptone, 1% (v/v) NaCl, 0.5% (w/v) yeast
extract, pH 7.4) for plasmid transformations or Super optimal broth with catabolite repression
(SOC; 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM
MgCl2, 10 mM MgSO4 and 20 mM glucose) media for ligation transformations. Cells were
then incubated at 37oC for 1 h with agitation. Transformation cultures were plated onto prewarmed selective LB–agar plates (LB containing 15% (w/v) agar and the appropriate
antibiotic) and incubated overnight at 37oC.
Successfully transformed colonies were screened for the plasmid of interest by polymerase
chain reaction (PCR) using insert-specific primers. Plasmid DNA was extracted from the
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clone using the Wizard® Plus SV Miniprep DNA Purification System (Promega, Madison,,
U.S.A.) according to the manufacturer’s instructions. Colonies identified to contain the
correct plasmid DNA were then used to inoculate LB containing the appropriate antibiotic,
which was incubated overnight at 37oC. This culture was then combined 1:1 with a sterile
30% (v/v) glycerol solution, and stored in sterile cryogenic tubes at -80oC.
2.2.3

Sequence verification

Extracted DNA constructs were prepared for sequencing using the BigDye Terminator v3.1
cycle Sequencing Kit (Applied Biosystems, Foster City, U.S.A.) according to the
manufacturer’s instructions. The reaction mix contained 1X BigDye buffer, 1.6 µM of the
appropriate primer, 1X BigDye Ready Reaction Premix and an appropriate concentration of
plasmid DNA in a total of 10 µL. PCR was performed using a Mastercycler ProS (Eppendorf,
Hamburg, Germany) and consisted of 35 cycles, with each cycle consisting of denaturation at
96°C for 10 s, annealing at 50°C for 5 s, and extension at 60°C for 4 min. The resulting DNA
was then precipitated using 100% ethanol, 125 mM ethylenediaminetetraacetic acid (EDTA;
pH8.0) and 3 M sodium acetate (pH 5.2) for 2 h at room temperature. The reaction was then
centrifuged at 20000 x g for 20 min at 4 oC and the supernatant discarded. The DNA was then
washed with ice cold ethanol (70% (v/v)) and centrifuged as above. The supernatant was
again discarded and any remaining ethanol evaporated at room temperature prior to
sequencing. Sequencing was performed by Ms. Margaret Phillips (University of Wollongong,
Australia) using a Hitachi 3130xl Genetic Analyser (Applied Biosystems, Mulgrave,
Australia).
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2.3 Recombinant protein production
2.3.1 Expression and purification
Recombinant proteins were expressed in BL21(DE3) E. coli cells transformed with each
plasmid, and purified as described previously (Horwitz et al. 1998, Narhi et al. 1999,
Laganowsky et al. 2010). Briefly, 100 mL of LB containing the appropriate antibiotic (100
µg/mL ampicillin or 50 µg/mL kanamycin) was inoculated with BL21(DE3) E. coli
harbouring the plasmid of interest and incubated overnight at 37oC with constant agitation.
Overnight cultures were then diluted 1:20 into fresh LB containing the appropriate antibiotic
and incubated at 37oC with constant agitation. Once the optical density at 600 nm reached
0.6-0.8, protein expression was induced via the addition of 500 μM isopropyl β-D-1thiogalactopyranoside (IPTG) and cultures were incubated for a further 4 h at 37 oC with
constant agitation. Bacteria were harvested at 5000 x g for 10 min at 4oC using an RC6
Sorval centrifuge (ThermoFischer Scientific, Waltham, USA).
Bacterial pellets were resuspended in lysis buffer (50 mM Tris, 100 mM NaCl, pH 8.0)
supplemented with 0.5% (v/v) Halt™ Protease and Phosphatase Inhibitor Cocktail
(ThermoFischer Scientific, Waltham, USA) at 3 mL/g. The solution was briefly vortexed
before the addition of 0.25 mg/mL lysozyme, and was then incubated on ice for 20 min.
Deoxycholic acid was added to a final concentration of 1.3 mg/mL and the solution was
incubated at 37oC for 30 min. DNAse I was then added to a final concentration of 3.0 µg/mL
prior to incubation at room temperature for 30 min with gentle rocking. Cellular debris were
then pelleted at 5000 x g for 10 min at room temperature using an Heraeus Megafuge
(ThermoFischer Scientific, Waltham, USA), before the supernatant was collected and further
clarified by ultracentrifugation at 100000 x g for 30 min at 4oC in an MTX150 centrifuge
(ThermoFischer Scientific, Waltham, USA). The supernatant was then collected and
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dithiothreitol (DTT; 10 mM), polyethylenimine (0.3% v/v) and EDTA (1 mM) were added.
The solution was stirred at room temperature for 30 min, before ultracentrifugation as above
to remove any precipitate. The supernatant was again collected, and at this stage recombinant
sHsp samples were stored at -20oC for purification.
Alternatively, for recombinant α-syn samples, additional proteins were precipitated via the
dropwise addition of HCl such that the pH of the solution reached 4.0. The solution was again
stirred at room temperature for 30 min, and then the precipitate was cleared via
ultracentrifugation as above. The pH of the clarified supernatant was then raised to 8.0 via the
dropwise addition of NaOH, and the solution was stored at -20oC for purification.
Extracted proteins were purified via anion exchange and subsequent size exclusion
chromatography (SEC) using an AKTA Prime Plus FPLC system (GE Healthcare, Uppsala,
Sweden) with an in-line UV detector to monitor the absorbance of eluted proteins at 280 nm
(A280nm). Thawed protein extracts were buffer exchanged into 20 mM Tris containing 1 mM
EDTA and 0.02% (w/v) Na Azide (pH 8.0). Protein samples were then passed over a HiPrep
DEAE FF 16/10 column (GE Healthcare, Uppsala, Sweden) and eluted by the addition of 20
mM Tris containing 1 mM EDTA, 0.02% (w/v) Na Azide and 2 M NaCl (pH 8.0) using a
stepwise gradient (5% and 10%; each for 2 column volumes) for αB-c, or continuous gradient
of 0 – 10% over 8 column volumes, or 0 – 25% over 4 column volumes, for Hsp27 and αsyn, respectively. Fractions containing the protein of interest were identified via sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in combination with the inline A280nm profile. Fractions were pooled and concentrated using an Amicon stirred cell
model 8200 (Merck Millipore, Billerica, U.S.A.) according to the manufacturer’s
instructions, with a 10 000 MWCO membrane. Protein samples were then passed over a
HiPrep 26/60 Sephacryl S-300 High Resolution column (GE Healthcare, Uppsala, Sweden)
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equilibrated with 50 mM sodium phosphate buffer (PB) containing 0.02% (w/v) Na Azide
(pH 7.4). Fractions containing the protein of interest were identified, pooled and concentrated
as above.
2.3.2 Quantification and storage
The purity of the resulting recombinant protein was confirmed via SDS-PAGE, and found to
be > 90% in all instances. The concentration was routinely determined using a NanoDrop
2000c spectrophotometer (ThermoFischer Scientific, Waltham, USA) and the appropriate
molar absorptivity value for the protein of interest. In particular, a molar absorptivity value of
0.44 M-1.cm-1 for α-syn (Narhi et al. 1999), 0.83 M-1.cm-1 for αB-c (Horwitz et al. 1998) and
1.65 M-1.cm-1 for Hsp27 (Hayes et al. 2009) were used. Protein samples were then aliquoted
and stored at -20oC.
2.4 SDS-PAGE
Proteins were routinely assessed for purity and molecular weight using SDS-PAGE as
previously reported (Laemmli 1970). Briefly, a resolving gel (15% (w/v) acrylamide/bis, 375
mM Tris (pH 8.8), 0.1% (w/v) SDS, 0.25% (v/v) tetramethylethylenediamine, 0.02% (w/v)
ammonium persulfate) was overlaid with a stacking gel (4% (w/v) acrylamide/bis, 330 mM
Tris (pH 6.8), 0.1% (w/v) SDS, 0.4% (v/v) tetramethylethylenediamine, 0.04% (w/v)
ammonium persulfate). Samples were diluted into an appropriate volume of 3-times or 6times loading buffer to give final concentrations of 0.5 M Tris-HCl (pH 8.8), 2% (w/v) SDS,
25% (w/v) glycerol, 0.01% (w/v) and bromophenol blue, 5% (v/v) β-mercaptoethanol. Prior
to loading, samples were heated at 95oC for 5 min before being spun at 20000 x g for 30 s at
room temperature in a benchtop centrifuge 5254 (Eppendorf, Hamburg, Germany). Samples
were electrophoresed at 150 V using a Mini-Protean 2 Cell system (Bio-Rad, Hercules, CA)
alongside Precision Plus Protein™ dual colour molecular weight standards (10-250 kDa)
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(Bio-Rad, Hercules, CA) until the dye front reached the bottom of the resolving gel. Gels
were then stained with Coomassie blue stain (0.1% (w/v) brilliant blue, 40% (v/v) methanol,
10% (v/v) glacial acetic acid) at room temperature overnight and destained using destaining
solution (40% (v/v) methanol, 10% (v/v) glacial acetic acid). Gels were imaged using a Gel
Logic 2200 Pro Imaging System (Carestream Health, Rochester, USA).
2.5 Immunoblotting
Following SDS-PAGE, proteins of interest were transferred onto Amersham HyBond-ECL
nitrocellulose membrane (GE Healthcare, Uppsala, Sweden) at 100 V for 1 h in ice-cold
transfer buffer (0.192 M glycine, 25 mM Tris, 20% (v/v) methanol, pH 8.6). The membrane
was blocked for 1 h at room temperature in Tris-buffered saline (TBS; 50 mM Tris and 150
mM NaCl, pH 7.5) containing 5% (w/v) skim milk powder (Woolworths, Bella Vista,
Australia), then incubated overnight at 4oC in TBS-Tween-20 (TBST; TBS containing 0.05%
(v/v) Tween-20) containing 5% (w/v) skim milk powder and the appropriate primary
antibody (diluted 1:5000). Blots were washed four times in TBST for 10 min with constant
agitation, then incubated at room temperature for 1 h in TBST containing 5% (w/v) skim milk
powder and the appropriate secondary antibody (diluted 1:5000). Blots were washed as
above, and then labelled proteins were detected using SuperSignal West Pico
Chemiluminescent

Substrate

or

SuperSignal

West

Dura

Extended

Duration

Chemiluminescent Substrate according to the manufacturer’s instructions (ThermoFischer
Scientific, Waltham, USA). The membrane was exposed to Amersham Hyperfilm ECL
chemiluminescence film (GE Healthcare, Uppsala, Sweden), or directly imaged using a Gel
Logic 2200 Pro Imaging System (Carestream Health, Rochester, NY, USA) or Amersham
Imager 600 (GE Healthcare, Uppsala, Sweden).
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2.6 Fluorescent labelling of recombinant proteins
Recombinant proteins of interest were fluorescently labelled using succinimidyl ester or
maleimide variants of CF488A or CF647 (Biotium, Hayward, USA), or AlexaFluor488
(AF488) or AlexaFluor647 (AF647; ThermoFischer Scientific, Waltham, USA) dyes
according to the manufacturer’s instructions. Briefly, samples intended for maleimide
labelling were pre-incubated with a 10-fold molar excess of tris(2-carboxyethyl)phosphine
(TCEP) for 30 min at room temperature. Samples were then loaded onto a pre-equilibrated
PD10 column (GE Healthcare, Uppsala, Sweden) and eluted with degassed phosphate
buffered saline (PBS; 2.7 mM KCl, 1.75 mM K2HPO4, 135 mM NaCl, 10 mM NaH2PO4,
pH 7.4). Fractions were collected (500 µL) and protein elution was monitored by determining
the absorbance of each fraction at 280 nm using a NanoDrop 2000c spectrophotometer
(ThermoFischer Scientific, Waltham, USA). Fractions containing protein were pooled and
dye conjugates were added in a 1.5 molar (succinimidyl ester) or 10 molar (maleimide)
excess relative to the protein concentration for labelling. Labelling reactions were incubated
overnight at 4oC with agitation. Labelled protein was then separated from unreacted dye
using a pre-equilibrated PD10 column as described above, using 50 mM phosphate buffer
(pH 7.4). Labelled proteins were stored at -20oC, or flash frozen in liquid N2 and stored at 80oC. The concentration and degree of labelling of each protein was calculated as per the
manufacturer’s instructions and found to be greater than 60% in all cases. In some instances,
protein labelling with the fluorophore was also confirmed via electrospray ionisation mass
spectrometry by Mr. Blajoice Jovchevski (University of Wollongong, Australia).
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2.7 Mammalian tissue culture
2.7.1 Passaging and plating
Mammalian cell lines (N2a and HEK293) were cultured in Dulbecco's Modified Eagle's
Medium/Ham's Nutrient Mixture F-12 (DMEM/F12; ThermoFischer Scientific, Waltham,
USA) supplemented with 10% (v/v) foetal bovine serum (FBS; Bovagen Biologicals, East
Keilor, Australia) and 2.5 mM L-glutamine (ThermoFischer Scientific, Waltham, USA). All
media was sterile filtered and warmed to 37oC for use. All tissue culture was performed
within a laminar flow biosafety cabinet, and cells were incubated in a Heracell 150i CO2
incubator (ThermoFischer Scientific, Waltham, USA) under 5% CO2/95% air at 37oC.
Cells were passaged once at 80% confluency or after a period of 72 h, and reseeded into fresh
CELLSTAR flasks or culture plates (both from Greiner Bio-one, Frickenhausen, Germany)
where required. Briefly, culture media was removed from the cells and replaced with a
sufficient volume of trypsin containing 0.05% (w/v) EDTA (ThermoFischer Scientific,
Waltham, USA) to cover the cells. After incubation at 37°C for 5 min, the flask was gently
tapped, if necessary, to encourage cells to dislodge. The flask was then washed with
DMEM/F12 containing 1% (v/v) FBS. For passaging purposes, 10% of the cells were
collected and harvested via centrifugation at 300 x g for 5 min at room temperature. The
supernatant was discarded and cells resuspended in the appropriate volume of culture
medium before being transferred to a fresh culture flask, such that the flask was seeded at 1015% of the original density. For plating purposes, the remaining lifted cells were collected
and harvested via centrifugation at 300 x g for 5 min at room temperature before being
resuspended in culture medium. A sample of the cell solution was combined 1:1 with trypanblue and the cell density counted using a Neubauer-improved counting chamber (Marienfeld
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Superior, Lauda-Königshofen, Germany). Cells were then diluted with culture medium and
seeded in the appropriate vessel at the desired cellular density.
2.7.2 Storage
Cell lines are maintained in liquid nitrogen for long term storage. To generate stocks for
storage, culture media was removed from cells at 80% confluency and replaced with a
sufficient volume of trypsin containing 0.05% (w/v) EDTA (ThermoFischer Scientific,
Waltham, USA) to cover the cells. After incubation at 37°C for 5 min, if necessary the flask
was gently tapped to encourage cells to dislodge, and the flask was then washed with
DMEM/F12 containing 1% (v/v) FBS. The cells were collected and harvested via
centrifugation at 300 x g for 5 min at room temperature before being resuspended in
DMEM/F12 supplemented with 50% (v/v) FBS and 10% (v/v) dimethyl sulfoxide (DMSO).
The solution was then aliquoted (1 mL) into sterile cryovials and placed in a pre-cooled
Nalgene Cryo 1°C “Mr. Frosty” Freezing Container (ThermoFischer Scientific, Waltham,
USA) containing isopropanol. Cells were stored at -80oC overnight before being transferred
to liquid nitrogen.
When removing stocks from liquid nitrogen for use, cells were thawed and immediately
added to a 10 fold excess of DMEM/F12 containing 10% (v/v) FBS. Cells were harvested via
centrifugation at 300 x g for 5 min at room temperature before being resuspended in culture
medium and transferred to a flask. After 24 h, the culture medium was discarded and replaced
with fresh media and the cells were allowed to reach 80% confluency before being passaged.
2.8 Data Analysis
All statistical analyses (unless otherwise stated) were performed using GraphPad Prism v 5
(GraphPad Software Inc., San Diego, USA).
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3.1 Introduction
The ability of sHsps such as B-c and Hsp27 to prevent the fibrillar formation of -syn in
vitro is well established (Rekas et al. 2004, Waudby et al. 2010, Bruinsma et al. 2011).
However, the mechanism by which sHsps achieve this inhibition and the fate of α-syn as a
result of this interaction remains to be definitively established. Inhibition may involve one or
more of the following mechanisms: (i) weak transient interactions with α-syn which prevent
it from associating into oligomeric nuclei, (ii) the formation of a stable complex between αsyn and the sHsps which, when cellular conditions permit, enable monomeric α-syn to be
released, or (iii) α-syn being induced to form amorphous aggregates rather than fibrils.
Importantly, given the α-synucleinopathies (and other diseases) are associated with protein
aggregation, it is clear that, under certain circumstances, aggregation-prone proteins can
evade the chaperone action of the sHsps. This failure of the sHsps to prevent aggregation is
often attributed to them being “overwhelmed” in the context of disease (Healy et al. 2013,
Leak 2014, Bakthisaran et al. 2015). However, specific factors that lead to sHsp chaperone
activity being overwhelmed are yet to be determined.
3.1.1 Experimental rationale
The ability of dyes such as ThT to bind to β-sheet structures (such as those found in α-syn
fibrils) has been used to monitor the kinetics of α-syn aggregation and provide a quantitative
measure of fibril formation. Assays incorporating ThT have long been used to assess the
activity of aggregation modifiers such as molecular chaperones, including the sHsps (Ecroyd
et al. 2007, Bruinsma et al. 2011, Jovcevski et al. 2015, Cox et al. 2016). Therefore, ThT
fluorescence was used as a way to evaluate the effect of sHsps on α-syn aggregation in platebased assays. In addition, the nature of the interaction between the archetypal sHsps, αB-c
and Hsp27, and monomeric α-syn was addressed in this chapter using analytical SEC and
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analytical ultracentrifugation (AUC). Analytical SEC is specialised for detecting stable, high
molecular mass complexes which would be expected from a holdase-type interaction between
the sHsps and α-syn. In contrast, AUC can distinguish between the formation of high
molecular mass complexes and transient interactions between two proteins.
Finally, the parameter(s) of α-syn aggregation that act to overwhelm the sHsps were
characterised. When evaluating sHsp chaperone activity, maintaining consistent buffer
conditions is crucial given the confounding effects changes in temperature and pH may have
on their oligomeric size and subunit exchange rate (Bova et al. 2000, Fu and Chang 2004,
Sun and MacRae 2005, Lelj-Garolla and Mauk 2006). Therefore, the kinetics of aggregation
was altered by two methods (concentration and mutation) which did not require the buffer
conditions to be altered.
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3.2 Methods
3.2.1

In vitro α-syn aggregation assays

Fibrillar aggregation of α-syn, in the absence or presence of sHsps, was monitored using a
ThT fluorescence assay via a previously described method (Ecroyd et al. 2007) with
adaptations. Briefly, α-syn was incubated at 300 µM in 50 mM phosphate buffer containing
100 mM NaCl (pH 7.4) and 0.01% sodium azide, unless otherwise indicated. Assays were
conducted in triplicate using clear 384 microwell plates (Greiner Bio-One, Frickenhausen,
Germany) with each well containing 30 µL of sample. Plates were incubated in a POLARstar
OPTIMA plate reader (BMG Labtechnologies, Melbourne, Australia) at 37oC, with the plate
sealed to prevent evaporation. The ThT fluorescence was measured using excitation and
emission filters of 440 nm and 490 nm, respectively. Readings were taken every 625 s for a
period of up to 60 h. Plates were subjected to linear shaking at 600 rpm for 540 s after each
reading.
At the end of each assay, data for the change in ThT over time were fitted with Boltzmann
sigmoidal curves. Data were only used when the R2 coefficient of determination was > 0.8.
Parameters from these fits were used to derive the length of the lag phase and rate of α-syn
aggregation using equations previously derived (Nielsen et al. 2001), with modification
(Figure 3.1). The equation of the Boltzmann curve is given as:

𝐹 = 𝐹𝑖 +

(𝐹𝑓 − 𝐹𝑖 )
1+𝑒

(𝑡50 −𝑡)
𝑘
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Figure 3.1: Schematic illustration of the Boltzmann sigmoidal curve used to describe the
increase in ThT fluorescence upon α-syn fibril formation. Fi corresponds to the initial fluorescence
value, Ff corresponds to the final fluorescence value, t50 refers to the time taken to reach half the
maximal fluorescence (Ft50), tlag is the lag time and k denotes the steepness of the curve.

The slope of the line at any point is:
(𝑡50 −𝑡)
(𝐹𝑓 − 𝐹𝑖 )
𝑘
×
𝑒
𝑑𝐹
𝑘
=
(𝑡50 −𝑡) 2
𝑑𝑡
(1 + 𝑒 𝑘 )

When t = t50 (i.e. the inflexion point, when the elongation rate is maximal):

𝑑𝐹
=
𝑑𝑡

(𝐹𝑓 − 𝐹𝑖 )
× 𝑒0
𝑘
(1 + 𝑒 0 )2

Therefore the rate of α-syn aggregation at t50 was calculated according to the equation:

𝑅𝑎𝑡𝑒𝑡50 =

(𝐹𝑓 − 𝐹𝑖 )
4 ×𝑘
(1)

where Fi corresponds to the initial fluorescence value, Ff corresponds to the final fluorescence
value, t50 refers to the time taken to reach half the maximal fluorescence, and k describes the
gradient of the curve.
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The lag phase (tlag) is when

{

(𝐹𝑓 − 𝐹𝑖 )
} × 𝑡50 + 𝑏 = 𝐹𝑖
4×𝑘
(2)

To solve for b, at t50 (i.e. the mid-point between Ff and Fi):

𝐹𝑡50 =

𝑏= {

(𝐹𝑓 − 𝐹𝑖 )
2

(𝐹𝑓 − 𝐹𝑖 )
(𝐹𝑓 − 𝐹𝑖 )
}− {
} × 𝑡50
2
4×𝑘

So substituting b into equation (2):

𝐹𝑖 = {

(𝐹𝑓 − 𝐹𝑖 )
(𝐹𝑓 − 𝐹𝑖 )
(𝐹𝑓 − 𝐹𝑖 )
} × 𝑡𝑙𝑎𝑔 + {
}− {
} × 𝑡50
4×𝑘
2
4×𝑘

Solving for tlag:
4 × 𝑘 × 𝐹𝑖 = {(𝐹𝑓 − 𝐹𝑖 ) × 𝑡𝑙𝑎𝑔 } + {2 × 𝑘 (𝐹𝑓 − 𝐹𝑖 )} − {(𝐹𝑓 − 𝐹𝑖 ) × 𝑡50 }
(𝐹𝑓 − 𝐹𝑖 ) × 𝑡𝑙𝑎𝑔 = 4 × 𝑘 × 𝐹𝑖 + {(𝐹𝑓 − 𝐹𝑖 ) × 𝑡50 } − {2 × 𝑘 (𝐹𝑓 − 𝐹𝑖 )}
Therefore, tlag is determined using the equation:

𝑡𝑙𝑎𝑔 =

4 × 𝑘 × 𝐹𝑖
+ 𝑡50 − {2 × 𝑘 }
(𝐹𝑓 − 𝐹𝑖 )
(3)
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The relative efficacy of the sHsps to inhibit α-syn fibril formation was determined by
calculating the protection provided by each sHsp at the conclusion of the assay, according to
the difference in maximum ThT fluorescence in the absence and presence of the chaperone
using the equation:

% 𝑃𝑟𝑜𝑡𝑒𝑐𝑡𝑖𝑜𝑛 =

∆𝐼 − ∆𝐼𝑐ℎ𝑎𝑝𝑒𝑟𝑜𝑛𝑒
∆𝐼 × 100
(4)

where I and Ichaperone correspond to the change in ThT fluorescence of α-syn in the absence
and presence of the sHsp respectively. In each case, samples were assayed in triplicate and
the percent protection is reported as a mean ± S.E.M of at least 3 independent (biological)
replicates.
3.2.2

Analytical size exclusion chromatography (SEC)

The nature of the interaction between the sHsps and α-syn was analysed via SEC of the
samples at the end of the aggregation assays. Samples containing 300 µM α-syn, in the
absence or presence of 300 µM αB-c or Hsp27, were collected immediately following
incubation and centrifuged at 14000 x g for 10 min at 4oC to remove any insoluble protein.
Supernatants were collected and loaded onto a Superose-6 size exclusion column (GE
Healthcare, Uppsala, Sweden), pre-equilibrated with 50 mM phosphate buffer containing 100
mM NaCl (pH 7.4) and 0.01% sodium azide, at a flow rate of 0.5 mL/min. Protein elution
was monitored using an in-line UV detector, and concentrations were determined using the
peak integration function of PrimeView v5.0 (GE Healthcare, Uppsala, Sweden), to monitor
any loss of protein following centrifugation. Eluate fractions (1 mL) were collected and
analysed via SDS-PAGE and immunoblotting. Representative results are presented from two
independent experiments from two separate aggregation assays.
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3.2.3

Analytical ultracentrifugation (AUC)

UV absorbance-detected AUC was performed as previously described (Binger et al. 2013).
Briefly, the maximum concentration was calculated for each protein such that the absorbance
at 230 or 280 nm was within the optimal detection range of the instrument. Samples (380 µL)
were prepared at room temperature and incubated for 1 h before being loaded into a 12 mm
double-sector epon-filled centrepiece, alongside the relevant reference solution (400 µL).
Samples were centrifuged in an XL-I analytical ultracentrifuge (Beckman Coulter, CA, USA)
at 50000 rpm, using either a Ti60 or Ti50 rotor, at 20oC. Radial absorbance scans were
collected at 230 nm or 280 nm at 6 min intervals with a radial step size of 0.003 cm for a total
of 10 h. Sedimentation velocity (SV) profiles were analysed with SEDFIT software using a
continuous c(s) distribution model and regularisation by maximum entropy. Using a
regularisation parameter of p=0.95 and 200 sedimentation coefficient increments, the data
were fitted to produce c(s) distributions. Weight-average sedimentation coefficients (Sav) of
each sample were then calculated by integration of the sedimentation distributions over the
given range. The buffer density (), buffer viscosity () and partial specific volume (̅ ) used
for analysis were estimated using SEDNTERP software (http://sednterp.unh.edu).
Fluorescence-detected AUC was performed as previously described (Binger et al. 2013),
using Hsp27-WT labelled with CF488A and unlabelled, monomeric α-syn. Briefly, samples
(350 µL) were prepared at room temperature and incubated for 1 h before being loaded into a
12 mm double-sector epon-filled centrepiece, and covered with 50 µL of FC-43
perfluorotributylamine (Scientific Instrument Services Inc., NJ, USA). Samples were
centrifuged in an XL-A analytical ultracentrifuge fitted with a fluorescence detection system
(FDS; Aviv Biomedical, NJ, USA) at 50 000 rpm using either a Ti60 or Ti50 rotor at 20 oC.
Excitation was at 488 nm and fluorescence above 505 nm was measured. Radial fluorescence
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scans were collected at 3 min intervals with a radial step size of 0.002 cm for a total of 5 h.
Sedimentation velocity profiles were analysed as described above, fitting time-independent
noise and according to a fixed sample meniscus position.
3.2.4

Bulk Förster Resonance Energy Transfer (FRET) analysis of sHsp

subunit exchange rate
Subunit exchange rates of the sHsps were determined by monitoring changes in Förster
Resonance Energy Transfer (FRET) between fluorescently labelled sHsp oligomers. Aliquots
of fluorescently labelled sHsp, composed of an equimolar mixture of CF488A- and CF647labelled protein, were prepared in PBS (pH 7.4) at concentrations ranging from 3 – 90 µM.
Samples were incubated at 37oC with shaking at 60 rpm using a VorTemp incubator (Labnet,
Edison, USA) for 1 h, to allow complete mixing of the two labelled populations (confirmed
by monitoring the quenching of donor fluorescence at 495 nm). The labelled sHsps were then
diluted 10-fold into a sample of unlabelled sHsp at an equivalent concentration so as to
maintain the overall concentration of the sHsp. The loss of FRET due to subunit exchange of
labelled sHsps with unlabelled sHsps was determined by the decrease in acceptor
fluorescence at 670 nm and monitored using a POLARstar Omega platereader (BMG
Labtechnologies, Melbourne, Australia). Experiments were performed in the absence or
presence of a 10-fold molar excess of α-synWT, in black polystyrene clear-bottom 384-well
plates (Greiner Bio-One, Frickenhausen, Germany). Readings were taken every 120 s over a
period of 4 h, with linear shaking at 600 rpm for 90 s after each cycle. The rate constant was
determined by fitting the data to a one-phase exponential decay curve. The rate of subunit
exchange was derived from the equation:
𝑌 = (𝑌0 − 𝑌𝑡 ) × 𝑒 −𝑘𝑡 + 𝑌𝑡
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where k is defined as the rate constant of the reaction, and Y0 and Yt correspond to the
fluorescence intensity at time = 0 and t respectively.
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3.3

Results
3.3.1

sHsp inhibition of α-syn aggregation is concentration dependent

The amyloid fibrillar aggregation of α-synWT has been well characterised in vitro (Bruinsma
et al. 2011). As expected, there was no increase in ThT fluorescence when Hsp27, bovine
serum albumin (BSA) or buffer were incubated alone. However, incubation of α-syn under
these experimental conditions resulted in an increase in ThT fluorescence over time
indicative of fibril formation (Figure 3.2A). This increase in ThT fluorescence was inhibited
by the addition of Hsp27 at a 1:1 (α-syn:Hsp27) molar ratio, but was not inhibited by the
presence of the non-chaperone control protein BSA. The change in ThT associated with αsyn aggregation can be fitted by a Boltzman sigmoidal curve. This reveals that when α-syn
was incubated alone there was a lag phase of 15  3 h, and the maximum ThT fluorescence
occurred after 36  3 h (Figure 3.2B). Addition of the sHsps αB-c and Hsp27 prevented the
fibrillar aggregation of α-syn in a concentration-dependent manner (Figure 3.2B). At a 1:10
molar ratio (sHsp:α-syn), αB-c and Hsp27 inhibited the change in ThT fluorescence
associated with α-syn fibril formation by 65 ± 4% and 74 ± 5% respectively (Figure 3.2C).
3.3.2 In preventing the fibrillar aggregation of α-syn, the sHsps do not form
stable, high molecular mass sHsp-target protein complexes
To investigate whether the sHsps inhibit the fibrillar aggregation of α-syn via the formation
of high molecular mass complexes, as has been reported for the interaction with amorphously
aggregating proteins (Lee et al. 1997, Haslbeck et al. 1999, Kulig and Ecroyd 2012), the
samples containing a 1:1 molar ratio of the sHsp and α-syn (i.e. a concentration
corresponding to near complete inhibition of fibril formation of α-syn by the sHsps, see
Figure 3.2B) were collected after the aggregation assay for subsequent analysis by size
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Figure 3.2: sHsps inhibit α-syn aggregation in a concentration-dependent manner. Recombinant
α-syn was incubated at 300 μM in 50 mM sodium phosphate buffer with 100 mM NaCl and 0.01%
NaN3 (pH 7.4), in the absence or presence of sHsps or the non-chaperone control protein BSA. Fibril
formation was monitored by the change in ThT fluorescence at 490 nm over time. (A) A
representative trace of 2 independent experiments is shown for α-syn, in the absence or presence of
Hsp27 or BSA at a 1:1 molar ratio (Hsp27/BSA:α-syn). Hsp27, BSA and buffer alone samples are
also included for comparison, and the data for these overlay one another along the x-axis due to them
showing no change in fluorescence over the course of the assay. (B) A representative trace of 4
independent experiments is shown for α-syn in the presence of various ratios of αB-cWT. Data were
fitted with a Boltzmann sigmoidal curve. (C) Values obtained for the maximum change in ThT
fluorescence from these fits was used to determine the percent protection afforded by WT αB-c or
Hsp27 at a range of molar ratios. Results are presented as mean ± S.E.M (n ≥ 4).

exclusion chromatography (Figure 3.3A). Prior to incubation, in the absence of sHsp, α-syn
eluted from the column in a peak centred at 17 mL. Following incubation of α-syn in the
absence of sHsp, there was very little soluble α-syn present in the sample, consistent with its
aggregation into fibrils. When present alone in solution, αB-c eluted as a well-resolved peak
at 13 mL, consistent with it being a large polydisperse oligomer of average mass ~650 kDa
under these solution conditions (Haley et al. 1998, Horwitz 2005). In the sample containing
both αB-c and α-syn, there was no detectable shift in the elution volume or size of the
individual peaks corresponding to monomeric α-syn and oligomeric αB-c, or the appearance
of any additional peaks. Thus, there was no significant difference in the amount of soluble
oligomeric αB-c and monomeric α-syn in this sample compared to when each of these (nonaggregated) proteins were analysed alone. The presence of only αB-c in the peak eluting at
13 mL and only α-syn in the peak eluting at 17 mL in this sample was confirmed by
immunoblotting (Figure 3.3C) (the detectable limits of the immunoblotting procedure used in
this work was ~30 nM for each protein). Even when a crosslinker, bis[sulfosuccinimydyl]
(with a spacer arm length of 8 atoms or 11.4 Å), was added to the sample following
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incubation and prior to SEC, there was no evidence of co-elution of αB-c and α-syn from the
column (data not shown). Thus, under the conditions used in this work, there was no evidence
of a stable high molecular mass complex formed between αB-c and aggregation-prone α-syn.
Similar results were obtained for samples containing Hsp27 and α-syn (Figure 3.3B, D).

Figure 3.3: sHsps prevent α-syn aggregation but, in doing so, do not form a stable high
molecular mass sHsp-target protein complex. (A, B) Size-exclusion chromatograms of soluble αsyn (300 μM), αB-c (300 μM), Hsp27 (300 μM) or post-aggregation samples of soluble α-syn (300
μM) in the absence and presence of 1:1 molar ratio of αB-c or Hsp27. (C, D) Immunoblot analysis of
the eluate fractions collected from the size-exclusion column after loading with the sample from A or
C containing α-syn and αB-c or Hsp27. Aliquots from every fraction (1 mL) collected between 8–20
mL were loaded on to a SDS/PAGE gel, transferred to nitrocellulose membrane and blotted with an
anti-αB-c, anti-Hsp27 or anti-α-syn antibody. Results shown are representative of two independent
experiments.

To further investigate the interaction between these sHsps and aggregation-prone α-syn, AUC
was employed. Due to the propensity of the WT sHsps to form large, high molecular mass,
polydisperse oligomers in solution (see Figure 3.3A), variant forms of these sHsps that either
mimic phosphorylation (Hsp273D) or consist of only the core -crystallin domain (αB-ccore)
were selected for use in these experiments. This is because these variants exist predominately
as either monomers or dimers (Hochberg et al. 2014, Jovcevski et al. 2015) and therefore
their molecular masses more closely match that of α-syn (an important factor in these
absorbance-based AUC experiments as it ensures that both species sediment at similar rates).
63

Chapter 3: sHsps inhibit the aggregation of monomeric α-synuclein
The ability of these variant forms to inhibit the fibrillar aggregation of α-syn was first
established (Figure 3.4A). The protective capacity of these variants, as well as the αB-c3D and
Hsp27core variants (see Appendix I), was seen to be similar to that of the WT proteins.
Notably, the ability of the core domains (i.e. αB-ccore and Hsp27core) to inhibit α-syn
aggregation indicates that the ability of the sHsps to prevent α-syn fibril formation is inherent
to the α-crystallin domain, and does not require the N- or C-terminal regions.
Sedimentation velocity profiles for α-syn alone, and in the presence of either Hsp273D or αBccore are shown in Figure 3.4. These profiles were fitted using a c(s) model which considers
both sedimentation and diffusion to determine sedimentation coefficients for the species in
solution (Schuck 2000). Single peaks calculated for α-syn (Figure 3.4B), αB-ccore (Figure
3.4C) and Hsp273D (Figure 3.4D) correspond to sedimentation coefficients of approximately
1.1, 1.7 and 2.7 S, respectively. Fitting the SV profile resulting from co-incubation of α-syn
with αB-ccore (Figure 3.4E) results in a bimodal distribution, with peak positions of
approximately 1.2 and 1.9 S (Figure 3.4F). The small shift of the peak positions may suggest
that these proteins interact transiently. Comparison of the predicted Sav for the two
components with the Sav calculated for the mixture shows a small shift from 1.37 S to 1.40 S.
Similarly, co-incubation of α-syn with Hsp273D (Figure 3.4G) results in a bimodal
distribution, with peaks corresponding to sedimentation coefficients of approximately 1.1 and
2.7 S (Figure 3.4H). In contrast to the mixture of α-syn with αB-ccore, the peak positions for
α-syn and Hsp273D do not change significantly. The absence of additional peaks confirms the
lack of a detectable stable complex between α-syn and Hsp273D.
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Figure 3.4: Analysis of the interaction between sHsps and aggregation-prone α-syn by
absorbance-based AUC. (A) Recombinant α-syn was incubated at 300 μM in 50 mM sodium
phosphate buffer with 100 mM NaCl and 0.01% NaN3 (pH 7.4), in the absence or presence of sHsps
variants (30 µM). Fibril formation was monitored by the change in ThT fluorescence at 490 nm over
time, and data were fitted with a Boltzmann sigmoidal curve. Sedimentation velocity analysis of 5 µM
(B) α-syn, (C) αB-ccore or (D) Hsp273D. Data collected at 60 min intervals is presented, overlaid with
theoretical fits to the c(s) model generated by SEDFIT. Sedimentation velocity profiles of α-syn coincubated with (E) αB-ccore or (G) Hsp273D are also shown, along with c(s) distributions for these
profiles (F and H respectively).
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The use of fluorescently labelled protein allows specific detection of one component of a
complex mixture using fluorescence-detected AUC. As such, CF488A-labelled Hsp27WT
was used in fluorescence-based AUC experiments to obtain SV profiles with a range of α-syn
concentrations (Figure 3.5). As above, these profiles were fitted using the c(s) model and the
resulting distribution had three maxima (Figure 3.5B). The shoulder centred at 0.9 S results
from non-sedimenting fluorescence, and is attributed to residual free CF488A dye in solution
from the labelling process. The other two main peaks, centred at approximately 2.4 and 10.5
S, reflect the equilibrium characteristic of Hsp27WT in which smaller species (most likely
predominately dimers) dissociate from polydisperse oligomers in order to provide chaperoneactive subunits (Van Montfort et al. 2002). Importantly, with increasing unlabelled α-syn
concentration, there is no concentration-dependent increase in the Sav of Hsp27 that would
otherwise be indicative of a stable, high molecular mass complex being formed between
Hsp27 and α-syn. Rather, the Sav decreases as the concentration of α-syn increases (Figure
3.5C), indicating that the average size of Hsp27 species in solution decreases with increasing
amounts of α-syn. This trend is supported by a reduction in the signal at 10.5 S and an
increase in the signal at 2.4 S with increasing (unlabelled) α-syn concentration. Together,
these data suggest that the presence of aggregation-prone α-syn causes the dissociation of
Hsp27 polydisperse oligomers in a concentration-dependent manner.

Figure 3.5: Aggregation-prone α-syn induces the dissociation of oligomeric Hsp27. Sedimentation
velocity analysis of 0.5 µM CF488-labelled Hsp27 in the absence or presence of increasing
concentrations of α-syn (0 – 50 µM). (A) Radial scans are displayed for the highest α-syn
concentration overlaid with theoretical fits to the c(s) model generated by SEDFIT. Data are collected
at 60 min intervals is presented. (B) c(s) distributions for each profile are shown, and (C) the Sav was
calculated via integration from 1 - 25 S for each concentration of α-syn. Data were then fitted with a
linear regression model.
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3.3.3 The ability of sHsps to prevent the aggregation of α-syn is dependent on
the kinetics of the aggregation process
Despite the proven ability of the sHsps to prevent α-syn aggregation in vitro, the
mechanism(s) by which aggregation-prone α-syn may ‘overwhelm’ sHsps, and result in the
formation of disease-associated amyloid fibrils, remain unknown. To determine whether the
rate at which α-syn aggregates affects the ability of the sHsps to prevent fibril formation, two
methods were used to alter the kinetics of α-syn’s aggregation, both of which avoid the
confounding effect a change in solution conditions (e.g. pH, temperature) may have on the
chaperone activity of the sHsps (Bova et al. 2000, Fu and Chang 2004, Sun and MacRae
2005, Lelj-Garolla and Mauk 2006). First, we exploited the nucleation-dependent mechanism
of amyloid fibril formation of α-syn, whereby an increase in the concentration of
aggregation-prone monomeric protein increases the rate of aggregation (Wood et al. 1999).
Since the dissociation of small chaperone-active species from larger polydisperse oligomers
is proposed to be a key component of the chaperone activity of the sHsps (Aquilina et al.
2004, Ecroyd et al. 2007, Benesch et al. 2008), we first determined the rate of sHsp subunit
exchange over the sHsp concentration range to be used in these experiments (i.e. 3 – 90 µM)
using FRET. During subunit exchange, mixing of labelled and unlabelled sHsp subunits
resulted in an exponential decrease in the emission fluorescence intensity of the acceptor,
which can be used to calculate the rate of subunit exchange (Figure 3.6A). Over the
concentration range used in this work, the rate of subunit exchange of αB-c reached a
maximum at ~30 µM (Figure 3.6B). Importantly, this rate was not significantly affected by
the presence of α-syn (Figure 3.6B). Thus, in the samples containing 300 – 750 µM α-syn,
the rate of subunit exchange of αB-c is constant. In contrast to αB-c, the oligomeric state of
Hsp27 (Jovcevski et al. 2015) and its subunit exchange rate (Figure 3.6C) are both
significantly affected by concentration. Therefore, Hsp27 was unsuitable for use in these
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Figure 3.6: The ability of αB-c to inhibit the fibrillar aggregation of α-syn is dependent on the
kinetics of aggregation. (A) Fluorescently labelled αB-c was incubated for 1 h at 37oC in PBS (pH
7.4) at concentrations ranging from 3 – 90 µM, consisting of an equimolar mixture of fluorescently
labelled protein capable of FRET. Samples were diluted 10-fold into unlabelled αB-c, in the absence
or presence of α-syn at a 1:10 (αB-c:α-syn) molar ratio, and the loss of fluorescence in the acceptor
fluorescence channel was used to calculate (B) the rate of subunit exchange in the absence and
presence of α-syn. (C) The rate of subunit exchange was similarly calculated for Hsp27, in the
absence and presence of α-syn. (D) Recombinant A53T α-syn was incubated at concentrations
ranging from 150 – 750 μM in 50 mM phosphate buffer containing 100 mM NaCl and 0.01% NaN3
(pH 7.4), in the presence or absence of a 1:10 molar ratio of αB-c. Samples were incubated at 37oC for
60 h and aggregation was monitored via the change in ThT fluorescence at 490nm. (A) A
representative plot is shown for α-syn in the absence of αB-c with Boltzmann-sigmoidal curves fitted
to the data. Values obtained from A were used to calculate the lag phase, elongation rate and plateau
phase for each α-syn concentration. The percent protection afforded by αB-c when present in the
sample was calculated and correlated with the (B) duration of the lag phase and (C) rate of elongation.
Symbols represent the calculated parameters from each of three independent repeats, with each point
corresponding to values calculated from a fit of triplicate samples and shaded according to the
concentration of α-syn as indicated in panel A. Data in B, E and F were fitted with non-linear
regression analysis, while data in C were fitted with linear regression analysis, and the R 2 coefficients
of determination are shown.

experiments due to these confounding effects. Thus, the disease-associated A53T variant of
α-syn was incubated at concentrations from 150 – 750 µM in the absence and presence of
αB-c (Figure 3.6D). In the absence of the chaperone, increasing the concentration of α-syn
led to an increase in the rate and maximum ThT fluorescence associated with α-synA53T
fibril formation, and a decrease in the lag phase (from 9 ± 2 h to 3 ± 1 h over this
concentration range). When αB-c was present, such that the molar ratio of α-syn:αB-c
remained constant (i.e. 1:10 αB-c:α-syn), the ability of αB-c to inhibit α-syn fibril formation
was dependent on the kinetics of the aggregation process (Figure 3.6E-F). Thus, when the
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kinetics of α-syn aggregation were relatively slow (i.e. longer lag phase and slower rate of
aggregation), αB-c was a more effective inhibitor of aggregation. When the kinetics of
aggregation increased (i.e. shorter lag phase and faster rate of aggregation), αB-c was a less
effective chaperone, only decreasing the amount of aggregation of α-syn by ~20%.
The second method employed to alter the aggregation kinetics of α-syn aggregation was the
use of disease-related mutants which aggregate at different rates (Bruinsma et al. 2011).
Recombinant α-syn mutant proteins were incubated at 300 µM in the absence or presence of
either αB-c or Hsp27 (1:10 molar ratio, sHsp:α-syn). As expected, each of the mutant
proteins displayed different aggregation kinetics, with α-synA30P having a similar lag phase,
elongation rate and maximal fibril formation to that of α-synWT (Figure 3.7A). In contrast,
α-synA53T had the shortest lag phase (3  1 h), slowest elongation rate and lowest maximum
increase in ThT fluorescence. The α-synE46K variant was characterised by a slow rate of
elongation, high maximal ThT fluorescence, and longest lag phase (42  9 h) of any of the αsyn variants tested. Whilst both αB-c and Hsp27 were able to inhibit the aggregation of the αsyn proteins (Figure 3.7A), their ability to do so was dependent upon the isoform of α-syn.
Both chaperones were least effective at inhibiting the aggregation of α-synA53T, which
aggregated the fastest (i.e. shortest lag phase), whereas they were most effective at inhibiting
α-synE46K, which aggregated the slowest (i.e. longest lag phase) (Figure 3.7B and C).
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Figure 3.7: The ability of the sHsps αB-c and Hsp27 to prevent the aggregation of diseaseassociated mutant forms of α-syn. Recombinant WT or disease-related mutant forms of α-syn
(A30P, A53T or E46K) were incubated at 300 μM in 50 mM phosphate buffer containing 100 mM
NaCl and 0.01% NaN3 (pH 7.4), in the presence or absence of 30 μM αB-c or Hsp27. Samples were
incubated at 37oC for 60 h and aggregation was monitored via the change in ThT fluorescence at 490
nm. (A) Representative plots of the four independent repeats, each consisting of triplicate samples, are
shown for each of the α-syn proteins, including Boltzmann-sigmoidal curves fitted to the data. Values
obtained from these fits were used to calculate the lag phase for each protein, which was then
correlated with the percent protection when (B) αB-c or (C) Hsp27 was present in the sample. Data
shown are the results of four independent repeats, with each point corresponding to values calculated
from a fit of triplicate samples. Non-linear regression analysis of the correlation between the lag phase
and the percent protection was then performed.

70

Chapter 3: sHsps inhibit the aggregation of monomeric α-synuclein
3.4 Discussion
The sHsps play a critical role in maintaining cellular proteostasis by preventing protein
aggregation associated with disease. Here, the sHsps αB-c and Hsp27 are confirmed as potent
inhibitors of α-syn fibril formation in vitro (Rekas et al. 2004, Wang et al. 2008, Aquilina et
al. 2013). The phosphomimicking variants of αB-c and Hsp27 (i.e. αB-c3D and Hsp273D)
were also effective chaperones at inhibiting α-syn fibril formation, adding to the growing
debate surrounding the effect of phosphorylation on chaperone activity (Bakthisaran et al.
2016). Notably, the αB-ccore and Hsp27core isoforms inhibited the aggregation of α-syn with
similar efficacy to the WT (full length) protein, demonstrating that the sites required to
inhibit α-syn aggregation are present in the core domain of these sHsps. The finding that the
core domain is sufficient to prevent α-syn aggregation is consistent with previous studies
showing that this region is capable of preventing other target proteins from forming
amorphous or fibrillar aggregates (Hochberg et al. 2014, Mainz 2015).
Although the ability of the sHsps to inhibit the amyloid fibrillar aggregation of a range of
target proteins in vitro is well established, the mechanism by which they do so is not clearly
defined and may be dependent on the target protein (Hatters et al. 2001, Raman et al. 2005,
Wilhelmus et al. 2006, Kulig and Ecroyd 2012). The molecular mechanism by which αB-c
and Hsp27 interact with α-syn to prevent its aggregation was therefore characterised by
several techniques. The results presented here demonstrate that both Hsp27 and αB-c increase
the lag phase of α-syn aggregation and inhibit the elongation phase, suggesting that they
primarily act through stabilising aggregation-prone monomeric α-syn to prevent it forming
fibrils. However, a high molecular mass complex between α-syn and αB-c or Hsp27 was
unable to be detected under the experimental conditions used in this work. Thus, in the
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absence of any evidence of a stable interaction, it is inferred that these proteins interact
transiently and this acts to prevent α-syn aggregation.
Transient interactions between the sHsps and α-syn are difficult to detect. Small shifts in the
c(s) distributions and calculated Sav for the α-syn/αB-ccore mixture may suggest a transiently
interacting, rapidly exchanging system. That these shifts were not observed for Hsp273D does
not rule out that a transient interaction occurs between α-syn and Hsp273D. Rather, it indicates
that this interaction was below the detection limit for these experimental conditions. This may
be due to differences in the binding kinetics or the amount of α-syn interacting with Hsp273D
compared to αB-ccore. If the fraction of species in this interacting population is too small, or if
the interaction occurs too fast, the interaction may not be resolved in the sedimentation
experiment (Lebowitz et al. 2002, Balbo and Schuck 2005, Howlett et al. 2006). Transient
interactions between αB-c and α-syn (and also of αB-c with other fibril-forming target
proteins) are also apparent from NMR spectra acquired on mixtures of these proteins due to
general broadening of spectra of the target protein with no indication of specific binding
site(s) (Rekas et al. 2004, Rekas et al. 2007, Robertson et al. 2010, Esposito et al. 2013). It is
therefore concluded that these sHsps prevent α-syn aggregation via transient interactions in a
similar way as has been previously described for apoC-II (Hatters et al. 2001) and reduced
and carboxymethylated α-lactalbumin (α-lac) (Kulig and Ecroyd 2012). In doing so, the
manner by which these sHsps act as chaperones to prevent α-syn aggregation is not through a
‘holdase’ mechanism, as has been well characterised for amorphously aggregating target
proteins under stress conditions (Lee et al. 1997, Haslbeck et al. 1999). Instead, these data
support a model in which sHsps can act as protein stabilisers, interacting transiently with
relatively ordered protein intermediates that have entered off-folding pathways, a process that
facilitates them re-entering the on-folding pathway (Jakob et al. 1993). Considering the
cellular implications of this type of interaction, a transient interaction mechanism is
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favourable as it does not deplete the pool of sHsps available to interact with aggregationprone proteins in the cells. In contrast, a holdase-type chaperone mechanism, in which stable
high molecular mass complexes are formed, likely occurs with more disordered
intermediates. These intermediates commonly expose higher degrees of hydrophobicity on
their surface prior to undergoing aggregation, as occurs under significant stress conditions
with the formation of amorphous aggregates (Kulig and Ecroyd 2012).
Importantly, it is unclear at this stage whether the interaction between the sHsps and α-syn
impacts the conformation of aggregation-prone monomeric α-syn. However, previous studies
have demonstrated that depletion of αB-c from aggregation-inducing conditions containing
amyloidogenic substrate can allow aggregation to proceed (Kulig and Ecroyd 2012). This
implies that transient interactions between aggregation-prone species and sHsps may not
significantly alter the conformation or aggregation propensity of the target protein.
Previous work has extensively investigated the interaction of αB-c with a variety of
amorphously aggregating target proteins under conditions of elevated temperature, reductive
stress or chemical stress. As a result of these studies, it is apparent that there are similarities
between the mechanisms of sHsp chaperone interaction with amorphous and fibrillar
aggregating target proteins. As observed here with fibril-forming α-syn, sHsps are more
efficient chaperones when interacting with slowly (amorphously) aggregating target proteins
(Lindner et al. 2001, Carver et al. 2002). They also interact with target proteins early along
their aggregation pathway, i.e. monomeric forms that are in a disordered, intermediate state
(Lindner et al. 2001, Carver et al. 2002). Dynamic, transient interactions between the target
protein and the sHsp are also crucial factors in determining chaperone efficacy with target
proteins (Devlin et al. 2003).
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Given that both αB-c and Hsp27 are highly effective molecular chaperones at inhibiting αsyn fibril formation in vitro, the question remains as to how α-syn intermediates escape the
sHsps to form fibrils and plaques in the context of the α-synucleinopathies? A key factor
explored in this chapter was whether the rate of aggregation has a significant effect on the
ability of these chaperones to prevent aggregation. Similar to the reported effect of metals
(Uversky et al. 2002), pesticides , membrane lipids (Lee et al. 2002) and molecular crowding
(Uversky et al. 2002, Munishkina et al. 2004), increases in the initial monomer concentration
of α-syn promotes nucleation during the rate-limiting step, increasing the kinetics of
aggregation (Shtilerman et al. 2002, Uversky 2002, Munishkina et al. 2004, Uversky 2007).
Furthermore, the three most studied disease-related mutations in α-syn results in markedly
different aggregation kinetics (Bruinsma et al. 2011), which was also observed in this study.
Increases in α-syn monomer concentration and disease-related mutants of α-syn were
therefore exploited in order to alter the kinetics of α-syn’s fibrillar aggregation. In both cases,
increasing the rate of α-syn aggregation led to a decrease in the chaperone ability of αB-c and
Hsp27 to prevent fibril formation. In particular, there was a marked correlation between the
efficacy of the chaperone and the lag phase of aggregation, i.e. the longer the time taken to
form nuclei, the more efficacious the chaperones were in preventing aggregation. These
results also support previous work in which the rate of α-syn fibril formation was increased
by adding the inert crowding agent dextran (Rekas et al. 2004). Under these conditions αB-c
was a much poorer chaperone (Rekas et al. 2004). However, the presence of a crowding agent
also reduces the rate of subunit exchange of αA-c (HSPB4) (Ghahghaei et al. 2007), which
may have contributed to the decrease in αB-c’s chaperone efficacy in this case.
The effect of aggregation kinetics on the ability of sHsps to prevent fibril formation is
significant given the association of mutations and duplication or triplication of the SCNA
gene with early onset PD (Polymeropoulos et al. 1997, Baba et al. 1998, Kruger et al. 1998,
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Campbell et al. 2001, Zarranz et al. 2004). Moreover, the link between increased aggregation
rate and a decrease in chaperone efficacy provides a potential mechanism for aggregationprone α-syn overwhelming the chaperone capability of the sHsps. While fluorescence-based
AUC suggested that the presence of aggregation-prone α-syn causes the dissociation of
Hsp27 oligomers, this technique provides a measure of the oligomeric distribution at
equilibrium. The real-time availability of chaperone-active subunits, through their
dissociation from large polydisperse oligomers that are able to interact with aggregationprone proteins, is governed by the subunit exchange rate (Vos et al. 2008). The rate of
subunit exchange for αB-c increased with concentration up to ~30 µM, after which it
remained constant, which supports the notion that subunit exchange is a result of dissociation
from sHsp oligomers, as opposed to oligomeric collisions, similar to that demonstrated for
αA-c (HSPB4) (Bova et al. 2000). Moreover, factors that increase the rate of α-syn
aggregation in cells (such as mutation, gene multiplication or macromolecular crowding) are
likely to overwhelm the protective capacity of the sHsps due to an insufficient supply of
chaperone-active subunits capable of interacting with the aggregation-prone α-syn monomer.
Such a mechanism is also consistent with the dissociated subunits of sHsps being the
chaperone-active species in cells.
The results presented here contribute to a greater understanding of the molecular mechanisms
by which sHsps interact with monomeric disease-related target proteins to prevent their
aggregation. Importantly, this provides further support for the reclassification of the sHsps as
protein stabilisers rather than holdase chaperones since the latter does not fully describe the
manner by which they can interact with aggregation-prone proteins (Kulig and Ecroyd 2012).
Thus, although the ability to form complexes with destabilised, particularly amorphously
aggregating, proteins is a key element of their chaperone activity (Arrigo et al. 2007), this
work adds to a growing body of evidence highlighting that this is not the only mechanism by
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which sHsps inhibit protein aggregation (Hatters et al. 2001, Rekas et al. 2004, Robertson et
al. 2010, Bruinsma et al. 2011, Kulig and Ecroyd 2012). Furthermore, the rate of aggregation
is highlighted as a significant factor that governs the relative ability of αB-c and Hsp27 to
prevent α-syn fibrillar aggregation. This provides a potential rationale for how sHsp
chaperone activity is ‘overwhelmed’ in the context of diseases associated with protein
aggregation, i.e. factors that increase the rate at which aggregation occurs also compromise
the ability of sHsps to prevent it.
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4.1

Introduction
4.1.1 sHsps interact with aggregation intermediates

Many investigations of sHsp chaperone activity have focussed on their interaction with
aggregation-prone monomers. The work presented in Chapter 3 aimed to characterise the
interaction of the sHsps, αB-c and Hsp27, with monomeric α-syn. This required the addition
of chaperone prior to aggregation commencing, in a similar manner to previous studies
examining the ability of sHsps to prevent aggregation (Horwitz 1992, Rekas et al. 2004,
Ecroyd et al. 2007, Bruinsma et al. 2011). However, little is known about the potential for
sHsps to interact with species formed during the aggregation of α-syn. Recently, the
interaction of sHsps with preformed amyloid fibrils has been investigated; it has been
reported that αB-c can bind along the length of amyloid fibrils formed by α-syn (Waudby et
al. 2010), Aβ (Shammas et al. 2011) or apoC-II (Binger et al. 2013) with moderate (µM)
affinity.
Addition of monomeric units to fibril ends occurs during the elongation phase of aggregation.
In addition, sites of exposed hydrophobicity along the face of the fibril have been identified
as possible locations for secondary nucleation (via surface-templated nucleation or
fragmentation), leading to rapid fibril growth. These secondary nucleation processes can
dominate the overall kinetics of aggregation once fibrils have formed (Ruschak and Miranker
2007, Knowles et al. 2009, Cohen et al. 2011). Interaction of the sHsps with amyloid
oligomers or fibrils may contribute to the ability of sHsps to inhibit further aggregation, by
competing with monomeric units for access to fibril ends or occluding sites of potential
secondary nucleation (Waudby et al. 2010). These mechanisms may complement the
interaction of the sHsps with monomeric α-syn. The association of small amyloid aggregates
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with cytotoxicity highlights the importance of considering them as potential targets of the
sHsps.
4.1.2 Single molecule techniques
Traditional techniques for the study of protein aggregation, such as the ThT assays used in
Chapter 3, rely on triggering aggregation in a population of molecules and monitoring the
ensemble average of the population. These techniques have great utility in evaluating the
effect of aggregation modulators, such as chaperones, on the process of aggregation.
However, a significant limitation of such bulk techniques is the inability of these methods to
detect short-lived or rare species that may be present due to ensemble averaging over the
population of molecules. Given intermediates of α-syn aggregation (oligomers) typically
comprise a small fraction of the total protein concentration, traditional techniques are illsuited to detect and characterise them (Horrocks et al. 2015). Single molecule analyses have
thus been employed to study both oligomers and fibrils formed during protein aggregation, as
these methods allow detection, characterisation and direct observation of rare and/or shortlived species, as well as their potential interactions with the sHsps, that are otherwise
inaccessible to bulk analyses (Horrocks et al. 2016).
The two most common single molecule experimental setups are confocal microscopy and
TIRF microscopy. Confocal microscopy is routinely used to detect molecules as they diffuse
(or are flowed) one-by-one through the confocal volume, and thus, with regards to protein
aggregation, is ideally suited to detecting and characterising rare oligomeric intermediates
formed during aggregation (Horrocks et al. 2011, Cremades et al. 2012). Flowing molecules
through the confocal volume greatly reduces the acquisition time required to detect rare
species, and limits the heterogeneous paths taken by molecules through the confocal volume,
such that experiments can be conducted on time-frames relevant to aggregation (min)
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(Horrocks et al. 2011). In addition, application of FRET in this context enables some
structural characterisation of oligomers, with a resolution of approximately 8 nm (Cornish
and Ha 2007). This technique was previously employed to demonstrate that α-syn oligomers
undergo a structural reorganisation from amorphous oligomers possessing low FRET
efficiencies to more ordered, β-sheet rich oligomers possessing high FRET efficiencies
(Cremades et al. 2012).
In contrast to confocal microscopy, TIRF microscopy involves imaging entire fields of view
simultaneously (Cornish and Ha 2007). Combining amyloid-specific dyes, such as ThT, with
this technique (in a method known as SAVE imaging (Horrocks et al. 2016)), enables
oligomeric and fibrillar structures to be distinguished from their monomeric counterparts
without the need for covalent attachment of a fluorophore (Horrocks et al. 2016). In addition,
the newly developed technique of sPAINT enables simultaneous characterisation of the
spatial position and emission spectrum of single dye molecules (Bongiovanni et al. 2016).
Using nile red, a phenoxazone-based dye whose fluorescence emission wavelength is known
to be sensitive to the hydrophobicity of its environment (Greenspan and Fowler 1985)
(Bongiovanni et al. 2016), it is possible to characterise the hydrophobicity of regions along
the surface of mature fibrils at superresolution (Bongiovanni et al. 2016).
4.1.3 Experimental rationale
Whilst the work described in Chapter 3 established that the sHsps, Hsp27 and αB-c, interact
transiently with monomeric α-syn to prevent its aggregation, little is known about the
interaction of sHsps with other species formed during the aggregation of α-syn. Although αBc has been shown to bind fibrillar α-syn (Waudby et al. 2010), the mechanism of this
interaction and whether it provides a protective effect by inhibiting the cytotoxicity of the
fibrils themselves is yet to be established. Moreover, it remains to be determined whether
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other sHsps, such as Hsp27, can also bind to amyloid fibrils, and thus whether fibril binding
is likely to be a generic property of the sHsps. The following chapter specifically addresses
these gaps in knowledge by examining the ability of Hsp27 to interact with oligomeric and
fibrillar forms of α-syn. Single molecule techniques, such as those described above, are
employed, along with traditional bulk techniques, in order to gain a comprehensive
understanding of how Hsp27 interacts with aggregated forms of α-syn and the potential
physiological relevance of these interactions.
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4.2

Methods
4.2.1 Single molecule confocal microscopy
4.2.1.1 Microscope setup

smFRET measurements were performed using a custom built confocal microscope assembled
by Dr. Mathew Horrocks (University of Cambridge, UK). The components, filter spectra and
layout of this microscope have been previously published (Horrocks et al. 2013). Prior to use,
the alignment of the microscope optics was measured using dual labelled DNA duplexes.
Synthetic DNA oligonucleotides synthesised by IBA GmbH (Gottingen, Germany) and
labelled

with

AF488

(5’ – TAGTGTAACTTAAGCCTAGGATAAGAGCCAGT

AATCGGTA – 3’) or AF647 (5’ – TACCGATTACTGGCTCTTATCCTAGGCTTAAGTT
ACACTA – 3’) were prepared to a final concentration of 2 µM (containing a 1:1 mixture of

each oligonucleotide) in 10 mM Tris containing 1 mM EDTA and 100 mM NaCl (pH 7.5,
0.02 µm filtered). To form duplexes, the mixture was heated to 95oC then cooled to room
temperature over a 7 h period. smTCCD measurements (Orte et al. 2008, Cremades et al.
2012) of the duplex were then performed and the association quotient (Q) was determined,
where Q is defined as:

𝑄=

𝐶−𝐷
𝐴 + 𝐵 − (𝐶 − 𝐷)

In this instance, A and B refer to the event rates in the donor and acceptor channels
respectively, C refers to the rate of coincident events (i.e. events above background in both
channels), and D refers to the rate of desynchronised events (i.e. coincident events that occur
after randomisation of one channel, acting as a measure of chance coincidence) (Clarke et al.
2007). This calculation was completed using custom software for Python 2.7 (available at:
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https://github.com/drwhiten/Appendices.git) written by Dr. Daniel Whiten. The instrument
was considered sufficiently aligned when the Q value exceeded 20.
4.2.1.2 Preparation of microfluidic devices
Microfluidic devices were prepared as described by Horrocks et al (2011). Briefly, ‘master’
moulds used for the fabrication of these devices were generated by spin-coating
approximately 1 mL SU-8 3025 photoresist (Microchem, Westborough, U.S.A.) onto a 76.2
mm silicon wafer (Compart Technology Ltd, Tamworth, UK) using a Spincoat G3P-8
(Specialty Coating Systems, Indianapolis, U.S.A.). The wafer was spun at 800 rpm for 5 s,
then accelerated to 3000 rpm at a rate of 300 rpm/s for 60 s, resulting in a final thickness of
25 µm. The wafer was prebaked by heating at 96oC for 12 min using an SD300 digital
hotplate (Stuart Equipment, Staffordshire, UK), before being exposed to UV light for 15 s
using an OAI UV source (OAI, USA) through a UV-blocking mask. A single design
containing 25 straight 100 x 10000 µM channels was used in this work, and the appropriate
mask was provided by Dr. Mathew Horrocks. The master was then washed with propylene
glycol monomethyl ether followed by isopropanol to remove any unexposed photoresist.
Microfluidic devices were produced by casting the master mould with SYLGARD 184
PDMS elastomer according to the manufacturer’s instructions. Approximately 25 mL of
elastomer mixture (containing elastomer and curing agent at a 10:1 volumetric ratio) was
vigorously mixed, poured over the master and degassed to remove any air pockets. The
elastomer was hardened by incubation at 65oC overnight in a laboratory oven (CarboLite
Gero, Hope Valley, UK). Individual devices were cut from the elastomer according to the
design, and access holes for inlet tubes were introduced using Unicore biopsy punches of 1.0
mm or 0.75 mm diameter (ThermoFischer Scientific, Waltham, USA). Devices were then
exposed to oxygen plasma for 7 s using a Plasma system FEMTO (Diener Electronic,

83

Chapter 4: sHsps interact with mature α-synuclein fibrils
Ebhausen, Germany), sealed to borosilicate glass cover slides (thickness number 1; VWR
International, Radnor, U.S.A.) and baked overnight at 65oC overnight in a laboratory oven
(CarboLite Gero, Hope Valley, UK).
The straight channel design used in this work enables the detection of oligomeric proteins
under conditions of flow, allowing the rate of detection to be increased and removing the bias
for small, faster diffusing species (Horrocks et al. 2011). For use, the device was connected to
a PhD 2000 Infusion or PhD 2000 Programmable syringe pump (Harvard Apparatus, USA)
using FineBore polyethylene tubing (Scientific Laboratory Supplies, UK), and the sample
drawn through the device from a sample reservoir at 200 µL/h (equivalent to 2 cm/s).
4.2.1.3 Single molecule Fӧrster resonance energy transfer (smFRET)
smFRET was performed to measure the accumulation, growth and structural conversion of
fluorescently labelled, oligomeric α-syn species in solution. To enable site specific
conjugation of a fluorophore to α-syn, the α-synA90C variant was chosen, which allows the
engineered cysteine to be targeted by succylimide fluorescent dyes (see Section 2.6 for
labelling details). To monitor the aggregation of α-syn, an equimolar mix of AF488 and
AF647 labelled α-synA90C was prepared to a total concentration of 70 µM in PBS (pH 7.4,
0.02 µm filtered), in the absence or presence of Hsp27 (7 µM). Samples were incubated for
up to 48 h at 37oC with shaking at 200 rpm in an Innova43 Incubator Shaker (Eppendorf,
Hamburg, Germany), and aliquots taken at the time points indicated in the corresponding
figure legend. To monitor the disaggregation of α-syn fibrils, an equimolar mix of AF488 and
AF647 labelled α-synA90C was prepared to a total concentration of 70 µM in PBS (pH 7.4,
0.02 µm filtered) and incubated as above for up to 7 days. The sample was centrifuged at
17000 x g for 20 min at 4oC to isolate mature fibrils, before the supernatant was discarded
and gently replaced with fresh PBS. The fibrils were washed with PBS twice, before being
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resuspended in fresh PBS in the absence or presence of αB-c or Hsp27, at a 1:5 molar ratio
(chaperone:α-syn), according to the original α-syn monomer concentration. Samples were
incubated for up to 21 days at 37oC without shaking, and aliquots taken at the time points
indicated in the corresponding figure legends. All incubation steps were completed in DNA
LoBind 1.5 mL tubes (Eppendorf, Hamburg, Germany) wrapped in aluminium foil to limit
protein adsorption and photobleaching over the course of the assay.
Immediately prior to analysis, aliquots were centrifuged at 20000 x g for 20 min at room
temperature to remove any large, insoluble aggregates. The supernatant was then collected
and diluted to approximately 100 pM using fresh PBS. Samples were then loaded into the
sample reservoir of a microfluidic channel and drawn through the confocal volume (see
Section 4.2.1.2). Samples were excited at 488 nm and the emitted fluorescence from both the
donor (AF488) and acceptor (AF647) fluorophores was then detected.
4.2.1.4 Data analysis
Data analysis was completed in Origin and IgorPro v 6.3.4.1 using custom scripts written by
Dr. Mathew Horrocks (University of Cambridge, UK). Datasets were first thresholded to
remove background photons and data points falling below this threshold were discarded.
Thresholding was completed using the ‘and’ criterion, such that only those bursts which were
above the threshold in both the acceptor and donor channels simultaneously were selected. To
determine the appropriate thresholds, the Q value (see Section 4.2.1.1) was calculated at each
possible pair of thresholds ranging from 0 – 100 in both the donor and acceptor channels
(equating to over 10000 possible threshold pairs). The thresholds for the donor and acceptor
channels were then selected as those which produced the maximum value of Q.
Once data has been thresholded, the size of oligomeric α-syn was then calculated according
to the following equation:
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1
𝐼𝐷 + 𝐼𝐴 ( )
𝛾
𝑆𝑖𝑧𝑒 = 2 (
)
𝐼𝑀

where ID and IA correspond to the intensity in the donor and acceptor channels respectively,
IM corresponds to the intensity of the monomer (calculated as the average intensity of noncoincident events in the donor channel prior to incubating the sample under aggregationinducing conditions) and γ is an experimentally determined calibration factor, in this case
1.01, used to compensate for inter-instrumental differences (Ye et al. 2012).
The efficiency of FRET can also be used as a measure of proximity, as it is dependent on the
distance between two fluorophores. This property was exploited as an indirect measure of the
structurally compact nature of the detected oligomers, such that more compact, well ordered
species exhibit a higher FRET efficiency (Cremades et al. 2012). The FRET efficiency of a
given coincident burst was calculated according to the following equation:

𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =

𝐼𝐴
𝐼𝐴 + 𝛾 × 𝐼𝐷

where ID and IA correspond to the intensity in the donor and acceptor channels respectively,
and γ is an experimentally determined calibration factor used to compensate for interinstrumental differences (Ye et al. 2012).
Populations of small (2 – 6 mers) and medium (7 – 300 mers) oligomers were then identified,
and the FRET efficiency histograms for each were fitted by a Gaussian distribution. This
distinguishes small oligomers with low FRET from medium oligomers with low or high
FRET efficiencies, such that the change in these populations can be characterised over time
as a measure of the structural conversion of oligomers from relatively disordered to more
stable, compact proteinase-K-resistant oligomers (Cremades et al. 2012). Oligomers larger
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than 300 monomeric units were excluded from the analysis as there were too few events in
this range.
4.2.2 Seeded aggregation assays
In an attempt to differentiate an interaction of Hsp27 with monomeric or fibrillar α-syn,
seeded aggregation assays were employed that were an adaption of a method previously
described (Buell et al. 2014). Briefly, to produce seed fibrils, 1 mL aliquots of monomeric αsyn were prepared at concentrations ranging from 100 – 200 µM in 50 mM phosphate buffer
(pH 7.4), in the absence of added salt. Samples were incubated at 45oC with maximal stirring
with a Teflon flea on a WiseStir heat plate (Witeg, Wertheim, Germany) for 24 h, then
sonicated (three cycles of 10 s at 30% power). Samples were then incubated for a further 24 h
under the conditions described above, before being sonicated again as described. Finally,
samples were distributed into aliquots, flash frozen in liquid N2 and stored at -20oC. In the
experiments described below, the concentration of fibril seeds is reported as the monomerequivalent concentration.
Seeded aggregation of α-syn was monitored using a microplate assay. Assays were conducted
in clear 384 microwell plates (Greiner Bio-One, Frickenhausen, Germany) with each well
initially containing a total of 40 µL of sample (all samples were run in duplicate). In order to
probe the interaction of Hsp27 with monomeric α-syn, α-syn was incubated at concentrations
from 10 – 100 µM in the absence or presence of 50 µM Hsp27 (or the negative control
protein BSA) in 50 mM phosphate buffer (pH 7.4). Samples were equilibrated to 37oC, then
seed fibrils were spiked into each sample to a final concentration of 5% (w/w), resulting in a
final volume of 50 µL for each sample. Alternatively, to probe the interaction of Hsp27 with
fibrillar α-syn, 50 µM α-syn was incubated in the absence or presence of Hsp27 (or BSA) at
concentrations ranging from 0.1 – 10 µM in 50 mM phosphate buffer (pH 7.4). Samples were
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equilibrated to 37oC, then seed fibrils were spiked into each sample to a final concentration of
1 – 10% (w/w), resulting in a final volume of 50 µL for each sample. All wells contained a
final concentration of 50 µM ThT, with the plate sealed to prevent evaporation. Plates were
incubated in a FLUOstar Optima plate reader (BMG Labtechnologies, Melbourne, Australia)
at 37oC with no shaking, and ThT fluorescence measured using excitation and emission filters
of 440 nm and 490 nm, respectively. Readings were taken every 300 s for a period of up to
20 h.
The change in ThT fluorescence intensity was calculated by subtracting the value at t = 0 h
from subsequent measurements. The elongation rate for each sample was then determined by
fitting data from the linear elongation phase of the assay (consisting of the initial 1 – 3 h or 0
– 2.5 h where appropriate) with linear regression. The relationship between rate and
concentration was then fit to a Michaelis-Menten kinetic model.
4.2.3 Preparation of mature, unlabelled α-syn fibrils
Mature α-syn amyloid fibrils were grown from recombinant monomeric α-syn by adding preformed seeds to the reaction. Briefly, monomeric α-syn, at concentrations ranging from 50 –
300 µM, was incubated in 50 mM phosphate buffer (pH 7.4) in the presence of 1% (w/w)
pre-formed α-syn seeds (formed as described above). To monitor fibril growth, samples were
incubated in the presence of 50 µM ThT using a black-walled, clear bottom 96-well
microplate (Greiner Bio-One, Frickenhausen, Germany), with each well containing 100 µL of
sample. Plates were incubated without agitation at 37oC in a FLUOStar Optima plate reader
(BMG Labtechnologies, Melbourne, Australia), with the plate sealed to prevent evaporation.
The ThT fluorescence was monitored via excitation and emission at 440 nm and 490 nm,
respectively. Readings were taken every 300 s for a period of up to 48 h. Samples were
considered to contain mature amyloid fibrils once the ThT fluorescence had reached a plateau
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(typically after 24 h of incubation). Fibril samples were collected from the plate and stored at
4oC for use.
4.2.4 Analytical sucrose gradient centrifugation
Mature α-syn fibrils (formed as described above, Section 4.2.3) were prepared at a final
concentration of 75 µM in 50 mM phosphate buffer containing 100 mM NaCl (pH 7.4).
Fibrils were incubated at 37oC for 1 hr in a VorTemp shaking incubator (Labnet
International, Edison, USA) with shaking at 60 rpm, in the absence or presence of Hsp27 or
αB-c variants (15 µM). An aliquot was taken (load sample) prior to samples (100 µL) being
layered on top of a 20% (w/v) sucrose solution (900 µL; Amresco, Solon, USA) prepared in
50 mM phosphate buffer containing 100 mM NaCl (pH 7.4). Following centrifugation at
200000 x g for 20 min at 4oC using an MTX150 ultracentrifuge (ThermoFischer Scientific,
Waltham, USA), 100 µL fractions were collected and any pelleted material resuspended in
the final 100 µL (top – fraction 1, bottom – fraction 10). SDS-PAGE analysis of the load, and
sample fractions was performed using 15% polyacrylamide gels, which were visualised via
staining with Coomassie Brilliant Blue R250.
4.2.5 Fluorescence fibril pelleting assay
In order to determine the binding affinity (Kd) of Hsp273D (i.e. a Hsp27 isoform containing
mutations that mimic phosphorylation at residues S15, S78 and S82) for mature α-syn fibrils,
a pelleting assay was developed. CF488-labelled Hsp273D (or the non-binding control protein
α-lac) was incubated at concentrations ranging from 0 – 20 µM in the absence or presence of
25 µM α-syn fibrils. Samples were incubated in 50 mM phosphate buffer (pH 7.4) at 37oC for
1 h without shaking using an Accublock digital dry bath (Labnet International, Edison, USA),
before being centrifuged at 20000 x g for 1 h at 4oC. The supernatant was collected, and the
pellet washed with an equivalent volume of fresh 50 mM phosphate buffer. Samples were
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again centrifuged at 20000 x g for 1 h at 4oC, and the supernatant was discarded. Pelleted
material was then resuspended in an equivalent volume of fresh 50 mM phosphate buffer, and
the absorbance at 495 nm (A495nm) was determined in triplicate using a NanoDrop 2000c
spectrophotometer (ThermoFischer Scientific, Waltham, USA). The concentration of bound
labelled protein was then determined using a standard curve ranging from 0 – 20 µM. The
concentration of bound Hsp273D was correlated with the total amount of Hsp273D added to
the sample, and the data fitted with a one-site saturation model, such that the Kd and Bmax
could be determined.
4.2.6 Total internal reflection fluorescence (TIRF) microscopy
4.2.6.1 Microscope setup
TIRF microscopy, including super resolution imaging, of mature α-syn fibrils was performed
using a custom designed microscope built by Dr. Mathew Horrocks. Briefly, an inverted
microscope (Nikon Eclipse TI, Tokyo, Japan) was configured to operate in objective-type
TIRF with three light sources, a 405 nm CW diode 200mW Obis laser (Coherent, Santa
Clara, USA), a 514 nm solid-state 200 mW Sapphire laser (Coherent, Santa Clara, USA) and
a 647 nm CW diode 200mW Obis laser (Coherent, Santa Clara, USA). The lasers were
directed via dichroic mirrors through a high numerical aperture, 60X oil immersion CFI
Apochromate objective lens (Nikon Eclipse TI, Tokyo, Japan) to the sample coverslip. The
emitted fluorescence was collected and filtered through long-pass filters specific for each
excitation (see Section 4.2.6.2) and finally projected onto an electron multiplied charged
coupled device (EMCCD) camera (Evolve II 512, Photometrics, Tuson, AZ). For sPAINT
imaging, a physical aperture (VA100/M, Thorlabs) and a transmission diffraction grating
(300 Grooves/mm 8.6° Blaze Angle - GT13-03, Thorlabs) were mounted on the camera port
path prior to the detector.
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4.2.6.2 Sample preparation
To prepare slides for microscopy, glass coverslips were cleaned using an argon plasma
cleaner (Diener Electronic, Ebhausen, Germany) for 1 h and frame-seal 99 mm slide
chambers (Bio-Rad, Hercules, CA) were fixed to the cleaned surface. The glass surface
within the chamber was coated with poly-L-lysine (0.01% w/v), and incubated for 30 min at
room temperature. The chamber was then washed three times with filtered PBS, before the
slide was transferred to the microscope stage and coupled to the lens using immersion oil
(n=1.518, Olympus, Tokyo, Japan). Samples for microscopy were prepared in 50 mM
phosphate buffer (pH 7.4) or PBS containing 50 µM α-syn and 1 µM fluorescently labelled
Hsp27-WT or negative control proteins (α-lac or lysozyme). Samples were incubated for 5
min at room temperature, before being diluted 100-fold in the appropriate imaging buffer.
Imaging buffer consisted of GLOX-mercaptoethylamine buffer (0.5 mg/mL glucose oxidase,
40 μg/mL catalase and 10% (v/v) glucose in 50 mM Tris-HCl (pH 8.0) with 10 mM NaCl and
10 mM β-mercaptoethylamine) supplemented with 5 µM ThT for SAVE imaging, or 100 nM
nile red for sPAINT imaging (Bongiovanni et al. 2016). These buffers enable the detection of
fibrillar α-syn (via ThT or nile red fluorescence), while also allowing the labelled Hsp27 (or
control fluorescent proteins) to be imaged via the red fluorescence. Excitation of ThT at 405
nm allowed the detection of fluorescence using an ET488LP long pass filter (Semrock,
Rochester, USA). Alternatively, nile red was excited at 514 nm and fluorescence collected
using an ET590LP long-pass filter (Semrock, Rochester, USA). In both cases, CF647labelled Hsp27 or control proteins were imaged via excitation at 647 nm and the emitted
fluorescence was detected using an ET655LP long-pass filter (Semrock, Rochester, USA).
Each channel was imaged sequentially such that there was no spectral overlap in detected
fluorescence.
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4.2.6.3 Image processing
Data were analysed to generate sPAINT images as described previously (Bongiovanni et al.
2016) using the Genome Damage and Stability Centre Single Molecule Localisation
Microscopy (GDSC SMLM) ImageJ Plugin (University of Sussex, Brighton, UK), using a
typical ‘signal strength’ threshold of ~30. Quantitative co-localisation analyses were
performed using IgorPro v 6.3.4.1 using custom scripts (Appendix II) written by Dr. Daniel
Whiten, and wavelength analyses were completed using custom scripts written for Python 2.7
(Appendix III).
4.2.7 Dihydroethidium (DHE) assay
A dihydroethidium (DHE) cell-based method, similar to that described previously (Cremades
et al. 2012, Zhang and Soldati 2013), was used to investigate the toxicity of α-syn fibrils
when added exogenously to cells. N2a cells were routinely cultured as described in Section
2.7.1. For use, cells were seeded into 8-well chamber slides (Ibidi, Martinsried, Germany)
and cultured to 60% confluency. Treatments containing monomeric or fibrillar α-syn (to a
final concentration of 20 µM) were prepared in PBS in the absence or presence of sHsps (or
the control proteins BSA or α-lac) at a 1:100 molar ratio (sHsp:α-syn) and incubated at 37oC
for 30 min. Immediately prior to use, DHE (to a final concentration of 2 µM) was also added
to these treatments to exclude effects due to dilution of the DHE.
Prior to addition of the samples, cells were washed with PBS and then DHE (2 µM in PBS)
was added. Images were taken every 30 s for 15 min using an epifluorescence microscope to
quantify the amount of DHE (excitation 325 – 375 nm and emission 435 – 485 nm) and its
oxidised product (i.e. ethidium, excitation 540 – 580 nm and emission 592 – 668 nm) as a
measure of basal ROS production (Zhang and Soldati 2013). Treatments were then added to
cells, and images were taken every 30 s for a further 15 min. Data analysis was completed
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using custom programs written for Python 2.7 (Appendix IV) and, where appropriate, data
fitted with linear regression. Briefly, the change in fluorescence, corresponding to the
conversion between DHE and its oxidised product ethidium, was monitored for 20 cells and
the ratio of DHE fluorescence to ethidium fluorescence calculated for each of these cells. The
difference in the rate of change of the DHE/ethidium fluorescence ratio before and following
treatment was then determined, and normalised to the PBS control. Statistical analysis was
performed using a one-way analysis of variance followed by a Bonferroni’s multiple
comparison test.
4.2.8 Analytical ultracentrifugation (AUC) of fibrils
Absorbance-detected AUC was performed as previously described (Binger et al. 2013).
Briefly, the maximum concentration of each protein in the experiment was calculated such
that the absorbance at 260 or 280 nm was within the optimal detection range of the
instrument. Samples (380 µL) containing α-syn fibrils (25 µM) in the absence or presence of
αB-c or Hsp27 (5 µM) were prepared at room temperature and incubated for 1 h before being
loaded into a 12 mm double-sector epon-filled centrepiece, alongside the relevant reference
solution (400 µL). Samples were centrifuged in an XL-I analytical ultracentrifuge (Beckman
Coulter, CA, USA) at 3000 rpm using either a Ti60 or Ti50 rotor at 20 oC. Radial absorbance
scans were collected at 280 nm at 6 min intervals with a radial step size of 0.003 cm for a
total of 10 h. Sedimentation velocity (SV) profiles were analysed with SEDFIT software
using the least-squares (ls) boundary model, ls-g*(s) (Schuck 2000, Schuck and Rossmanith
2000). Regularisation by second derivative was used to obtain the apparent (g*(s))
distribution (Schuck 2000, Schuck and Rossmanith 2000). The Sav of each sample was then
determined by integration of the distributions. Samples were again analysed via AUC as
described above, following incubation at room temperature for 48 h without shaking.
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4.3 Results
4.3.1 Hsp27 inhibits the growth and structural conversion of α-syn oligomers
during early aggregation
To investigate the interaction of Hsp27 with intermediates formed during the early stages of
α-syn aggregation, smFRET was employed (Cremades et al. 2012). This enables
fluorescently labelled oligomeric species, which typically represent <1% of the total α-syn
species present in solution, to be detected and characterised with regards to their size and
relative structure. Incubation of α-syn alone resulted in an increase in the total number of
oligomeric species over time, which was inhibited by the presence of Hsp27 at a 1:10 molar
ratio (Hsp27:α-syn) (Figure 4.1A). When considering the proportion of events corresponding
to small (2-6 monomeric subunits) α-syn oligomers, Hsp27 inhibited the formation of these
small oligomers but did not completely prevent their formation (Figure 4.1B). The growth of
these small oligomers can be monitored by measuring the proportion of medium sized (7 –
300 monomeric equivalent) α-syn oligomers formed over time. In addition, the conversion of
medium sized oligomers from a disordered to more ordered, compact species can also be
monitored via the relative FRET efficiency of the medium sized oligomers (Cremades et al.
2012). Analysis of the medium sized α-syn oligomer population revealed that, in the absence
of Hsp27, there was an accumulation of medium sized, low FRET oligomers over time
followed by an increase in the proportion of medium sized high FRET population in solution
(Figure 4.1C, D). This is consistent with previous observations, supporting the structural
conversion of α-syn oligomers during aggregation to more structured, compact oligomers
over time (Cremades et al. 2012). Hsp27 prevented the growth of small oligomers into
medium sized oligomers, such that there was negligible appearance of medium oligomers of
either low or high FRET efficiency when Hsp27 was present (Figure 4.1C, D). This may be
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reflective of Hsp27 interacting either with monomeric subunits to prevent their addition to
growing oligomeric nuclei, or directly with the small α-syn oligomers to prevent monomer
addition.

Figure 4.1: Hsp27 inhibits the growth of oligomers formed during α-syn aggregation. An
equimolar mix of AF488- and AF647-labelled α-synA90C was prepared to a total concentration of 70
µM in PBS (pH 7.4), in the absence (blue) or presence of Hsp27 (7 µM, orange). Samples were
incubated for up to 32 h at 37oC. Aliquots were analysed via smFRET to determine (A) the proportion
of events that corresponded to oligomers. The fraction of these events was normalised to time 0, and
those events corresponding to (B) small α-syn oligomers (2 – 6 monomer equivalents) and (C and D)
medium α-syn oligomers (7 – 300 monomer equivalents) were determined. For those events
corresponding to medium α-syn oligomers (7 – 300 monomer equivalents), the population was
separated into those exhibiting (C) low and (D) high FRET efficiencies, corresponding to lower and
higher degrees of structural compactness respectively. Data is presented as mean ± S.E.M. of
triplicate samples, and is representative of three biological repeats.

4.3.2

Hsp27 inhibits the elongation of α-syn fibril fragments

Seeded aggregation assays were employed to enable direct analysis of the elongation rate of
small α-syn amyloid fibril fragments (seeds). Under these conditions, aggregation occurs
primarily through monomer addition at fibril ends, while primary nucleation and secondary
fibril amplification processes do not contribute significantly to the observed aggregation
kinetics (Buell et al. 2014). For example, incubation of monomeric α-syn in the presence of
5% (w/w) fibril seeds does not produce an observable lag phase typical of non-seeded
aggregation (in which primary nucleation occurs), and instead is best described by a onephase association model (Figure 4.2A). Elongation of these α-syn fibril seeds is inhibited by
the addition of Hsp27 (Figure 4.2A), and this effect is specific to the chaperone as there is no
inhibition when a non-chaperone control protein (BSA) is used at the same concentration.
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Figure 4.2: Hsp27 inhibits the elongation of α-syn fibril fragments. (A) Recombinant monomeric
α-syn (50 µM) was incubated in 50 mM phosphate buffer and 0.01% NaN3 (pH 7.4) in the absence or
presence of 50 μM Hsp27 or the control protein BSA. After equilibration at 37oC, α-syn seeds (5%
(w/w)) were added to each sample containing monomeric α-syn and the elongation of these seeds
monitored via the change in ThT fluorescence at 490 nm over time. Data shown are representative of
two independent repeats. (B-E) Recombinant monomeric α-syn was incubated in 50 mM phosphate
buffer (pH 7.4) at concentrations ranging from 10 – 100 μM in the (B, C) absence or (D, E) presence
of 50 μM Hsp27. After equilibration at 37oC, α-syn seeds (5% (w/w)) were added to each sample and
the elongation of these seeds monitored via the change in ThT fluorescence at 490 nm over time. The
data from 1 – 3 h (red dotted box) of incubation were (C, E) fit to a linear regression. (F) The rate of
elongation of the α-syn seeds, in the absence and presence of Hsp27, was calculated using values from
these fits and correlated with the monomeric α-syn concentration. Data for α-syn alone were fit to a
Michaelis-Menten non-linear regression model. Data in B – E are representative of four independent
repeats, and data in F is presented as mean ± S.E.M. of these four repeats.

Moreover, there is no increase in ThT fluorescence in the absence of α-syn (i.e. in samples
that contain Hsp27, BSA or buffer alone) (Figure 4.2A). Importantly, when the concentration
of monomeric α-syn is increased in the presence of a constant ratio of seeds (i.e. 5% (w/w)),
the rate of elongation and maximal fibril formation increases (Figure 4.2B, D). By
considering the linear elongation phase of the reaction (in this case the time between 1 – 3 h;
Figure 4.2C, E), the relationship between elongation rate and the concentration of monomeric
α-syn is best described by a Michaelis-Menten model. In this case, elongation is predicted to
reach a half maximal rate at approximately 300 µM monomeric α-syn (Figure 4.2F). In the
presence of Hsp27 (50 µM; Figure 4.2D, E), there is no significant increase in the rate of
elongation at low concentrations of monomeric α-syn (up to 50 µM) (Figure 4.2D). However,
when the concentration of Hsp27 is held constant (50 µM) and the concentration of
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monomeric α-syn is increased (to 75 and 100 µM), such that the molar ratio of monomeric αsyn:Hsp27 exceeds 1:1, the rate of α-syn aggregation increases (Figure 4.2F). Importantly,
the elongation rate in the presence of Hsp27 is no longer able to be fitted to a MichaelisMenten model. Together, these data suggest that the interaction between Hsp27 and
monomeric α-syn is elongation-rate dependent. These findings may also reflect an interaction
between Hsp27 and the fibrillar seeds of α-syn, whereby Hsp27 is in direct competition with
monomeric α-syn for access to fibril ends, thus inhibiting elongation of the fibril seeds. As
the concentration of monomeric α-syn increases, it may out-compete Hsp27 leading to the
observed increase in the rate of elongation.
To further explore these possibilities, the ratio of α-syn fibril seeds to monomeric α-syn was
varied and Hsp27 added to the samples at a range of concentrations (Figure 4.3). As
expected, incubation of monomeric α-syn in the presence of 2.5% (w/w) α-syn seeds resulted
in a characteristic aggregation profile without an observable lag phase (Figure 4.3A).
Addition of Hsp27 inhibited this aggregation, such that there was a concentration-dependent
decrease in the rate and maximal amount of α-syn aggregation as the concentration of Hsp27
was increased (Figure 4.3A and 2B). By repeating this experiment using different
concentrations of α-syn fibril seeds (from 1%-10% (w/w) of the monomeric α-syn
concentration, Appendix V) the relationship between the elongation rate and concentration of
Hsp27 was established (Figure 4.3C). This relationship is best described by a one-phase
exponential decay curve (Figure 4.3C), whereby, the rate constant from this fit provides a
measure of the ability of Hsp27 to prevent fibril elongation at each ratio of seed:monomeric
α-syn (Figure 4.3D). There was a strong negative exponential correlation between the
concentration of seed and the ability of Hsp27 to prevent fibril elongation, i.e. as the
percentage of α-syn seed in a sample increased, Hsp27 was less effective at inhibiting fibril
elongation. Together, these data therefore support a stable interaction between Hsp27 and
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fibrillar α-syn. Importantly, binding of Hsp27 to fibrillar α-syn is in stark contrast to the
transient interaction seen between Hsp27 and monomeric α-syn (Chapter 3).

Figure 4.3: Hsp27 interacts with α-syn fibril fragments. Recombinant monomeric α-syn was
incubated in 50 mM phosphate buffer and 0.01% NaN3 (pH 7.4) at 50 μM in the absence or presence
of Hsp27 at concentrations ranging from 0.1 – 10 μM. After equilibration at 37oC, α-syn seeds were
added at concentrations ranging from 0.5 – 5 μM (i.e. 1%-10% (w/w) when expressed as a percentage
of the soluble protein concentration) and elongation monitored via the change in ThT fluorescence at
490 nm over time. (A) A representative trace is shown in the presence of 5% seed, and the linear
portion (0 – 2.5 h, indicated by red dotted box) was (B) fit to a linear regression curve. (C) The rate of
elongation was calculated using values from this fit, which was then normalised to the α-syn alone
sample and correlated with Hsp27 concentration at each seed ratio. These data were then fit with one
phase exponential decay. (D) Parameters of this fit were used to compare the chaperone efficacy of
Hsp27 at each seed ratio, and the data fit to a one phase exponential decay. Data in A – C is
representative of at least three independent experiments, and data in D is reported as mean ± S.E.M.
of these independent repeats.

4.3.3

sHsps forms a stable complex with mature α-syn fibrils and this is

mediated by the N- and/or C-termini
Although the interaction between fibrillar α-syn and Hsp27 significantly impacts the rate of
α-syn aggregation in vitro, the mechanism by which Hsp27 interacts with fibrillar α-syn
remained to be established. In addition, whilst αB-c has been shown to bind α-syn fibrils
(Waudby et al. 2010), the regions responsible for this interaction had not been determined.
Sucrose centrifugation assays were therefore employed to investigate the ability of both
Hsp27 and αB-c to form stable complexes with α-syn fibrils (Figure 4.4). When non-fibrillar
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(monomeric) α-syn was applied to the top of the sucrose gradient it was retained in the upper
fractions (fraction 1-3). In contrast, fibrillar α-syn sedimented through the sucrose gradient
and was detected in the bottom fraction (fraction 10) (Figure 4.4A). When Hsp27 or αB-c
was incubated alone, they did not sediment, and were localised in fractions 1-5 from the
sucrose gradient consistent with the large, polydisperse and oligomeric nature of these sHsps
(Figure 4.4B, D) (Haley et al. 1998, Jovcevski et al. 2015). However, pre-incubation of
Hsp27 and αB-c with mature α-syn fibrils resulted in these sHsps co-sedimenting with the
fibrils and therefore being detected in the bottom fraction from the sucrose gradient (Figure
4.4C, E).
To gain further insight into the mechanism by which these sHsps form complexes with
mature α-syn fibrils, core domain (i.e. sHsps forms which lack the flanking N- and Cterminal domains, Hsp27core and αB-ccore) and a phosphomimicking variant (Hsp273D) of the
sHsps were used in this assay. These variants were chosen as they only form dimers and
monomers under these experimental conditions rather than large polydisperse oligomers such
as those formed by WT αB-c and Hsp27 (Hochberg et al. 2014, Jovcevski et al. 2015). Thus,
these sHsp variants enabled us to test whether only large oligomeric forms of sHsp are
capable of binding to α-syn fibrils. Since αB-c3D does not form small oligomeric species
(Ecroyd et al. 2007) it was not used in these experiments. Importantly, the core domain and
Hsp273D variants have all previously been shown to retain the ability to prevent monomeric
α-syn aggregation and therefore are chaperone active (Chapter 3, Appendix I) (Hochberg et
al. 2014, Jovcevski et al. 2015). Consistent with them existing as monomers and dimers under
these experimental conditions, Hsp273D (Figure 4.4F), Hsp27core (Figure 4.4H) and αB-ccore
(Figure 4.4J) were found in fractions 1-4 from the sucrose gradient when incubated alone.
Incubation of Hsp273D with α-syn fibrils resulted in the Hsp273D co-sedimenting with the
fibrils, such that it was detected in the bottom fraction from the sucrose gradient (Figure
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4.4G). However, when Hsp27core and αB-ccore were incubated with mature α-syn fibrils, they
did not co-sediment with the fibrils (Figure 4.4I, K). Together these data demonstrate that the
small oligomeric forms of sHsps can bind to α-syn fibrils, however, binding requires the Nand/or C-terminal regions of these sHsps.

Figure 4.4: sHsps bind to α-syn fibrils and this is mediated by the N- and/or C-termini. α-Syn
fibrils (75 µM) were incubated in 50 mM phosphate buffer and 0.01% NaN3 (pH 7.4) in the (A)
absence or presence of (C, E) WT, (G) phosphomimicking and (I, K) core domain isoforms of Hsp27
(C, G and I) or αB-c (E and K). The sHsp isoforms were present at a final concentration of 15 µM.
Hsp27 and αB-c (B, D) WT, (F) phosphomimicking and (H, J) core domain isoforms, incubated in the
absence of α-syn fibrils, are also included for comparison. Samples were incubated for 1 h at 37oC
before being layered on top of a 20% (w/v) sucrose cushion and centrifuged at 200000 x g for 20
minutes. Sequential fractions were collected from the top of the cushion and analysed via SDS-PAGE.

In order to determine the binding affinity of Hsp27 for α-syn fibrils, a fluorescence binding
assay was developed. In this instance, Hsp273D was selected as a representative sHsp, as it
exists primarily as a dimer and does not sediment independently under the conditions used.
The presence of a cysteine at position 137 of Hsp27 enabled site-specific labelling of
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Hsp273D, such that a maximum of one fluorophore can be conjugated to each Hsp273D
monomer. Incubation of a range of concentrations of Hsp273D with mature α-syn fibrils
resulted in a saturable binding curve, which was not evident when the non-chaperone control
protein α-lac was incubated with α-syn fibrils (Figure 4.5). Fitting of the data revealed a Kd
and Bmax for the binding of Hsp273D to α-syn fibrils of 2.7 ± 1.9 µM and 5.4 ± 1.1 µM
respectively. Given the concentration of α-syn utilised here (25 µM monomer equivalent),
this Bmax corresponds to approximately 1 molecule of Hsp273D for every 5 α-syn monomeric
units at saturation.

Figure 4.5: Hsp27 binds mature α-syn fibrils with µM affinity. Mature α-syn fibrils (25 µM)
were prepared in 50 mM phosphate buffer and 0.01% NaN3 in the absence or presence of a range of
concentrations of fluorescently labelled Hsp273D or the non-binding control protein α-lac. After
incubation at 37oC for 1 h, samples were centrifuged and washed to remove unbound protein. The
concentration of bound Hsp273D (or α-lac) was determined by correlating the absorbance at 495 nm
with a known concentration of labelled protein. The concentration of bound Hsp27 3D was correlated
with the total concentration of Hsp273D added to the sample, and fit with a one-site saturation model
to enable the Kd and Bmax to be calculated. Data is displayed as mean ± S.E.M., where n=3 and n=2
for Hsp273D and α-lac respectively.

4.3.4

Binding of Hsp27 to α-syn fibrils occurs along the surface, leading

to a decrease in hydrophobicity
Given the stable association of Hsp27 with α-syn fibrils, we sought to visualise this
interaction directly using TIRF microscopy. In this instance, fibrils were detected using
SAVE imaging, which works by staining the aggregates with the amyloid specific dye ThT
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(Figure 4.6A; α-syn) (Bongiovanni et al. 2016), while CF647-labelled Hsp27 was imaged via
its red fluorescence (Figure 4.6A; Hsp27). The merged image (Figure 4.6A) demonstrates the
association of the labelled Hsp27 with α-syn fibrils. Hsp27 was seen to be distributed along
the fibril surface. There was a significant increase in the co-incidence between ThT-reactive
and red-fluorescent localisations when fibrils were co-incubated with Hsp27 (65 ± 6%)
compared to the control (non-chaperone) proteins α-lac (20 ± 7%) or lysozyme (25 ± 0.4%),
providing further evidence that the binding of Hsp27 to α-syn fibrils is the result of a specific
interaction.

Figure 4.6: Hsp27 binds along the surface of α-syn fibrils. α-Syn fibrils (50 µM) were incubated in
the presence of 1 µM CF647-labelled Hsp27, α-lac or lysozyme for 30 min at room temperature.
Samples were incubated in PBS containing 50 µM ThT to allow α-syn fibrils to be visualised and
imaged via TIRF microscopy. (A) TIRF images are shown for α-syn fibrils stained with ThT (top left
panel) in the presence of Hsp27 (bottom left panel), along with the corresponding merge of these two
images (right panel). Scale bars represent 5 µm. (B) The percentage of red fluorescent pixels
coincident with ThT-reactive pixels was quantified. Data are mean ± S.E.M. (n=9 images) and were
analysed via a one-way ANOVA with a Bonferroni post-hoc test (** denotes p<0.01). Data are
representative of two separate experiments.

In an attempt to further characterise the nature of the interaction between Hsp27 and α-syn
fibrils, the recently described TIRF-based imaging technique sPAINT (Bongiovanni et al.
2016) was used. This technique relies on the use of nile red in solution to image the fibrils in
place of ThT. Importantly, when nile red interacts with amyloid, it undergoes a characteristic
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shift in its emission wavelength according to the hydrophobicity of its surrounding
environment (Greenspan and Fowler 1985, Bongiovanni et al. 2016). Thus, sPAINT enables
regions of hydrophobicity along the face of fibrils to be mapped at super-resolution (Figure
4.7A). The addition of fluorescently labelled Hsp27, which was imaged below the
diffraction-limit using STORM (Rust et al. 2006), allows the association of the chaperone
with the fibrils to be mapped at the nanometer level (Figure 4.7B), and correlated with
regions of higher or lower hydrophobicity along the fibril surface (Figure 4.7C). The
emission wavelengths of the nile red bound to α-syn fibrils recorded for each localisation in
the absence or presence of Hsp27 were grouped into regions of low (550 - 600 nm), medium
(600 - 650 nm) or high (650 - 700 nm) hydrophobicity. Notably, binding of Hsp27 to α-syn
fibrils significantly affected the emission wavelength of the nile red associated with the fibrils
(F(5, 27) = 1255, p<0.0001). The presence of Hsp27 significantly decreased the proportion of
localisations corresponding to high levels of hydrophobicity (i.e. 650 – 700 nm; p<0.0001)
and significantly increased the proportion of localisations corresponding to medium levels of
hydrophobicity (i.e. 600 – 650 nm; p<0.0001) (Figure 4.7D).
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Figure 4.7: Hsp27 decreases the relative hydrophobicity at the surface of α-syn fibrils. α-Syn
fibrils (50 µM) were incubated in the absence or presence of CF647-labelled Hsp27 in GLOX buffer
containing 100 nM nile red, to allow α-syn fibrils to be visualised and imaged via TIRF microscopy.
(A) An example super-resolution image is shown for α-syn, with localisations coloured according to
the wavelength of emission of the nile red. (B) The labelled Hsp27 is coloured according to pixel
intensity. (C) In the corresponding merged image, the nile red localisations have been binned into
low, medium and high levels of hydrophobicity according to their wavelength of emission (colour
scale given at the bottom of the figure). (D) The percentage of localisations in each wavelength range
in the absence and presence of Hsp27 was quantified and data are displayed as the mean ± S.E.M.
(n=6). Scale bars represent 2 µm, or 1 µm in inset. Data were analysed via a student’s t-test, where
*** denotes a significant (p<0.001) difference between group means. Data are representative of two
separate experiments.

4.3.5

sHsps protect against the cellular toxicity of exogenous α-syn

fibrils
To establish whether, by binding to α-syn fibrils, αB-c and Hsp27 decrease fibril-associated
cytotoxicity, a DHE assay was developed. The dye DHE has been used extensively to
monitor the intracellular production of ROS, specifically superoxide (Zhao et al. 2003, Wang
et al. 2013, Zhang and Soldati 2013), as a measure of cellular toxicity. Therefore, this was
chosen as a method to measure the cellular toxicity of α-syn fibrils when added exogenously
to cells. Traces of the fluorescence ratio before and after treatment with monomeric or
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fibrillar α-syn demonstrated that there is an increase in the ratio of reduced to oxidised DHE
upon introduction of α-syn, indicative of ROS being produced by the cells (Figure 4.8A, B).
The difference in the rate of change in the fluorescence ratio (reported as a fold change
relative to the PBS control) is a measure of relative cytotoxicity, i.e. a faster rate of change in
the fluorescence ratio is due to higher rates of ROS production associated with increased
toxicity. There was a significant effect of treatment on the generation of ROS within cells
(F(7,247) = 33.96, p<0.001). Post-hoc tests revealed mature α-syn fibrils induced
significantly more ROS production than monomeric α-syn (p<0.0001) (Figure 4.8F).
However, when the α-syn fibrils were pre-incubated with αB-c, ROS production was
decreased by 50 ± 4% when compared to α-syn fibrils alone (Figure 4.8D). Similarly, when
the α-syn fibrils were pre-incubated with Hsp27 there was a dramatic decrease (by 65 ± 7%)
in ROS production compared to when fibrils alone were added to cells (Figure 4.8D).
Importantly, pre-incubating α-syn fibrils with the non-chaperone control proteins BSA or αlac did not significantly decrease the production of ROS by cells. Thus, the cytoprotective
effect was specific to the sHsps binding to the α-syn fibrils. Also, incubation of the chaperone
or control proteins in the absence of α-syn fibrils did not significantly alter basal levels of
ROS production.

105

Chapter 4: sHsps interact with mature α-synuclein fibrils

Figure 4.8: sHsps reduce the generation of ROS by N2a cells exposed to exogenous α-syn fibrils.
N2a cells were incubated in PBS containing DHE (2 µM) before addition of monomeric (Mono) or
fibrillar α-syn (20 µM) that had been pre-incubated in the absence or presence of αB-c or Hsp27 (or
the control proteins BSA and α-lac; each at 2 µM). The ratio of oxidised to reduced DHE before
(blue) and after (red) treatment was determined for 20 cells per treatment. Example traces are shown
for an individual cell treated with (A) monomeric α-syn, (B) fibrillar α-syn, and fibrillar α-syn
preincubated with (C) BSA, (D) αB-c or (E) Hsp27. The fluorescence ratio before and after treatment
was fit by linear regression and the change in the rate of ROS production due to treatment was
calculated as the difference in the gradient of the fitted lines. (F) The fold change in ROS production
was then determined relative to a buffer only control (dashed line) and is reported as mean ± S.E.M.
(n=3 biological repeats, with each repeat an average of 20 cells). Data were analysed via one-way
ANOVA with a Bonferroni’s multiple comparison post-hoc test, where *** denotes a significant
(p<0.001) difference compared to the fibril alone sample.
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4.3.6

Binding of sHsps promotes dissociation of mature α-syn fibrils

In order to investigate how sHsps bound to α-syn fibrils may influence the size distribution of
the fibrils, absorbance AUC was employed. Sedimentation velocity profiles are shown for αsyn in the absence and presence of αB-c or Hsp27 (Figure 4.9A-C). Fitting these profiles with
the least-squares (ls) boundary model, ls-g*(s), allows the g*(s) distributions to be calculated
(Figure 4.9D). In the absence of sHsps, the sedimentation coefficient distribution reveals a
large range of species, reflective of fibrils with a broad size distribution (Figure 4.9D). In the
presence of αB-c and Hsp27, the maximum sedimentation coefficients decrease by
approximately 40% and 60% respectively (Figure 4.9D). Following integration of these
distributions it is evident that the presence of chaperone increases the abundance of small (1 –
4000 S) species (Figure 4.9E), and this is accompanied by a corresponding decrease in the
proportion of large (4000 – 100000 S) species in solution. This difference was noted in both
the 0 h and 48 h distributions. Importantly, this apparent change in the size distribution of αsyn fibrils when bound by αB-c or Hsp27, is also reflected by the Sav values (Figure 4.9F).
Thus, in the presence of αB-c, the Sav of α-syn fibrils decreased by 27% when compared to αsyn fibrils alone. Similarly, the presence of Hsp27 resulted in a 47% decrease in the S av.
Similar results are also evident at the 48 h time point (Figure 4.9F). Furthermore, incubation
of α-syn fibrils alone resulted in an increase in the Sav over 48 h (Figure 4.9F), indicating the
species present in solution increase in size over this time. In contrast, the presence of
chaperone resulted in decreases in the Sav over this time frame, as the Sav values of α-syn
fibrils decreased by 9% and 21% when incubated with αB-c or Hsp27 respectively (Figure
4.9F). This indicates that, when sHsps were present, the species in solution decreased in size
over the 48 h of incubation. Therefore, the presence of αB-c and Hsp27 prevents any increase
in the Sav of α-syn fibrils which would otherwise occur over this period. This may be
reflective of sHsps preventing ‘clumping’ of fibrils together (e.g. by coating the fibril
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surface), or influencing the monomer-oligomer-fibril equilibrium such that the size of fibrils
themselves decreases in the presence of the sHsps.

Figure 4.9: sHsps decrease the apparent size of mature α-syn fibrils. Mature α-syn fibrils (µM)
were prepared in 50 mM phosphate buffer (pH 7.4), in the absence or presence of αB-c or Hsp27
(µM). Samples were incubated for 48 h at room temperature, with aliquots being analysed via
absorbance-based AUC after 0 h and 48 h. Sedimentation velocity profiles of (A) α-syn fibrils alone,
or α-syn fibrils in the presence of (B) αB-c or (C) Hsp27 are shown, with radial scans collected at 6
min intervals. Data is presented for every 10th scan overlaid with theoretical fits to the c(S) model
generated by SEDFIT. (D) Continuous g*(s) distributions for all samples were obtained from the raw
data using SEDFIT. (E) The percentage of species having low (1 – 4000) and high (4000 – 100000) S
values was determined by integration of D over the ranges indicated. (F) The Sav was determined by
integration of D over the whole range. Representative data is shown in A-E following 48 h incubation.

To further investigate these possibilities, smFRET was employed. Given this technique is
specialised to detect oligomers, it was utilised to monitor the dissociation of fibrils in the
absence and presence of bound Hsp27 or αB-c during prolonged incubation (i.e. once residual
monomeric and oligomeric α-syn had been removed by washing). When incubated alone, the
liberation of oligomers declined for up to 13 days (Figure 4.10). The presence of αB-c or
Hsp27 increased the proportion of oligomeric events detected, relative to α-syn incubated
alone (Figure 4.10A, B). This suggests that, by binding fibrils, both αB-c and Hsp27 promote
their dissociation into smaller oligomeric species.
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Figure 4.10: sHsps promote the dissociation of α-syn fibrils into smaller oligomers. An equimolar
mix of AF488- and AF647-labelled α-synA90C was prepared to a total concentration of 70 µM in
PBS (pH 7.4), and incubated for up to 7 days at 37oC. Mature fibrils were then washed, and
resuspended in PBS in the absence or presence of (A) αB-c or (B) Hsp27 (7 µM). Aliquots were
analysed via smFRET to determine the fraction of events that corresponded to oligomers. Data is
presented as mean ± S.E.M. of triplicate samples.
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4.4 Discussion
Given small oligomeric species formed during amyloid fibril aggregation are considered the
most toxic to neurons (Kayed et al. 2003, Glabe 2008, Winner et al. 2011), primary and
secondary nucleation processes become a crucial element to understanding the pathogenesis
of aggregation-prone α-syn. Although the soluble oligomer model of amyloid cytotoxicity
suggests that mature fibrils are a relatively inert end product, it is important to note that fibrils
themselves can be a significant source of these small cytotoxic species, through secondary
nucleation and fibril fragmentation. In contrast to the transient interaction between the sHsps
and monomeric α-syn (Chapter 3), the data presented in this chapter demonstrates that the
sHsps are able to stably interact with oligomeric and fibrillar forms of α-syn to prevent
further aggregation and mitigate fibril-associated cytotoxicity.
Hsp27 was able to inhibit, but not prevent, the formation of small soluble α-syn oligomers
when present prior to aggregation being initiated in a population of soluble, monomeric αsyn. This suggests small oligomers, which were not detected via ThT fluorescence in
Chapter 3, accumulate even in the presence of Hsp27 and represent a small proportion of αsyn species present. However, the results presented here demonstrate Hsp27 prevented the
growth of these small oligomers into larger aggregates, and therefore prevents the
accumulation of oligomers consisting primarily of β-sheet (i.e. high FRET oligomers). It
remains unclear whether this effect is primarily mediated by an interaction with monomeric
α-syn (to prevent its addition to growing oligomers), or with the small oligomers themselves
(to occlude sites of monomer addition). However, it suggests a role for Hsp27 in protecting
against soluble α-syn oligomers, given these small, β-sheet-rich oligomers are thought to
exert intracellular toxicity (see Section 1.2.5) (Cremades et al. 2012).
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Another source of small aggregates during α-syn aggregation is the fragmentation of fibrils.
Incorporating these fragments in bulk aggregation assays allows their elongation to be
considered, free from the confounding effects of primary nucleation due to the association of
monomers. In this case, increases in the elongation rate associated with increasing monomer
concentration are consistent with previous studies completed in the absence of chaperone
(Buell et al. 2014). The results presented here support those of Chapter 3 by showing that the
ability of Hsp27 to prevent the aggregation of monomeric α-syn is dependent on the rate of
aggregation. The elongation of α-syn seeds is completely inhibited by Hsp27 at low
concentrations of α-syn monomer, however, when the molar ratio of monomeric α-syn:Hsp27
exceeds 1:1, some aggregation occurs. The finding that Hsp27 inhibits the growth of the αsyn seed fibrils (significantly decreasing the rate of elongation) are comparable to those of
earlier work showing that αB-c inhibits further aggregation of α-syn when introduced during
the elongation phase of fibril growth (Rekas et al. 2007). The α-syn fibril seeds used in this
case likely represent physiologically relevant products of fibril fragmentation that have a
range of potentially toxic effects in the cell.
Fragmentation decreases the length of individual fibrils, which may increase their membrane
permeability or cellular uptake (Jakhria et al. 2014). The surface area of fibrils is also
increased by fragmentation as the fibril face is exposed when fibril-fibril associations are
disrupted. Thus, fragmentation increases the potential for deleterious interactions with
cellular components (Xue et al. 2009). Fragmentation also increases the number of fibrillar
particles, resulting in an increase in the likelihood of particle-dependent interactions such as
lipid-associated depolymerisation (Martins et al. 2008). Finally, fragmentation increases the
total surface area of fibril ends available to solution, which can act as seeds for further fibril
extension and thereby enhance the rate of amyloid deposition (Shvadchak et al. 2015), or
alternatively drive the dissociation of cytotoxic species that exist in a dynamic equilibrium
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with exposed fibril ends (Carulla et al. 2005). In this way, not only does fragmentation have
the potential to drive amyloid production, but also the ability to alter the physical properties
of the fibrils themselves. Therefore, fragmentation has the capacity to enhance the
cytotoxicity of so-called inert fibrillar material. Given this, the ability of these sHsps to
prevent the elongation of fibril fragments suggests a potential protective role for them in cells
when fibrils have formed and are prone to fragmentation.
The rate of elongation of α-syn fibrils was also dependent on the amount of seeds added, such
that increases in seed concentration resulted in increases in the apparent elongation rate
(Buell et al. 2014). At each concentration of monomeric α-syn, when the concentration of αsyn fibril seed added was increased, more Hsp27 was also required to completely inhibit
elongation. Thus, the efficacy of Hsp27 to inhibit elongation (as measured by the rate
constant of the elongation process) was inversely correlated to the seed concentration. This
suggests that there is a strong interaction between Hsp27 and the α-syn fibril seeds. Together,
this implies that the ability of Hsp27 to inhibit fibril elongation may result from a
combination of transient interactions with monomeric α-syn (to prevent association and
addition to fibril ends) and interactions with fibrillar material (essentially outcompeting
monomeric α-syn for access to the fibril ends). The overall outcome is the inhibition of
elongation of α-syn fibrils, and suggests that Hsp27 (and possibly other sHsps) can prevent
further fibril formation of α-syn even after aggregation has commenced. This highlights the
potential to target sHsps levels and/or activity in cells as a means of halting both the onset
and progression of α-syn aggregation associated with the α-synucleinopathies.
The mechanism by which sHsps interact with α-syn fibrils was also characterised. The results
presented here demonstrate that both αB-c and Hsp27 form a stable complex with α-syn
fibrils. Moreover, an Hsp27 phosphomimicking variant (Hsp273D) that forms dimers and

112

Chapter 4: sHsps interact with mature α-synuclein fibrils
monomers in solution (not large oligomers) was shown to be capable of binding to α-syn
fibrils, however, the core-domain variants of αB-c or Hsp27 do not. Thus, the sHsps do not
need to be large oligomers in order to bind to α-syn fibrils. However, the inability of αB-ccore
and Hsp27core to bind to α-syn fibrils demonstrates that binding is mediated by the N- and/or
C-terminal regions of the protein. Given that these core domains are still chaperone active
(Hochberg et al. 2014, Cox et al. 2016) (Appendix I), these data suggest that the sHsp
domains play distinct functional roles with regards to interactions with aggregation-prone
proteins. The central α-crystallin domain interacts with monomeric proteins to prevent them
entering off-folding pathways leading to aggregation (Hochberg et al. 2014, Cox et al. 2016),
whilst the flexible N- and/or C-terminal regions mediate stable interactions with aggregated
(fibrillar) protein (Mainz 2015).
The affinity of the binding interaction between sHsps and α-syn fibrils was probed using
Hsp273D, and found to be in the micromolar range, consistent with previous estimates of the
affinity of αB-c for apoC-II and Aβ fibrils (5µM and 2µM respectively) (Shammas et al.
2011, Binger et al. 2013). In addition, the binding interaction was saturated at
substoichiometric molar ratios of Hsp27, which is also consistent with previous investigations
of αB-c binding to apoC-II fibrils (Shammas et al. 2011, Binger et al. 2013). Together, the
data presented here suggests that the ability to bind to fibrils is a generic property of the
sHsps, independent of the protein from which the fibrils are initially formed.
Using TIRF microscopy, it was possible to directly visualize the interaction between Hsp27
and α-syn fibrils. It was observed that Hsp27 binds along the surface of fibrils in a similar
manner as described for αB-c (Waudby et al. 2010). By coating the fibril surface, Hsp27 may
act to inhibit surface-dependent templated secondary nucleation and/or fibril fragmentation,
both of which lead to increases in the abundance of small oligomeric species and total fibril
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load (Xue et al. 2009, Jakhria et al. 2014, Shvadchak et al. 2015). Importantly, it was noted
that the distribution of Hsp27 bound to the fibril was not uniform, suggesting that it may bind
preferentially to specific regions along the surface of the fibril. To investigate this further, a
novel imaging technique, known as sPAINT, was employed. This TIRF microscopy-based
technique utilises nile red (a fluorescent dye exhibiting a characteristic emission wavelength
shift according to the hydrophobic nature of the surrounding environment) to provide a
quantitative measure of the relative hydrophobicity at any given region along the fibril
surface. The results presented here demonstrate that, by binding to α-syn fibrils, Hsp27
significantly decreases hydrophobicity at the fibril surface. This is significant given that the
toxicity of aggregates formed from both pathogenic and non-pathogenic proteins correlates
with the level of exposed hydrophobicity at the aggregate surface (Bolognesi et al. 2010),
such that the more hydrophobic the aggregate the higher the toxicity. The observed reduction
in the relative hydrophobicity of Hsp27-bound α-syn fibrils suggests that, by binding to
regions of high hydrophobicity, Hsp27 may decrease the toxicity of aggregates.
In light of this, to assess whether binding of the sHsps to α-syn fibrils acts to decrease their
cytotoxicity, the production of ROS by cells was monitored upon exposure to preformed αsyn fibrils. The production of ROS associated with protein aggregates is thought to be a
significant mediator of neuronal toxicity in neurodegenerative disorders, including PD
(Tabner et al. 2001). ROS can damage DNA, induce modification of macromolecules, inhibit
protein function and promote apoptotic cell death (Simon et al. 2000, Circu and Aw 2010).
As anticipated, exposure of cells to exogenous α-syn fibrils resulted in a specific, rapid and
significant increase in cellular ROS production. However, pre-incubation of the α-syn fibrils
with Hsp27 or αB-c prevented this toxicity, indicating that the binding of these sHsps to
fibrillar α-syn represents a previously uncharacterised protective function of these
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chaperones, i.e. by binding to fibrils, Hsp27 and αB-c (and most likely other sHsps) prevent
the toxicity associated with extracellular amyloid fibrils.
Although α-syn has traditionally been considered an intracellular protein, recent
advancements in understanding the transmission of pathology between neuronal cells has
highlighted the role of extracellular α-syn in disease progression (Lee et al. 2005, Kordower
et al. 2008, Lee et al. 2008, Lee et al. 2008, Li et al. 2008). Aggregates may be released via
exocytosis of calcium-dependent exosomes or direct penetration of the cell membrane,
entering the extracellular space and gaining access to neighbouring cells (Lee et al. 2008,
Emmanouilidou et al. 2010). Aggregates have been shown to enter neighbouring cells,
through endocytosis, membrane-receptor mediated access or direct penetration of the cellular
membrane (Lee et al. 2008, Tang et al. 2012), where they can then seed the aggregation of
endogenous α-syn (Desplats et al. 2009, Luk et al. 2009, Volpicelli-Daley et al. 2011). In
addition to inducing intracellular ROS production, exogenous α-syn fibrils have been
associated with active adaptation of the proteome, whereby cells upregulate defence
mechanisms against dysfunction and death (Pieri et al. 2016). These effects have been
demonstrated in cultured cells as well as in mouse models recapitulating disease-related
inclusion body formation (Luk et al. 2012). It remains to be determined whether Hsp27 can
impact these other cytotoxic effects resulting from exposure to exogenous fibrils, e.g. by
binding to fibrils sHsps may prevent the uptake of fibrils by cells or may inhibit other
downstream, intracellular effects. However, due to their well-described anti-apoptotic
activity, it is likely that the sHsps play multiple roles in preventing the toxicity associated
with fibrils, in addition to those involving direct interactions with the aggregated protein.
Whilst the relevance of extracellular aggregates is becoming apparent, the accumulation of
intracellular aggregates remains a defining characteristic of α-syn aggregation. Currently,
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these deposits are thought to be storage spaces for the cell in which they may sequester
potentially toxic intermediates (Yerbury et al. 2013). In fact, chaperones have been shown to
promote the accumulation of cytotoxic oligomers into larger, non-toxic aggregates (Ojha et
al. 2011, Mannini et al. 2012). Cells may go on to live with these ‘storage’ inclusions over
extended periods of time, as they continually attempt to re-establish proteostasis. The
association of sHsps with these deposits may therefore have implications for their clearance,
as dismantling or degradation of these structures would expose the cell to potentially toxic
aggregates. Previous work using apoC-II fibrils and AUC demonstrated that the binding of
αB-c to fibrils both prevents their fragmentation and causes the dissociation of monomeric
species (Binger et al. 2013). The results presented here support these findings and extend
them to a disease-relevant model of protein aggregation: by binding to α-syn fibrils, Hsp27
and αB-c decrease the apparent size of the fibrils and promote their dissociation over a period
of up to 21 days. Whilst the production of monomeric α-syn from sHsp-bound fibrils was not
directly assessed here, the ability of the sHsps to dissociate α-syn fibrils into oligomers
suggests that the sHsps play an important role in assisting the clearance of aggregates should
cellular proteostasis be restored. In addition, by coating the dissociating species, the sHsps
could mitigate any cytotoxic effects. The potential protective effects of the sHsps being
bound to aggregated α-syn represent a significant area for future investigation.
Given that both αB-c and Hsp27 bind α-syn fibrils, it appears fibril binding may represent a
generic aspect of sHsp chaperone action. The work presented here provides evidence that the
fibril-binding capacity of the sHsps provides a second protective mechanism by which these
chaperones may prevent the toxicity associated with protein aggregation. Thus, rather than
being ‘caught up’ in inclusions as a by-product of their failed attempt to prevent aggregation,
the work presented in this chapter indicates that the localisation of sHsps to protein deposits
is likely due to their specific association with the aggregated protein as a protective measure
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in cells. Investigating the molecular mechanisms by which sHsps are able to interact with
aggregating proteins, including monomeric, oligomeric and fibrillar species, is essential to
understanding

the

potential

protective

capabilities

of

sHsps

in

cells.
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5.1 Introduction
The work in Chapters 3 and 4 of this thesis demonstrated that the sHsps αB-c and Hsp27
interact with various α-syn species formed during its aggregation into fibrils. This work
involved characterising the mechanisms by which sHsps interact with α-syn in simple buffers
in vitro, however, it is essential to consider the relevance of this interaction in a cellular
context. Much of what is known about the interaction between sHsps and α-syn in cells
comes from qualitative studies using cell-based models of α-syn aggregation (as summarised
in Section 1.4). One issue with these cell culture models of α-syn aggregation, which has
hampered their use in quantitative studies, is that typically only a small proportion of the cells
in culture develop inclusions (typically less than 5% in studies where this is quantified)
(McLean et al. 2001). This severely limits the types of biochemical analyses that can be
undertaken with these models. Therefore, there is a need to develop a robust and reliable cellbased model of α-syn aggregation so that the effect the sHsps have on this process can be
quantified in cells.
5.1.1 Modelling cellular aggregation
Detecting and quantifying aggregates in cell models most commonly relies on biochemical or
fluorescence microscopy techniques (Shiber et al. 2014). The formation of aggregates in a
population of cells is often assessed via techniques such as differential centrifugation,
detergent insolubility and/or size exclusion gel filtration, however, these methods are not
suited to resolving the time-dependent changes that occur during the aggregation process
(Shiber et al. 2014). In addition, exposure to detergents can dissociate aggregates producing
false-negative results (Muchowski 2002), while lysis and centrifugation techniques may
increase the non-specific adhesion of proteins resulting in false-positive results (Shiber et al.
2014). Fluorescence microscopy can provide qualitative co-localisation analyses and is
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amenable to real-time investigation of protein aggregation, however, the subjective nature of
this technique can result in bias and random error (Shiber et al. 2014). Obtaining quantitative
information from microscopy analyses is possible, although it generally requires manuallyassisted counting as image analysis algorithms can be highly dependent on background
thresholding and restricted in their capacity for feature extraction and segmentation of
individual cells (Ramdzan et al. 2012). As such, these techniques are inherently incompatible
with high throughput analyses.
In addition to these challenges, perhaps the most significant limitation of these techniques is
the inability to recover distinct populations for further analysis (Ramdzan et al. 2012). The
emergence of flow cytometry-based methods for detecting aggregate-associated fluorescence
overcomes this limitation and is amenable to high throughput analyses. Mitsui and colleagues
(2006) describe a method for purification of fluorescently labelled Htt aggregates from N2a
cell lysates, in which fluorescence activated cell sorting (FACS) selectively collects
aggregates of the labelled protein of interest. This technique is powerful as it enables further
biochemical analysis of the aggregates, e.g. identification of proteins within the aggregate via
mass spectrometry (Mitsui et al. 2006). More recently, a method using flow cytometric
analysis of intact cells was described by Ramdzan and colleagues (2012). The technique,
termed pulse-shape analysis (PulSA), exploits the reduction in pulse width and increase in
pulse height associated with an intracellular (fluorescently tagged) protein when it is in an
aggregate compared to when it is diffuse in the cytoplasm. PulSA also enables cells with
aggregates to be sorted via FACS, thereby allowing a population of live, intact cells which
are enriched with aggregates to be isolated. However, whilst this technique works well when
large inclusions are formed by an aggregation–prone protein in cells (e.g. the exon 1 fragment
of the Htt protein containing an extended poly-glutamine repeat), it is limited in its sensitivity
to detect the smaller aggregates formed in cells by other disease-relevant proteins (e.g. TDP-
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43 or SOD1). This limitation is a result of PulSA not being capable of distinguishing shifts in
the pulse height and pulse width when small aggregates are present in a cell, despite
inclusions being visible via microscopy (Ramdzan et al. 2012, Shiber et al. 2014, Whiten et
al. 2016).
There currently exists a plethora of cellular models which recapitulate the cellular
aggregation of disease-associated proteins, each displaying characteristics specific to the
protein of interest. Ideally, when developing model systems to investigate the cellular
aggregation of a protein, compatibility with high throughput assays that provide the
capability to recover live cells is advantageous. This enables aggregation to be related to
specific biological outcomes, or the utility of targeting specific aggregation events with
therapeutic agents to be established (Ramdzan et al. 2012). However, the characteristics of a
given cell-based model of aggregation will determine which techniques are suitable to
analyse the aggregation process. In any case, such cell-based models have provided crucial
insight into protein-specific or generic aggregation properties associated with disease, and
represent an essential link between in vitro and in vivo studies.
5.1.2 Monitoring chaperone action in cells
As described in Section 1.1.3, tagging a protein expressed in cells with a fluorescent protein
or fluorophore is a common way of tracking its intracellular localisation. However, Hsps
often form dynamic oligomers which interact with various cofactors and substrate proteins. In
particular, the sHsps αB-c and Hsp27 form large polydisperse oligomers which undergo
dynamic subunit exchange (Bova et al. 2000, Van Montfort et al. 2002), a process that is
thought to be a critical mediator of their chaperone activity. As such, these functions can be
significantly affected by the addition of bulky fluorescent tags. Recent work has
demonstrated that the addition of a fluorescent protein tag to the N- or C-terminus of αB-c or
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Hsp27 significantly impacts the ability of these sHsps to form oligomeric assemblies and act
as chaperones, compared to the non-labelled protein (Datskevich et al. 2012, Datskevich et al.
2012, Datskevich and Gusev 2014). Thus, the addition of bulky fluorescent tags to sHsps is
not a suitable option when attempting to study their chaperone activity in cells. However, the
expression of untagged sHsps in cells does not allow differences in transfection efficiency
and expression levels to be taken into account when comparing between individual cells and
samples in an experiment, which can confound analyses.
There is therefore a need to develop an alternative method to evaluate the effect of sHsps in
cells that does not involve tagging them with a fluorescent protein, but does take into account
potential differences in transfection efficiencies and protein expression levels. One such
method is the use of bicistronic expression constructs which enable the expression of a gene
of interest (in this case a sHsp) and a fluorescent (reporter) protein (in this case EGFP)
(Assoc. Prof. Heath Ecroyd, personal communication). In these bicistronic constructs, the
mRNA contains an internal ribosome entry site (IRES) such that the expression of the sHsp
of interest and fluorescent protein is correlated. In this way the levels of the fluorescent
protein acts as a reporter of the expression of the sHsp. Use of these IRES constructs
therefore enables transfected cells to be detected, and the relative levels of chaperone to be
quantified (based on the expression levels of the fluorescent reporter) without the addition of
a fluorescent tag directly to the protein.
5.1.3 Experimental rationale
Despite their many limitations, cell-based models of α-syn aggregation have revealed some
evidence for sHsps inhibiting α-syn aggregation or toxicity in cells (Klucken et al. 2004,
Zourlidou et al. 2004, Outeiro et al. 2006). In order to advance our understanding of the
ability of sHsps to prevent the aggregation of α-syn in cells, a suitably robust and reliable
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cell-based model of α-syn aggregation was sought. Once this cell-based assay was developed,
the ability of sHsps to prevent the aggregation of α-syn in cells was assessed. Since the
addition of a fluorescent tag potentially impacts the function of sHsps in cells (Datskevich et
al. 2012, Datskevich et al. 2012, Datskevich and Gusev 2014), bicistronic IRES vectors were
used to evaluate and compare the ability of αB-c and Hsp27 to prevent intracellular
aggregation of α-syn. In these assays, an IRES construct encoding EGFP and a nonchaperone control protein EGFPinv was utilised to ensure all cells received equal DNA
concentrations and an equivalent number of proteins to express. Finally, in order to assess
whether the sHsps are able to prevent the aggregation of other disease-relevant proteins in
cells, the IRES constructs encoding EGFP and a range of other Hsps (or the non-chaperone
controls EGFPinv or LacZ) were used in the well characterised cell model of Htt exon 1
aggregation and evaluated via PulSA.
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5.2 Methods
5.2.1 Cloning strategy to produce truncated variant of α-synA53T-EGFP
Two variants of the α-syn expression construct (see Section 2.2.1) were employed in an
attempt to generate a robust and reliable cellular model of α-syn aggregation. First, constructs
encoding EGFP-tagged α-synWT and α-synA53T were utilised without modification. The
cloning strategy for the second construct is summarised in Figure 5.1, and was designed
according to findings published by McLean and colleagues (2001) in which an aggregationprone cleavage product of α-syn was identified within cells initially transfected to express αsyn with a C-terminal EGFP tag (i.e. α-syn-EGFP). Specifically, this product was
approximately 27 kDa, and corresponded to a cleaved form of α-syn-EGFP in which the last
155 residues from the C-terminal region of EGFP were removed. This resulted in α-syn fused
to a non-fluorescent EGFP fragment. The region corresponding to α-synA53T and the first 85
residues of EGFP (i.e. lacking the last 155 residues, designated α-synA53T*) was amplified
from the original α-synA53T-EGFP construct by PCR using MyTaq DNA polymerase, the
CMV-F primer (5’ – CGCAAATGGGCGGTAGGCGTG – 3’) and a custom designed primer
(5’ – CTTGCGGCCGCCTAGAAGAAGTCGTGCTGC – 3’) containing the NotI
restriction site (bold text). PCR was performed using a Mastercycler ProS (Eppendorf) and
consisted of 35 cycles, with each cycle consisting of denaturation at 95°C for 15 s, annealing
at 55°C for 15 s, and extension at 72°C for 10 s. The amplified product was combined with
agarose loading buffer (final concentrations: 30% (v/v) glycerol, 0.25% (w/v) bromophenol
blue in dH2O) and resolved via electrophoresis using a 1% (w/v) Tris-acetate-EDTA (TAE;
40 mM Tris-base, 20 mM glacial acetic acid, 1 mM EDTA, pH 8.0) agarose gel alongside the
Hyperladder I (200 – 10037 bp) and Hyperladder II (50 – 2000 bp) molecular weight
markers. Gels were submerged in 1 × TAE buffer in a MiniSub Cell GT electrophoresis tank
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(Bio-Rad, Hercules, USA) and electrophoresis was performed at 100 V until the dye front
reached the end of the gel. DNA bands were briefly visualised under UV light using a Gel
Logic 2200 Pro Imaging System (Carestream Health, Rochester, USA) following staining
with 0.005% (w/v) ethidium bromide solution for 15 min and destaining with dH2O for 5
min.
The PCR product was excised from the gel and purified using the Isolate II PCR and Gel kit
(Bioline, Toronto, Canada) according to the manufacturer’s instructions. The purified PCR
product (insert) and the pEGFP-N3-α-synA53T-EGFP construct were double digested using
Acc65I and NotI, according to the manufacturer’s instructions, before heat inactivation at
80oC for 20 min. The desired products were separated from the digestion fragments via
agarose gel electrophoresis, and purified using the Isolate II PCR and Gel kit (Bioline,
Toronto, Canada) as described above. Ligation of the insert and digested plasmid was
performed at 16°C for 16 h using T4 DNA ligase (5 μg/mL) in a 20 μL reaction mixture
containing 1 × ligase buffer and 1 × ATP solution. The ligation mixture was then used to
transform chemically competent DH5α E. coli as per Section 2.2.2. Successfully transformed
colonies were screened for the α-synA53T* insert by PCR using the CMV-F and SV40 (5’ –
CTCTACAAATGTGGTATGGC – 3’) primers. PCR was performed using a Mastercycler
ProS (Eppendorf) and consisted of 30 cycles, with each cycle consisting of denaturation at
95°C for 15 s, annealing at 52°C for 15 s, and extension at 72°C for 15 s. A colony positive
for the α-synA53T* insert was selected and plasmid DNA was extracted using the Wizard®
Plus SV Miniprep DNA Purification System (Promega, Fitchburg, U.S.A.) according to the
manufacturer’s instructions. The construct was then verified via restriction digest with the
preparative enzymes as described above to confirm the correct size of the liberated insert, and
sequencing (see Section 2.2.1).
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Figure 5.1: Cloning strategy used to generate α-synA53T* construct for mammalian expression.
From the original α-synA53T-EGFP construct, PCR amplification and restriction enzyme digestion
generated a linear construct and insert fragment, which was then ligated using T4 DNA ligase.
Construct maps are annotated with solid, coloured arrows to indicate genes of interest, primer sites
(red text) and enzyme digestion sites (purple text). Orange line in the original construct indicates the
original PCR amplification product.
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5.2.2 Transfection and treatment with inducers of cellular stress
For transfection, cells were seeded at 100 000 cells/mL in 6-well, 12-well or 24-well plates
(Greiner Bio-One, Frickenhausen, Germany), or 8-well chamber slides (Ibidi, Martinsried,
Germany) and grown overnight. Cells were then transfected using Lipofectamine® LTX
(Invitrogen, Waltham, U.S.A.) according to the manufacturer’s instructions. Briefly,
DNA:liposome complexes were generated by incubation of 1 μg of plasmid DNA in serum
free DMEM/F12 with 3 µL of Lipofectamine® LTX and 1 µL PLUS™ reagent per ~3.5 cm 2
of cells to be transfected, at room temperature for 30 min. In the case of dual transfections,
DNA complexes for each plasmid were prepared separately then combined after the 30 min
incubation period to allow mixing. In this way, each plasmid is incorporated into separate
liposomes, which can then be independently taken up by cells. Dual transfections (unless
stated) were completed at a 1:4 (IRES:α-syn or Htt) (w/w) ratio of DNA. Complexes were
then applied to cells in fresh culture medium and incubated for 48 h at 37°C under 5%
CO2/95% air.
Where necessary, cells were treated with various inhibitors of proteostasis pathway
components to induce cellular stress. Treatments included a proteasome inhibitor (MG132;
10 µM), an autophagy inhibitor (3-methyladenine (3-MA); 10 mM), an inducer of ER stress
(thapsigargin; 3 µM), or an inducer of oxidative stress (FeCl2; 10 mM), all of which were
solubilised in DMSO as 1000-times stocks and subsequently diluted into serum free
DMEM/F12 for addition to cultured cells. Mock treated cells were exposed to the appropriate
concentration of DMSO in serum free DMEM/F12.
5.2.3 Immunocytochemistry
Proteins of interest were routinely visualised in cells via immunocytochemistry. Cells were
seeded at 100 000 cells/mL onto sterilised 19 mm glass coverslips (ProSciTech, Thuringowa,
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Australia) or in 8-well chamber slides (Ibidi, Martinsried, Germany) and transfected as
described above. After 48 h, or following treatment for the times indicated, culture medium
was removed from the cells and the cells washed twice with PBS. Cells were fixed via
incubation with 4% (w/v) paraformaldehyde (PFA, pH 7.4) for 20 min at room temperature
and washed twice with PBS. Cells were then permeabilised using 0.5% (v/v) Triton X-100 in
PBS for 20 min at room temperature, before being washed twice with 1% (w/v) BSA in PBS.
Cells were then blocked using 5% (w/v) BSA in PBS, and washed twice in 1% (w/v) BSA in
PBS-Tween 20 (PBS-T; PBS containing 0.05% (v/v) Tween-20).
Intracellular proteins were immunolabelled using the appropriate primary antibody diluted
1:500 with 1% (w/v) BSA in PBS-T. Cells were incubated at 37oC for 1 h in a humidity
chamber, before being washed three times with 1% (w/v) BSA in PBS-T. The appropriate
fluorophore-conjugated secondary antibody was diluted 1:500 with 1% (w/v) BSA in PBS-T,
and applied to the cells. Following incubation at 37oC for 1 h in a humidity chamber, cells
were then washed four times with 1% (w/v) BSA in PBS-T.
5.2.4 Confocal microscopy imaging
Coverslips with cells containing fluorescent or immunolabelled proteins were mounted onto
26 × 76 mm glass slides (ThermoFischer Scientific, Waltham, USA) using Citifluor™ AntiFadent Mounting Solutions (9:1 (v/v) ratio of Citifluor™ CFPVOH: Citifluor™ AF100 antifadent; ProSciTech, Thuringowa, Australia) and allowed to set at room temperature for 1 h
prior to imaging. Alternatively, cells in chamber slides were overlayed with PBS containing
10% (v/v) Citifluor™ AF100 anti-fadent (ProSciTech, Thuringowa, Australia) and imaged
immediately. Cells were observed using a Leica TCS SP5 confocal microscope (Leica
Microsystems, Wetzlar, Germany). Fluorescent conjugates were excited at 488 nm, 561 nm,
or 633 nm by argon, DPS 561, and HeNe lasers, respectively. Fluorescent emissions were
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acquired by sequential scanning using the Leica Application Suite –Advanced Fluorescence
(LAS-AF) software v3 (Leica Microsystems, Wetzlar, Germany). Either photomultiplier tube
(PMT) or hybrid (HyD) detectors were selected and custom filter windows set according to
the intensity and emission spectrum of the fluorophore of interest. Gains and filter windows
were set according to the untransfected and isotype (mouse or rabbit IgG) stained controls
using the overflow colour map, such that samples were below the saturation point,
background fluorescence was not visible and bleed through was eliminated.
5.2.5 Inclusion quantification
5.2.5.1

Flow cytometry

A recently described flow cytometry method of distinguishing inclusions in whole cells,
known as PulSA, was used (Ramdzan et al. 2012). Briefly, transfected cells were harvested
by replacing culture media with a sufficient volume of trypsin containing 0.05% (w/v) EDTA
to cover the cells. After incubation at 37°C for 5 min the plate was gently tapped to dislodge
cells, if necessary. The plate was then washed with DMEM/F12 containing 1% (v/v) FCS,
and cells were collected. Cells were harvested via centrifugation at 300 x g for 5 min at room
temperature, and washed twice in PBS. Cells were then resuspended in PBS and analysed via
flow cytometry using an LSR II or LSRFortessa X-20 Flow Cytometer (BD Biosciences, San
Jose, U.S.A). In addition to forward and side scatter, area, height and width parameters of
GFP fluorescence (excited at 488 nm) and mCherry fluorescence (excited at 561 nm) were
collected at 525/50 nm and 586/15 nm respectively, using FACS Diva™ software v6.1.3 (BD
Biosciences, San Jose, U.S.A.). Gating and data analysis was performed using FlowJo
software v10 (Tree Star, Ashland, U.S.A.). Using the PulSA gating strategy (Ramdzan et al.
2012), live transfected cells of interest were selected, then a scatterplot of the GFP
fluorescence width versus height parameters was generated for cells that did not contain
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inclusions (nipop) but instead contain diffuse, cytosolic fluorescence. It was then possible to
distinguish cells containing compact, punctate fluorescence (indicating protein inclusions),
according to a shift in both GFP fluorescence height and width which results in the
appearance of a population of cells with inclusions (ipop) in the upper left quadrant (i.e.
narrower pulse width and higher pulse height than cells without inclusions). The percentage
of cells in this population was then compared across treatment groups relative to the EGFP inv
control.
5.2.5.2

Manual quantification using ImageJ

Images collected via confocal microscopy were processed manually with ImageJ (National
Institutes of Health, Bethesda, U.S.A.) using custom written macro scripts (Appendix VI).
These methods were developed to enable non-subjective quantification of the number of cells
with aggregates between samples. Briefly, cell boundaries of individual cells were defined
using the brightfield image, and the transfected cells determined automatically via
thresholding of the fluorescent image. Cells containing inclusions (visually defined as
fluorescent puncta) were manually selected according to the fluorescent image, and the
percentage of transfected cells (or co-transfected cells in experiments involving the IRES
constructs) with and without inclusions for each treatment was calculated using a custom
written Python script (Appendix VII). This was completed with at least 50 cells per treatment
over four biological repeats.
5.2.6 Cell lysate analysis via filter trap assay
In order to confirm the presence of insoluble aggregates in cellular α-syn inclusions, a filter
trap assay was performed. Cells were transfected, treated with inhibitors where appropriate
and harvested as described in Section 2.7.1. Cell pellets were washed twice in PBS, and then
resuspended in lysis buffer (PBS containing 0.5% (v/v) Triton-X 100, pH 7.4, supplemented
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with 0.5% (v/v) Halt™ Protease and Phosphatase Inhibitor Cocktail). The total protein
concentration for each sample was then determined using a Pierce BCA assay
(ThermoFischer Scientific, Waltham, USA) according to the manufacturer’s instructions.
Samples were diluted using lysis buffer to generate 200 µL aliquots containing 200 µg total
protein, and kept on ice until use. In addition, aliquots containing known concentrations of
recombinant monomeric or fibrillar α-syn were similarly prepared in PBS or spiked into lysis
buffer and kept on ice.
In order to determine the concentration of α-syn in samples produced following transfection
with the α-synA53T* construct, a dot blot was first performed using these samples. Samples
were spotted (to a total volume of 5 µL) onto nitrocellulose membrane, and left to dry at
room temperature for 1 h. The membrane was then blocked at room temperature for 1 h in
5% (w/v) skim milk powder in TBS, before being analysed via the immunoblotting technique
described in Section 2.5. The intensity of spots of interest were analysed using the gel
quantification function in ImageJ, and a standard curve of concentration of recombinant αsyn versus spot intensity was generated. The concentration of α-syn in the transfected cell
extracts was then determined via interpolation from the standard curve and was found to be
less than 1 µM (see Appendix VIII).
The Bio-Dot microfiltration apparatus (Bio-Rad, Hercules, CA) was prepared according to
the manufacturer’s instructions. Briefly, 0.22 µm cellulose acetate membrane (Whatman,
Maidstone, UK) and three sheets of Bio-DOT SF filter paper (Bio-Rad, Hercules, CA) were
equilibrated in PBS containing 1% (w/v) SDS (pH 7.4) for 10 min at room temperature. The
Bio-Dot apparatus was then assembled containing the membrane and filter paper and
tightened under vacuum. Each slot for use was rehydrated with 200 µL PBS, which was then
filtered under vacuum immediately prior to the addition of 200 µL of the prepared cell lysate
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or appropriate control samples. Any unused slots were sealed with clear sealing film, and
samples filtered under gentle vacuum. Once all samples had been filtered, 200 µL of PBS
was added to the sample well and filtered under gentle vacuum. The membrane was then
removed and blocked in 5% (w/v) skim milk powder in TBS, before being analysed via the
immunoblotting technique described in Section 2.5.
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5.3 Results
5.3.1 Developing a cell model of α-syn aggregation
5.3.1.1

Transfection with fluorescently tagged α-syn constructs

Transfection with fluorescently tagged aggregation-prone proteins is a common method for
investigating cellular aggregation, including that of α-syn (McLean et al. 2001, Outeiro et al.
2006), and was therefore first explored in the search for a robust cell model of α-syn
aggregation. Constructs encoding α-synWT or the disease-associated mutant α-synA53T, Cterminally fused to a fluorescent EGFP tag, were used to determine whether α-syn aggregates
and forms inclusions in cells. First, the expression of the α-syn-EGFP fusion proteins was
confirmed via immunoblotting of transfected cell lysates (Figure 5.2A). This revealed a band
at approximately 44 kDa immunoreactive against the α-syn antibody in both the α-synWTEGFP and α-synA53T-EGFP samples, consistent with the expected mass of 41.5 kDa
resulting from fusion of EGFP (27 kDa) to α-syn (14.5 kDa). However, a significant amount
of smaller bands (ranging from 27 – 37 kDa) were also immunoreactive against the α-syn
antibody in the α-synA53T-EGFP cell lysate, suggesting this protein is prone to degradation.
The expression and localisation of the α-syn-EGFP proteins was examined via confocal
microscopy. Cells expressing the aggregation-prone TDP-43-tGFP were used as controls in
this experiment, as TDP-43 aggregation has been extensively examined both in vitro and in
vivo, displaying characteristics of amyloid oligomer and fibril formation (Guo et al. 2011,
Fang et al. 2014). Importantly, TDP-43-tGFP has previously been demonstrated to form
small intracellular inclusions in N2a cells when treated with a proteasome inhibitor (MG132)
and an inducer of ER stress (thapsigargin) (Dr. Daniel Whiten, University of Wollongong,
personal communication) similar to those previously detected for α-syn (McLean et al. 2001,
Outeiro et al. 2006). Imaging of cells expressing TDP-43-tGFP revealed the presence of
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small fluorescent puncta corresponding to inclusions in approximately 30% of GFP-positive
cells (Figure 5.2B). No clearly defined fluorescent puncta were detected in cells expressing
either WT or A53T isoforms of α-syn-EGFP (Figure 5.2B). However, accumulations of
fluorescence were evident in some cells expressing high levels of α-syn-EGFP, which may
represent aggregated α-syn-EGFP (Figure 5.2B, inset).

Figure 5.2: Fluorescently tagged α-syn variants produce visible inclusions. N2a cells were
transiently transfected with constructs encoding EGFP-tagged α-synWT or α-synA53T, or the
aggregating control protein TDP-43-tGFP. Cells transfected with TDP-43-tGFP were treated with
proteostasis inhibitors (10 µM MG132 and 3 μM thapsigargin), and all cells were incubated for a
further 48 h. (A) Cells were harvested and lysed such that whole cell protein extracts could be
analysed via SDS-PAGE. Following transfer to nitrocellulose membrane, EGFP-tagged α-synWT
(lane 1) or EGFP-tagged α-synA53T (lane 2) were detected using a mouse monoclonal anti-α-syn
primary antibody and a HRP-conjugated anti-mouse IgG secondary antibody. The position of
molecular weight markers in kDa are indicated by the arrows. Transfected cells were also grown on
glass coverslips and (B) imaged via confocal microscopy. Scale bars represent 10 µm (or 5 µm in
inset). Arrows indicate regions of concentrated fluorescence.

To evaluate whether the inclusion-like particles observed in cell expressing α-syn-EGFP were
detectable via PulSA, N2a cells were transfected to express α-syn-EGFP (WT or A53T) or
TDP-43-tGFP and compared to cells expressing EGFP-alone (which acted as a negative
control). The forward and side scatter signals of events were used to select live, viable cells
(Figure 5.3A), and to exclude events corresponding to cellular debris and cell-doublets. Cells
expressing the proteins of interest were then selected based on their GFP fluorescence
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compared to untransfected cells (Figure 5.3B), and these live GFP-positive cells were then
analysed via PulSA by plotting their pulse height and pulse width signals. Cells expressing
EGFP alone were used to identify the inclusion-negative population of cells (nipop) and to set
the gate to identify cells with inclusions (ipop) (Figure 5.3C). The proportion of cells
expressing α-synWT-EGFP or α-synA53T-EGFP in the ipop gate was very low (<5%) (Figure
5.3D and E). However, even in cells expressing TDP-43-tGFP, which had previously been
observed to contain fluorescent aggregates in approximately 30% of cells (see Figure 5.2),
the proportion of cells in the ipop was low (4.5%) (Figure 5.3F). Thus, PulSA does not appear
to be suitable for detection of cells with smaller inclusions, such as those formed by α-syn in
cells. It was therefore concluded that fluorescence-based microscopy would likely be a more
suitable method for assessing α-syn aggregation in cells.

Figure 5.3: Fluorescently tagged α-syn variants do not produce inclusions detectable via PulSA.
N2a cells were transiently transfected with constructs encoding the control protein EGFP, EGFPtagged α-synWT or α-synA53T, or TDP-43-tGFP, and incubated for 48 h. Cells transfected with
TDP-43-tGFP were treated with proteostasis inhibitors (10 µM MG132 and 3 μM thapsigargin) and
all cells were incubated for a further 48 h before being analysed via flow cytometry. Scatter plots of
the forward and side scatter signals were used to select (A) live cells, and GFP fluorescence of
untransfected cells were used to select (B) EGFP-positive cells. These cells were then analysed using
PulSA. (C) The population of cells with inclusions (ipop) was identified based on the PulSA plot of
cells expressing EGFP alone (very few of these cells develop inclusions). Cells expressing (D) αsynWT-EGFP, (E) α-synA53T-EGFP or (F) TDP-43-tGFP with inclusions were then identified. The
proportion (as a percentage) of GFP-positive cells in the ipop is given in each plot.
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Given the importance of the proteostasis network in modulating cellular aggregation,
targeting members of this network is a common method of inducing the aggregation of
proteins into inclusions, including in cellular models of α-syn aggregation (Outeiro et al.
2006, Bertoncini et al. 2007, Wan and Chung 2012) and as observed for TDP-43 (see Figure
5.2). To determine the effect of disrupting elements of proteostasis on the number of
fluorescent puncta observed in N2a cells transfected to express α-synWT-EGFP, α-synA53TEGFP, EGFP alone (negative control) or TDP-43-tGFP (positive control), cells were
incubated in the absence or presence of MG132 (10 µM, proteasome inhibitor), thapsigargin
(3 µM, inducer of ER stress) or FeCl2 (10 mM, inducer of oxidative stress). Cells were
imaged via confocal microscopy (Figure 5.4A), and the number of EGFP-positive cells
containing diffuse fluorescence (left box, 1) or fluorescent puncta (right box, 2) was
determined for each treatment. The percentage of transfected cells (diffuse + puncta cells)
containing inclusions following treatment was then compared with the untreated EGFP
expressing control cells (Figure 5.4B). As expected, there was a significantly higher
(p<0.001) proportion of cells expressing TDP-43-tGFP with inclusions (41.5 ± 7.20%)
compared to those expressing EGFP (2.92 ± 1.14%). However, treatment of cells expressing
either of the α-syn-EGFP variants with these agents had no significant effect on the
percentage of cells containing inclusions compared to those expressing EGFP alone.
Moreover, the proportion of cells expressing α-syn with inclusions remained very low
(<10%). To determine whether the lack of aggregation of α-syn into inclusions was due to the
cell line being used in this work (i.e. N2a cells), this experiment was repeated using HEK293
cells (Figure 5.4C). As expected, treatment of HEK293 cells expressing TDP-43-tGFP with
MG132 and thapsigargin significantly (p<0.001) increased the proportion of cells with
inclusions (36.1 ± 8.56%) compared to treated cells expressing EGFP alone (5.40 ± 2.45%).
However, as seen for N2a cells, there was no significant difference in the percentage of α-
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syn-EGFP expressing HEK293 cells containing fluorescent puncta following treatment with
MG132, thapsigargin or FeCl2 compared to cells expressing EGFP alone. In all cases the
percentage of transfected cells with inclusions remained very low (<7%). As such, it was
concluded that expression of EGFP-tagged α-syn variants was not sufficient to produce a
robust model of α-syn aggregation in cells, and therefore an alternate model was pursued.

Figure 5.4: Expression of fluorescently tagged α-syn isoforms does not result in robust inclusion
formation in N2a or HEK293 cells. N2a or HEK293 cells were transiently transfected with
constructs encoding EGFP (as a negative control), or EGFP-tagged variants of α-synWT or αsynA53T, or TDP-43-tGFP. Cells were treated with proteostasis inhibitors (10 µM MG132, 3 μM
thapsigargin, or 10 mM FeCl2) as indicated and incubated for 48 h before being mounted on glass
slides and imaged via confocal microscopy. Images were randomly collected according to the
brightfield channel, and the number of GFP-positive cells containing diffuse or aggregated fluorescent
protein was manually quantified using (A) an overlay of the brightfield and fluorescent images.
Examples of cells counted as (1) diffuse fluorescence and (2) punctate fluorescence are shown. Scale
bars represent 25 μm. The percentage of GFP-positive cells containing inclusions for (B) N2a or (C)
HEK293 cells following each treatment is displayed as mean ± S.E.M. (n=3), and was analysed via a
one-way ANOVA with a Dunnett’s post-test compared to the untreated EGFP control, where ***
indicates p<0.001.
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5.3.1.2

Transfection with α-synA53T*

Previous work attempting to develop a cell model of α-syn aggregation in which a
fluorescently tagged α-syn was expressed in human H4 neuroglioma cells led to the discovery
of intracellular puncta which were non-fluorescent but immunoreactive to α-syn (McLean et
al. 2001). This work identified a cleavage product of the expressed α-syn-EGFP in these
inclusions. This product consisted of α-syn with a C-terminal fragment of EGFP in which the
last 155 residues of EGFP has been cleaved from the protein. According to the sequences
provided for these cleavage products, a construct was designed for the expression of α-syn
fused to a fragment of EGFP (designated α-synA53T*). Using custom PCR primers, the
appropriate region of the α-synA53T-EGFP construct was amplified and the product analysed
via agarose gel electrophoresis (Figure 5.5A). The generation of a product of 850 bp was
consistent with the expected size (849 bp) of the target sequence to be amplified. This PCR
product, along with the original construct containing the α-synA53T-EGFP gene, were
digested and ligated, before being transformed into chemically competent E. coli. Colonies
were selected from the transformation and screened for the insert of interest via PCR
amplification, which was analysed using agarose gel electrophoresis (Figure 5.5B). Clones
displaying a prominent band of approximately 1400 bp correspond to amplification of the
original, full length α-synA53T-EGFP sequence (which has an expected size of 1347 bp) and
are therefore consistent with re-ligation of the original construct. Conversely, clones positive
for the truncated construct were identified by the appearance of a band at approximately 900
bp, consistent with the expected size of 884 bp, due to the deletion of 155 amino acid
residues of EGFP from the C-terminus. To confirm the presence of the construct of interest,
clones were subjected to enzymatic digestion alongside the original construct, and analysed
via agarose gel electrophoresis (Figure 5.5C). Digestion of the original construct liberates two
linearised fragments of 4200 bp and 800 bp, corresponding to the vector and insert,
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respectively. This is consistent with the expected size of 752 bp for α-synA53T-EGFP. In
contrast, double digestion of clones predicted to contain the sequence of interest (i.e. αsynA53T*) liberated fragments of 4200 bp and 300 bp, corresponding to the vector backbone
and the truncated insert (which has an expected size of 284 bp), respectively. Two positive
clones were therefore selected for sequencing and both were found to contain the αsynA53T* insert, which was seen to be in frame and did not contain any mutations (data not
shown).

Figure 5.5: Cloning and expression of α-synA53T*. (A) Using custom-designed primers, the αsynA53T* gene was amplified from the original α-synA53T-EGFP construct via PCR and analysed
via agarose gel electrophoresis. (B) Following enzymatic digestion and ligation of the α-synA53T*
gene into the original pN3 vector in place of α-synA53T-EGFP, E. coli were transformed with the
ligation mixture. Colonies were screened via PCR, such that colonies containing the α-synA53TEGFP gene (lane 1) were distinguishable from those containing the α-synA53T* gene of interest (lane
2). (C) Enzymatic digestion of DNA extracted from positive colonies was analysed via agarose gel
electrophoresis, such that the α-synA53T-EGFP construct (800 bp, lane 1) is distinguishable from the
α-synA53T* construct (300 bp, lane 2). (D) Following transfection of N2a cells with a construct
encoding for expression of α-synA53T-EGFP (lane 1) or α-synA53T* (lane 2), whole cell lysates
were analysed via immunoblot in which α-syn was detected via a monoclonal mouse anti α-syn
antibody and a HRP-conjugated anti-mouse secondary antibody. For agarose gel electrophoresis, the
position of Hyperladder II and Hyperladder I bp markers are shown where appropriate to left and right
of gels respectively. For immunoblot analysis, arrows indicate the position of molecular weight
markers in kDa.
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The successfully cloned construct containing α-synA53T* was used to transfect N2a cells
and, following 48 hours incubation to allow overexpression of the protein, lysates were
analysed via immunoblotting (Figure 5.5D). As observed previously, transfection of cells to
express α-synA53T-EGFP (positive control) resulted in an immunoreactive band at
approximately 44 kDa, consistent with the full length α-synA53T-EGFP. In contrast, in cells
transfected to express α-synA53T* an immunoreactive band at approximately 27 kDa,
consistent with the expected size of the α-synA53T* protein was evident. As expected, cells
expressing α-synA53T* were non-fluorescent.
Having established that α-synA53T* is expressed in N2a cells following transfection, its
propensity to form intracellular inclusions was investigated. N2a cells transfected with the αsynA53T* encoding construct were immunostained for α-syn and mounted on glass slides for
imaging via confocal microscopy (Figure 5.6A-D). Qualitative analysis of cells positive for
α-syn revealed the formation of fluorescent puncta, which appeared to be both distributed
throughout the cytosol (Figure 5.6B, D) and at the periphery of cells (Figure 5.6C, D). The
presence of these puncta in transfected cells was quantified, and the percentage of transfected
cells containing inclusions found to be 31 ± 5.5%. Following treatment with the proteostasis
inhibitors 3-MA (autophagy inhibitor) or MG132 (proteasome inhibitor), there was a
significant increase in the percentage of cells containing inclusions compared to the untreated
or DMSO-vehicle treated samples (p<0.05; Figure 5.6E).
Filter trap assays have been used extensively in the past to assess inclusion formation in cells
(Chang and Kuret 2008, Juenemann et al. 2015, Nasir et al. 2015). Typically, soluble protein
moves through the membrane pores, however, aggregated protein is retained on the
membrane such that proteins in the aggregates can be detected by immunoblotting. Thus, in
order to confirm the immunoreactive puncta represent aggregated α-syn in inclusions, lysates
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from cells transfected to express α-synA53T* (or an EGFP control) were subjected to filter
trap analysis (Figure 5.6D). When recombinant monomeric α-syn was added into buffer at
concentrations that exceed the level of α-synA53T* expressed in cells (see Appendix VIII for
quantification), it was not trapped by the filter and therefore was not detected by
immunblotting (Figure 5.6F). Moreover, no signal was detected when recombinant
monomeric α-syn was added to the lysate from untransfected cells, thus demonstrating that
monomeric α-syn does not aggregate in the cell lysate as a result of the lysis procedure.
Importantly, recombinant fibrillar α-syn added to buffer or spiked into the lysate from
untransfected cells was trapped by the filter and detected when present at levels as low as
0.04 µM. As expected, no α-syn signal was detected in lysates from mock transfected or
EGFP transfected cells (Figure 5.6G). However, α-syn was detected in cells transfected to
express α-synA53T*, confirming that these cells contained aggregated forms of α-syn.
Moreover, there was a significant increase in the amount of aggregated α-syn detected in
lysates from cells following treatment with the proteostasis inhibitors, thus correlating with
the increase in the number of cells with inclusions following this treatment (Figure 5.6E).
Given the formation of α-syn immunoreactive fluorescent puncta corresponded to the
accumulation of aggregated α-syn, and that this accumulation was sensitive to treatment with
inhibitors of proteostasis, it was concluded that expression of α-synA53T* in N2a cells is a
robust model of α-syn aggregation.
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Figure 5.6: α-synA53T* forms punctate inclusions in N2a cells. N2a cells were transiently
transfected with a construct expressing α-synA53T* and incubated for 48 hours before being treated
(or not) with 3-MA (10 mM), MG132 (10 µM) or an equivalent volume of the vehicle control
(DMSO) and incubated for a further 48 hours. Intracellular α-syn was fluorescently labelled via
immunohistochemistry, using a monoclonal mouse anti-αsyn antibody and a DyLight650-conjugated
anti-mouse secondary antibody. (A-D) Fluorescent images of cells containing both cytosolic
intracellular (B, D) and membrane-localised (C, D) inclusions are presented. Scale bars represent 5
µm. (E) The percentage of cells containing inclusions was quantified by manually counting at least 50
cells and the number of α-syn positive cells containing fluorescent puncta. Data are displayed as mean
± S.E.M. (n=4), and was analysed via one-way ANOVA with a Dunnett’s multiple comparison posttest, where * indicates p<0.05 compared to untreated or DMSO-treated controls. (F) Monomeric or
fibrillar recombinant α-syn was added at (i) 5 µM (ii) 1 µM, (iii) 0.2 µM and (iv) 0.04 µM to either 50
mM phosphate buffer (pH 7.4) or 200 ug of untransfected cell lysate. Samples were analysed via filter
trap using a 0.2 µm membrane, and detected using a monoclonal mouse anti-α-syn followed by a
HRP-conjugated secondary antibody. (G) Cell extracts prepared from (i) mock transfected cells, and
cells transfected with (ii) an EGFP vector control or (iii) the α-synA53T* construct. Cells were
incubated in the absence (Untreated) or presence (Treated) of proteostasis inhibitors (10 µM MG132
and 3 µM thapsigargin). Samples were analysed via filter trap using a 0.2 µm membrane, and detected
using a monoclonal mouse anti-α-syn followed by a HRP-conjugated secondary antibody. Samples
were analysed on one membrane, and the image from this membrane has been truncated for clarity.

5.3.2 sHsps inhibit the deposition of α-syn into inclusions in cells
Having developed a cellular model of α-syn aggregation, it was used to examine the ability of
the sHsps αB-c and Hsp27 to prevent α-syn aggregation in cells. N2a cells were cotransfected to express α-synA53T* and αB-c (using an αB-c encoding IRES construct).
Following immunohistochemical labelling of both the α-syn and αB-c, cells were imaged via
confocal microscopy. The interaction between α-syn and αB-c can be qualitatively observed.
As expected, cells containing diffuse EGFP (expressed from the IRES construct and
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indicative of the presence of αB-c; Figure 5.7) were also immunoreactive for αB-c. Notably,
the subcellular localisation of the EGFP and αB-c fluorescence was not correlated. In
particular, EGFP was diffuse throughout the cytosol and nucleus, while αB-c
immunoreactivity was contained to the cytosol. Moreover, some cells had fluorescent puncta
that contained both αB-c and α-syn. However, not all α-syn inclusions contained αB-c; colocalisation of αB-c only occurred in approximately 10% of α-syn fluorescent puncta.

Figure 5.7: αB-c co-localises with α-synA53T* in some intracellular inclusions. N2a cells were
transiently transfected with a construct expressing α-synA53T* and an IRES construct resulting in the
expression of EGFP and αB-c. Forty-eight hours following transfection, cells were treated with
MG132 and thapsigargin (10 µM and 3 µM respectively), then incubated for a further 48 h. Cells
were immunolabelled for intracellular αB-c and α-syn using polyclonal rabbit anti αB-c and
monoclonal mouse anti-α-syn antibodies, which are detected using DyLight650- and DyLight550conjugated secondary antibodies respectively. The emitted fluorescence of the conjugates and EGFP
were then detected using a confocal microscope with fluorophore-specific excitation and emission
wavelengths. Arrows indicate co-localised staining of α-syn and αB-c in inclusions. Scale bars
represent 5µm.

Having established the potential for αB-c to interact with α-syn in this cell model, the ability
of αB-c and Hsp27 to influence the aggregation and deposition of α-syn in cells was
examined. N2a cells co-transfected with the α-synA53T* and IRES constructs encoding
EGFP and either αB-c, Hsp27 or EGFPinv were treated with proteostasis inhibitors. To enable
imaging via confocal microscopy, cells containing αB-c or Hsp27 (or the EGFPinv control)
were identified through expression of the fluorescent reporter EGFP (Figure 5.8A, green),
and cells expressing α-synA53T* were identified by immunohistochemical labelling of the αsynA53T* with DyLight-650 (Figure 5.8B, red). This allows identification of cells containing
only α-syn (red only), those containing only αB-c or Hsp27 (or the EGFPinv control; green
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only), and cells of interest, which contain both the α-syn and chaperone (or control) protein
(yellow) (Figure 5.8C). The number of cells containing inclusions was then manually
quantified using randomly imaged fields of view and semi-automated cell counting scripts
custom written for ImageJ. This involved cells being outlined using the brightfield image
following manual selection, and then overlayed with the red image in grayscale (Figure 5.8D)
to allow cells containing red fluorescent (α-synA53T*) inclusions to be manually identified.
Co-transfected cells were then automatically determined as those displaying fluorescence
above the threshold in both the EGFP and red fluorescent channels, and only those cotransfected cells were considered for further analysis. The percentage of co-transfected cells
containing inclusions was then calculated and normalised to the EGFP control (Figure 5.8E).
Expression of αB-c was found to significantly reduce the number of cells containing
inclusions in untreated cells (p<0.05) and in those treated with the proteostasis disruptors
thapsigargin and MG132 (p<0.01). Whilst αB-c also reduced the proportion of cells
containing inclusions following treatment with 3-MA, this effect was not found to be
significant (p>0.05, n=4). Co-transfection with Hsp27 was found to significantly reduce
inclusion formation in both the untreated and treated cells expressing α-synA53T* by
approximately 30% (p<0.05, n=4).
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Figure 5.8: sHsps inhibit the formation of α-syn inclusions in cells. N2a cells were transiently
transfected with a construct expressing α-synA53T*, along with an IRES construct expressing
EGFP/αB-c, EGFP/Hsp27 or EGFP/EGFPinv. Forty-eight hours following transfection, cells were
treated with MG132 and thapsigargin (10 µM and 3 µM respectively) or 3-MA (10 mM), then
incubated for a further 48 h. Intracellular α-syn was immunohistochemically labelled, using a
monoclonal mouse anti-αsyn antibody and a DyLight650-conjugated secondary antibody. (A) Cells
containing αB-c display EGFP fluorescence, and (B) α-syn positive cells contain diffuse cytosolic
staining, punctate intracellular inclusions and membrane-localised inclusions. (C) Fluorescence
images overlayed on the brightfield channel allows (D) automated detection of cells using ImageJ. (E)
The percentage of co-transfected cells containing inclusions was quantified by manually selecting
cells from D containing inclusions, and then automatically determining the number of co-transfected
cells. Data is displayed as mean ± S.E.M. (n=3 biological repeats, each consisting of at least 50 cells),
and was analysed via two-way ANOVA with a Bonferroni post-test, where * indicates p<0.05 and **
indicates p<0.01 within treatment groups when compared to the EGFPinv control.

5.3.3 Hsps do not prevent the accumulation of Htt inclusion bodies
Having demonstrated that the sHsps αB-c and Hsp27 can inhibit the intracellular aggregation
of α-syn, experiments were conducted to examine whether they are also capable of
preventing the intracellular aggregation of another disease-related protein, the exon 1
fragment of Htt. Expression of the fluorescently tagged exon 1 fragment of Htt is a well
characterised intracellular aggregation model (Olshina et al. 2010, Arrasate and Finkbeiner
2012, Ramdzan et al. 2012, Ormsby et al. 2013) and represents a robust, high throughput
model in which to test the efficacy of Hsps in preventing the formation of inclusions. Thus,
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the ability of αB-c and Hsp27 to prevent Htt aggregation in cells was compared to other Hsps,
namely Hsp40, Hsp70 and Hsp90, that have previously been shown to influence Htt
aggregation into inclusions in cells (Wyttenbach et al. 2000).
Following transfection of N2a cells with control (Htt25Q) or aggregation-prone (Htt46Q)
polyQ variants of Htt fused to the fluorescent protein mCherry, the cells were analysed via
PulSA. The forward and side scatter signals of events were used to select live, viable cells,
and to exclude events corresponding to cellular debris and cell-doublets. Live cells
expressing Htt were selected based on their mCherry fluorescence (Figure 5.9A), and were
then analysed via PulSA. The PulSA of the Htt25Q mCherry fluorescence (Figure 5.9C) was
used to define the population of cells not containing inclusions as described previously
(Ramdzan et al. 2012) (cells expressing Htt25Q do not develop a significant number of
inclusions under the experimental conditions). Some cells expressing Htt46Q exhibited a
narrower pulse width and higher pulse height, indicative of cells with inclusions (Ramdzan et
al. 2012) (Figure 5.9D). When considering the proportion of mCherry-positive cells
containing inclusions, there was a significant effect of co-transfection of the cells with an
IRES construct on the proportion of cells with inclusions (F(3,8) = 10.26, p<0.0001) (Figure
5.9E). Co-transfection of cells with the Htt-encoding and IRES constructs led to a significant
decrease in the proportion of cells with inclusions compared to when cells were transfected
only to express Htt46Q-mCherry alone (p<0.0001). However, there was no significant
difference in the proportion of cells containing inclusions in cells co-transfected to express
any of the Hsps compared to those co-transfected to express the control proteins EGFPinv or
LacZ.
By only accounting for cells expressing Htt-mCherry, the above analysis assumes that cells
expressing Htt-mCherry are co-transfected and therefore, in this case, express proteins from
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the IRES constructs. Moreover, it does not take into account potential differences in cotransfection efficiency between samples. The bicistronic constructs, in which the expression
of the Hsps (or control proteins, EGFPinv or LacZ) is correlated with the expression of a
fluorescent reporter (in this case EGFP) (Assoc. Prof. Heath Ecroyd, personal
communication), enable the identification and selection of co-transfected cells (i.e. cells
expressing both the Hsp or control protein and Htt46Q) for subsequent analyses. Thus,
mCherry-positive cells and EGFP-positive cells (Figure 5.9A, B) were selected and analysed
by PulSA (Figure 5.9C, D) in order to quantify the relative proportion of cells containing
inclusions. There was a significant effect of treatment on the proportion of cells containing
inclusions (F (7, 24) = 7.338, p<0.0001). Hsp90 significantly increased the proportion of cells
containing inclusions (2.10 ± 0.24 fold) relative to the EGFPinv control (p<0.0001, Figure
5.9F). Whilst there was trend towards cells expressing Hsp70, Hsp40 or Hsp70 and Hsp40
having a higher proportion of cells with inclusions, this was not significantly different to cells
expressing EGFPinv. There was no effect of αB-c or Hsp27 expression on the proportion of
cells with Htt-mediated inclusions.
Finally, it has previously been demonstrated that the propensity of an aggregation-prone
protein to form inclusions is strongly correlated with its level of expression in cells, i.e. cells
expressing higher levels of protein are more likely to develop inclusions (Ramdzan et al.
2012, Ormsby et al. 2013). The levels of expression of Htt46Q following co-transfection with
the various IRES constructs was therefore considered by using the median mCherry
fluorescence (Figure 5.9G) as a measure of the relative Htt content in cells. The median
mCherry fluorescence varied significantly with co-transfection with the different IRES
constructs (F (7, 3) = 5.684, p = 0.0009). Cells co-transfected to express Htt46Q and Hsp40
or Hsp90 had significantly higher levels of Htt than those co-transfected to express Htt and
the EGFPinv control. Interestingly, the relative levels of Htt in cells following co-transfection
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correlated with the trends observed in the relative proportion of cells with inclusions, such
that higher Htt levels were associated with a higher proportion of cells containing inclusions
(Figure 5.9F, G). By taking into account the levels of Htt in cells when comparing the effect
of Hsp expression on the proportion of cells with inclusions (Figure 5.9H), it was found that
there was no significant effect of the Hsps on the aggregation propensity of the Htt46Q in
N2a cells (F (7, 24) = 1.057, p = 0.4199).
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Figure 5.9: Hsps do not prevent the cellular deposition of Htt into inclusions. N2a cells were
transiently transfected with constructs encoding the aggregation prone Htt46Q-mCherry or control
Htt25Q-mCherry protein, in the absence or presence of a 1:4 (IRES: Htt) ratio of IRES constructs
encoding EGFP and Hsps (Hsp40, Hsp70, Hsp90, αB-c, or Hsp27), or control proteins (EGFPinv or
LacZ). Following transfection, cells were incubated for 36 h, before being analysed via flow
cytometry. Scatter plots of the FSC and SSC signals were used to select live cells, and levels of
mCherry fluorescence or EGFP fluorescence of untransfected cells were used to select (A) mCherry
and (B) EGFP-positive cells. These cells were then analysed using PulSA (Ramdzan et al. 2012). (C)
The population of cells with inclusions (ipop) was identified based on the PulSA plot of cells
expressing Htt25Q-mCherry (very few of these cells develop inclusions (Ramdzan et al. 2012)). (D)
Cells expressing Htt46Q with inclusions were identified and enumerated. (E) The percentage of
mCherry-positive (i.e. Htt-expressing) cells containing inclusions is expressed as a fold change
relative to the EGFPinv control. Alternatively, live mCherry positive cells can be further gated to select
cells co-transfected with the bicistronic construct and so expressing EGFP and a Hsp (or control
protein), as shown in B. (F) The percentage of co-transfected cells with inclusions is expressed as the
fold change relative to the EGFPinv control. (G) The median of mCherry fluorescence in cotransfected cells. (H) The proportion of co-transfected cells containing inclusions taking into account
the relative level of Htt expressed in the co-transfected cells. In panels E-H the data is presented as
mean ± S.E.M. (n=4) and was analysed via a one-way ANOVA and a Dunnett’s post-test, where *, **
and ***denotes a significant difference (p<0.05, p<0.01 and p<0.001 respectively) compared to the
EGFPinv control sample.
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5.4 Discussion
In order to capture the complex factors influencing aggregation in the cell, it is essential to
complement in vitro studies with cellular models of aggregation. In addition, models which
are robust and amenable to medium-to-high throughput analyses are invaluable when
pursuing quantitative evaluation of modulators of the aggregation process, such as molecular
chaperones. In this work several avenues were investigated to establish a robust and reliable
cell-based model of α-syn aggregation that could be used to assess the ability of Hsps to
prevent α-syn aggregation in cells. A significant finding of this work was that expression of
the sHsps αB-c and Hsp27 significantly decreased the proportion of cells containing α-syn
inclusions, even when the cells were treated with inhibitors of autophagy or the proteasome.
An important aspect of these experiments was the incorporation of a non-chaperone protein
as a control (in this case an ‘invisible’, non-fluorescent variant of EGFP, EGFPinv). This
ensured that all samples received the same amount of DNA and had a comparable ‘load’ with
regards to the number of proteins to produce due to co-transfection. This avoids confounding
effects resulting from higher protein expression levels of an aggregation-prone protein, which
itself influences the number of inclusions formed in cells (Appendix IX). Inhibition of α-syn
aggregation by the sHsps is consistent with previous work in which Hsp27 was shown to
decrease inclusion formation with similar efficacy to Hsp70 in a cellular model of α-syn
aggregation (Outeiro et al. 2006). In this previous study, αB-c reduced the percentage of cells
containing inclusions by approximately 10%, although this effect was not significant (Outeiro
et al. 2006). Taken together with the results presented here, these data provide strong
evidence that the sHsps are potent inhibitors of α-syn aggregation in cells.
It remains to be determined whether or not this inhibition leads to an increase in cell viability.
There is still much debate concerning whether or not inclusions represent a protective end
point of aggregation or a detrimental side effect of the process in cells. Sequestration of toxic
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species through the active partitioning of aggregates and formation of inclusions is thought to
be protective, with emerging theories relating the presence of Lewy bodies in healthy neurons
with the removal of toxic oligomers from the cytoplasm (Gibb and Lees 1988, Gertz et al.
1994, Hindle 2010). In contrast, the accumulation of cellular proteostasis machinery inside
these deposits likely depletes these essential components from the cytoplasm, leading to a
loss-of-function which may therefore be detrimental to the health of the cell. Furthermore,
correlations between increased α-syn inclusions and reduced cell viability have been
demonstrated in some cell models (Wan and Chung 2012). Therefore, it would be useful in
future studies to investigate whether populations displaying decreased inclusion formation in
the presence of sHsps have enhanced cell viability.
Fusion of a fluorescent protein to a protein of interest is a well described method for studying
intracellular aggregation and a key element in facilitating high throughput analyses (Ramdzan
et al. 2012). Thus, the first approach investigated in this work was to fuse EGFP to α-syn
variants. Transfection of cells and immunoblot analysis showed that the α-syn-EGFP-fusion
protein was expressed in cells. Whilst no obvious inclusions were observed in cells
expressing α-syn-EGFP via confocal microscopy (compared to cells expressing TDP-43tGFP in which inclusions were readily observed), there was some evidence of fluorescent
protein accumulations which may represent protein aggregates. However, in cells expressing
α-syn-EGFP, no cells with inclusions were able to be detected by PulSA. Importantly, cells
containing TDP-43 inclusions were also not able to be detected by PulSA. This is likely to be
because PulSA relies on relatively large changes in the pulse height and pulse width in cells
with inclusions compared to those in which the fluorescent protein is evenly distributed in the
cytosol. It therefore readily detects cells with inclusions when the inclusions are large (such
as those formed by Htt46Q), however, it is unable to detect cells that contain smaller
inclusions. This suggests that even if a significant proportion of cells expressing α-syn-EGFP
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developed inclusions, it is unlikely that the PulSA technique would be useful in detecting
them.
As an alternative approach to quantitatively evaluate the aggregation of α-syn into inclusions,
cells were assessed by fluorescence microscopy. Despite evidence that some cells expressing
α-syn-EGFP contain aggregates, the level of cells with inclusions remained very low (5 –
10% of cells) and did not increase even in the presence of proteostasis inhibitors or inducers
of cell stress, both of which have been previously reported to increase α-syn aggregation in
cells (Bertoncini et al. 2007). Thus, it was concluded that the fusion of the large fluorescent
protein EGFP is unsuitable for developing a robust cellular model of α-syn aggregation. The
addition of this relatively large (approximately 27 kDa) fluorescent protein to α-syn (14.5
kDa) is likely to interfere with the physical properties of α-syn, significantly altering the
structure, conformation and/or chemical properties of the protein, and, in this case, its
aggregation-propensity in cells (Crivat and Taraska 2012).
A cell-based model using untagged α-syn would be ideal, however, previous work has
demonstrated that expression of α-syn alone does not result in significant levels of
aggregation in cells (Paxinou et al. 2001, Matsuzaki et al. 2004). Previous work has reported
that whilst α-syn-EGFP did not readily aggregate in cells, a cellular cleavage product
consisting of α-syn-EGFP lacking the last 155 residues of EGFP, does readily aggregate into
inclusions in cells (McLean et al. 2001). Of note, a 27 kDa cleavage product immunoreactive
with the α-syn antibody was also observed in N2a cells overexpressing α-synA53T-EGFP in
this work (see Figure 5.2). Consistent with these previous studies (McLean et al. 2001), this
α-synA53T* protein was found to readily form inclusions in cells, which were detectable via
immunolabelling of α-syn and by filter-trap assay. Importantly, a significant proportion of
cells (~30%) developed inclusions under the experimental conditions used in this work and
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this could be significantly increased by treatment with inhibitors of proteostasis pathways
(i.e. the proteasome and autophagy). Moreover, it has been previously demonstrated that the
aggregation of α-synA53T* into inclusions is mediated by the α-syn portion of the protein,
since when the same region of EGFP was fused to other non-aggregation-prone proteins that
were expressed in cells, these cells did not develop aggregates (McLean et al. 2001). Thus, it
is likely that the additional EGFP fragment at the C-terminus of α-syn acts to destabilise it
and that this is key to recapitulating the cellular aggregation of α-syn associated with disease.
Importantly, C-terminal cleavage products of α-syn (α-synΔC) have been identified in vivo.
For example, human brain extracts containing pathological α-syn Lewy bodies have
significant levels of α-synΔC which preferentially localises to detergent-insoluble fractions
following extraction of protein aggregates (Li et al. 2005). Moreover, C-terminal truncation
of α-syn significantly increases its aggregation propensity when compared to α-synWT (full
length) in vitro using ThT-based aggregation assays (Hoyer et al. 2004, Li et al. 2005). In
addition, the incorporation of substoichiometric ratios of α-synΔC variants significantly
enhances the aggregation of α-synWT in vivo (Li et al. 2005). Finally, α-synΔC variants
increase the vulnerability of cells in culture to toxic assault by oxidative stressors (Kanda et
al. 2000). These effects have been attributed to the absolute net charge of α-syn, given the
highly acidic nature of the C-terminal region. In fact, truncation of just 16 residues from the
C-terminal region of α-syn decreases the net charge of the protein from 9.0 to 3.0 at pH 7.5
(Hoyer et al. 2004). Similar to other amyloid-forming proteins in which charge state
constitutes a major determinant of aggregation rate, electrostatic effects resulting from
interaction with or truncation of the C-terminal of α-syn lead to an increase in its aggregationpropensity (Chiti et al. 2002, Chiti et al. 2003, Schmittschmitt and Scholtz 2003). Together,
these data indicate that the C-terminal region of α-syn plays a critical role in governing its
propensity to aggregate. Thus, this may account, at least in part, for the increased propensity
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of α-synA53T* to form inclusions in cells. A cell model that incorporates co-expression of
full-length α-syn with an α-synΔC isoform may also result in a robust cellular model of α-syn
aggregation.
There is conflicting evidence regarding the co-localisation of sHsps with α-syn inclusions in
cell-based models of aggregation. Using a cell culture model in which co-transfection with αsyn and synphillin-1 produces intracellular inclusions of α-syn, McLean and colleagues
(2002) failed to find any evidence for the co-localisation of Hsp27 with aggregated α-syn.
Conversely, Outeiro and colleagues (2006), using a similar transfection model, found that
both Hsp27 and αB-c co-localise to α-syn positive inclusions. Notably however, both these
previous studies demonstrated the presence of Hsp27 (McLean et al. 2002, Outeiro et al.
2006) and αB-c (Outeiro et al. 2006) in α-syn positive Lewy bodies from diseased patient
tissues, providing evidence that sHsps can co-localise with α-syn inclusions in vivo. In this
work, αB-c was found to be co-localised in some, but not all, α-syn positive inclusions
formed in N2a cells. Whether sHsps co-localise with α-syn in an inclusion may be due to the
type of inclusion formed by α-syn. Although some inclusions are essentially static
depositions of protein aggregates, many inclusions are dynamic structures in which accessory
proteins, such as chaperones, may diffuse in to and out of over the lifetime of the structure
(Kaganovich et al. 2008).
Several distinct types of protein inclusions have been identified to date including aggresomes,
juxtanuclear quality control (JUNQ), insoluble protein deposits (IPODs), RNA interactor
specific compartments/inclusions, aggresome-like structures, ER-associated degradationassociated vesicles and intranuclear protein quality control compartments. These represent
discrete structures with diverse but specific mechanisms of formation. For example,
aggresomes are cell-driven, microtubule-dependent juxtanuclear inclusions which organise
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and sequester aggregates to regions of the cell where they are associated with chaperone and
proteasome subunits (Johnston et al. 1998, Kopito 2000). JUNQ inclusions are thought to be
closely related to aggresomes, as they are composed primarily of ubiquitinated proteins,
proteasomal subunits and refolding chaperones such as Hsp70 (Kaganovich et al. 2008).
These inclusions have been proposed to be central refolding or degradation hubs, and it
appears chaperones and proteases are able to freely diffuse in to and out of these structures
(Kaganovich et al. 2008), although how they maintain the aggregated proteins within the
inclusion is yet to be established. In contrast, IPODs consist mainly of aggregated proteins
(most commonly insoluble amyloid fibrils) which are not ubiquitinated, and are characterised
as extremely stable, dense, immobile compartments (Kaganovich et al. 2008). Partitioning of
aggregates appears to depend largely on their aggregation state and ubiquitination status, such
that soluble misfolded proteins are targeted for compartments capable of degradation and
refolding (e.g. aggresomes and JUNQ), whereas terminally aggregated proteins are
sequestered into compartments (e.g. IPOD) to prevent toxicity (Kaganovich et al. 2008).
Many of the intricate processes actively promoting formation of these structures in cells
remain to be established and the specific types of inclusions formed by many aggregating
proteins remains to be characterised. For example, TDP-43 has been shown to localise to
JUNQ inclusions (Farrawell et al. 2015), while Htt partitions to IPODs (Polling et al. 2014).
Little is known, however, of the types of inclusions formed by aggregation–prone α-syn in
cells. The co-localisation of sHsp with α-syn in some of these inclusions may be reflective of
a dynamic type of inclusion which evolves over the lifetime of a cell.
A range of potential mechanisms by which sHsps interact with -syn have been explored in
the preceding chapters of this thesis. For example, sHsps may interact primarily with
monomeric species to prevent the formation of oligomeric nuclei. Alternatively, sHsps may
bind to small -syn oligomers and, in doing so, prevent their growth into fibrillar species that
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would otherwise lead to their deposition. sHsps may also interact with fibrillar -syn in order
to prevent secondary nucleation processes that would otherwise increase the amount of
aggregated material and enhance deposition of -syn into inclusions. Finally, sHsps may
prevent the release or uptake of α-syn aggregates that seed aggregation and propagate
inclusion formation to neighbouring cells. Most likely, the inhibition of -syn inclusion
formation by the sHsps relies on a combination of these mechanisms. Development of
techniques that enable the aggregation state of α-syn to be tracked and related to specific
biological outcomes in intact cells would greatly assist future work in this area. For example,
the development of conformational sensors of -syn capable of distinguishing monomeric,
oligomeric and fibrillar species, such as those developed for Htt (Ormsby et al. 2013), would
facilitate investigation into the precise mechanism(s) by which sHsps act to prevent -syn
aggregation in cells.
This work also tested whether the sHsps, αB-c and Hsp27, inhibited the intracellular
aggregation of proteins other than -syn. Previous work has demonstrated that Htt undergoes
nucleation-dependent, fibrillar aggregation (Scherzinger et al. 1999) in vitro and in vivo.
Fusion of exon 1 of the Htt protein to a fluorescent protein enables Htt aggregates to be
distinguishable from diffuse cytosolic protein (Ramdzan et al. 2012). In this work the impact
of a range of Hsps, including Hsp40, Hsp70, Hsp90 and the sHsps Hsp27 and αB-c, on the
formation of Htt-mCherry inclusions in N2a cells was investigated. An important aspect of
this work was the use of non-chaperone proteins (i.e. EGFPinv and LacZ) as controls in these
experiments. Whilst both the EGFPinv and LacZ proteins significantly reduced the number of
cells containing aggregates when compared to cells transfected to express Htt46Q alone, this
was seen to be simply due to the decrease in the amount of Htt DNA used to transfect cells in
the co-transfection samples (Appendix IX).
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Overall, PuLSA of cells expressing Htt revealed that the Hsps had little effect on the
proportion of cells with inclusions. In analysing these flow cytometry data, the first approach
taken was that used in previous studies (Ramdzan et al. 2012), i.e. the analysis of cells that
express the aggregation-prone protein and comparison of the proportion of cells with
inclusions across treatments. However, whilst this approach has been used extensively in the
past, it does not take into account differences in co-transfection efficiencies that can occur
between treatments. In this work, this limitation was overcome by exploiting IRES constructs
which, through the expression of a fluorescent reporter protein (in this case EGFP), enabled
selection and analysis of only cells that had been co-transfected. Moreover, whilst cells
expressing the Hsps (or control proteins) could be identified, the Hsps themselves were not
tagged with a bulky fluorescent protein which could compromise their chaperone activity.
Analysis of co-transfected cells using this approach revealed that expression of Hsp90 led to
an increase in the proportion of cells containing Htt inclusions compared to cells expressing
EGFPinv.
An important regulator of the aggregation-propensity of a protein is the levels at which is
expressed in cells. For example, a previous study demonstrated that the aggregation of Htt in
cells is ‘concentration-dependent’, i.e. that cells containing more Htt were more likely to
develop inclusions (Ormsby et al. 2013). In this work the levels of Htt in co-transfected cells
was found to vary between treatments, with higher levels of Htt expressed in cells coexpressing Hsp40 and Hsp90. This may therefore account for the higher proportion of cotransfected cells expressing Hsp90 with inclusions. When these differences in Htt levels
between treatments were taken into account in the analysis, there was no significant
difference in the proportion of cells with inclusions when any of the Hsps were co-expressed
in cells compared to the controls.
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Little is known about the interaction of the sHsps or Hsp90 with Htt, however, the findings of
this work that Hsp27 and Hsp70 do not reduce the aggregation of Htt in cells is consistent
with earlier studies (Wyttenbach et al. 2000, Ormsby et al. 2013). However, in contrast to the
findings of this work, the previous studies by Wyttenbach et al. (2000) and Ormsby et al
(2013) reported that expression of Hsp40 reduces the proportion of Htt-expressing cells with
inclusions. The most likely reason for the discrepancy between the findings of this work and
these previous studies is the differences in the ratios of Htt to Hsp DNA used to transfect
cells. In this work a 4-fold excess of Htt DNA over IRES DNA was used to transfect cells,
however, an equal volume of both Htt and Hsp-encoding DNA constructs were used in these
previous studies (Wyttenbach et al. 2000, Ormsby et al. 2013). It is therefore likely that the
lower proportion of Hsp40-encoding DNA used in this work led to a lower ratio of Hsp40 to
Htt in cells and this was insufficient to prevent Htt aggregation in the cells. This suggests that
higher stoichiometric ratios of the Hsps to Htt may be necessary in order for the Hsps to
prevent the aggregation of Htt in cells.
Despite the limitations discussed above, this work was successful in using cellular models of
aggregation to investigate the activity and relevance of molecular chaperones in a cellular
environment. A robust cell-based model of -syn aggregation was developed, and was
subsequently exploited to demonstrate that the sHsps Hsp27 and αB-c prevent the
aggregation of -syn in cells. Ongoing investigation of the sHsps and their interaction with αsyn using models amenable to high throughput single cell analysis is critical in order to
provide a complete picture of their potential as mediators of the cellular aggregation and
toxicity of this protein. However, the results presented here highlight that the sHsps are viable
therapeutic targets in the context of the α-synucleinopathies. In addition, examining sHsp
activity against a suite of other aggregation-prone proteins, as done in this work with Htt, will
be essential when evaluating their protective capacity against other protein aggregation-
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related diseases. The use of chaperone-encoding IRES constructs will be invaluable in this
endeavour, as they enable cells expressing Hsps to be identified without the addition of a
fluorescent tag, which may otherwise compromise Hsp activity.
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The maintenance of proteostasis is crucial for cell and organism survival. The sHsps are
essential components of the proteostasis network, protecting the cell from pathogenic
aggregation of misfolded or non-native protein intermediates. However, the abundance of
neurodegenerative diseases linked with aberrant aggregation highlight that, under some
circumstances, the sHsps fail to prevent protein aggregation, and this facilitates the onset and
progression of disease. One such group of diseases, the α-synucleinopathies, are characterised
by the aggregation and deposition of α-syn in cells. Uncovering the mechanism(s) by which
sHsps interact with aggregation-prone target proteins, such as α-syn, is therefore of great
importance. Thus, the basis of the work described in this thesis was to determine how sHsps
interact with α-syn to prevent aggregation and mitigate the cellular toxicity associated with
this process.
6.1 sHsps interact transiently with aggregation-prone monomeric α-syn
A primary aim of this work was to establish the mechanism by which the sHsps inhibit
aggregation of monomeric α-syn into fibrils. As reported in Chapter 3, the sHsps αB-c and
Hsp27 interact transiently with aggregation-prone, monomeric α-syn to prevent its
aggregation. Thus, the mechanism of αB-c and Hsp27 chaperone action in preventing α-syn
aggregation does not involve the formation of high molecular mass complexes. Instead, the
sHsps are able to briefly stabilise the aggregation-prone intermediate, presumably such that it
can re-enter the protein folding-unfolding pathway. Thus, despite their traditional
classification as holdase chaperones, this work demonstrates that this does not fully describe
the mechanism of chaperone action of sHsps. It is yet to be determined whether the transient
interaction between the sHsps and α-syn results in a conformational change in the
aggregation-prone intermediate of α-syn. Previous work investigating the transient interaction
between αB-c and α-lac (a model amyloidogenic protein) demonstrated that, when the αB-c
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was removed from the sample, amyloid fibril aggregation of α-lac proceeded. Thus, these
results suggest that the transient interactions between sHsps and aggregation-prone proteins
do not substantially change the aggregation-propensity of amyloidogenic target proteins
(Kulig and Ecroyd 2012). Further characterisation of the effect of the transient interactions
between sHsps and α-syn would enhance our understanding of the fate of aggregation-prone
target proteins in the cell once they are stabilised by the sHsps.
This work also sought to identify, for the first time, factors that may account for aggregationprone proteins ‘escaping’ the chaperone action of sHsps, leading to disease. The work
presented in Chapters 3 and 4 demonstrates that the rate of aggregation is a significant factor
in determining how effectively the sHsps, αB-c and Hsp27, can prevent protein aggregation.
This was consistently found to be the case regardless of whether the kinetics of α-syn
aggregation were altered via increases in the monomeric α-syn concentration, fibril seed
concentration or the presence of disease-associated mutations. Given the association of PD
with duplication and mutation of the α-syn gene, all of which act to increase the rate at which
α-syn aggregates (Bruinsma et al. 2011), these investigations highlight the physiological
relevance of aggregation rate with respect to the failure of sHsps in neurodegenerative
disease.
Identifying the rate of aggregation as a crucial factor in the chaperone efficacy of sHsps also
serves to highlight the importance of subunit exchange dynamics with regards to the
chaperone action of sHsps. The release of subunits from oligomeric reservoirs formed by
αB-c and Hsp27 governs the amount of chaperone-active species available to interact with
aggregation-prone intermediates. As such, future work should investigate whether factors that
lead to the dissociation of sHsp oligomers into smaller subunits also increase chaperone
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activity. The identification of small drug-like molecules that induce dissociation of sHsps
may have therapeutic potential to treat diseases associated with protein aggregation.
6.2 sHsps bind to α-syn fibrils
Examining the potential for the sHsps to target α-syn aggregation intermediates, other than
monomeric species, was also a primary aim of this work. The results presented in Chapter 4
demonstrate that Hsp27 specifically inhibits the growth and structural conversion of
oligomeric nuclei formed during the aggregation of α-syn. This implies an interaction
between Hsp27 and small amyloid intermediates, and was also reflected in the ability of
Hsp27 to prevent the elongation of fibril fragments. These small amyloid species are key
mediators of elongation and secondary nucleation processes, and have a range of potentially
toxic effects in the cell (Martins et al. 2008, Xue et al. 2009, Jakhria et al. 2014, Shvadchak et
al. 2015). Therefore, the results presented as part of this work highlight another mechanism
by which sHsps may act to prevent further protein aggregation in the cell i.e. by binding to
oligomeric nuclei or fibril fragments, and, in doing so, protect the cell from the cytotoxicity
associated with this process.
Recent work has demonstrated that αB-c can interact with mature amyloid fibrils formed by
α-syn (Waudby et al. 2010), apo-CII (Binger et al. 2013) and Aβ (Shammas et al. 2011).
However, the mechanism of this interaction, and whether other sHsps are also capable of
binding to fibrils, has not been established. The results from this work show that both αB-c
and Hsp27 are able to bind to α-syn fibrils. In addition, this interaction was found to involve
the N- and/or C-terminal regions of the protein, as isoforms lacking these domains (i.e. core
domain variants) were unable to bind to the α-syn fibrils despite retaining the ability to
prevent the aggregation of monomeric α-syn. Thus, it is concluded that the N- and/or C-
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terminal regions of these sHsps are directly involved in fibril-binding, however, the ability to
prevent the aggregation of monomeric α-syn is inherent to the α-crystallin core domain.
A significant finding of this work was that the interaction of sHsps with α-syn fibrils
decreases the hydrophobic nature of the fibril surface and inhibits the cytotoxicity of the
fibrils. These findings are particularly important given the emerging theory of prion-like cellto-cell spreading of α-syn aggregates and the associated potential for extracellular aggregated
α-syn to exert toxic effects on neighbouring cells (Lee et al. 2005, Kordower et al. 2008, Lee
et al. 2008, Lee et al. 2008, Li et al. 2008). It remains to be established precisely how, by
binding to fibrils, sHsps mitigate the toxicity of the α-syn fibrils. Given the toxicity of
aggregates is strongly linked with their relative hydrophobicity (Bolognesi et al. 2010), and
the present study established the ability of sHsps to decrease the relative hydrophobicity at
the fibril surface, then shielding surface hydrophobicity is a likely mechanism by which the
sHsps inhibit toxicity. It is also possible that, by binding to fibrils, the sHsps prevent
fragmentation and secondary nucleation events that would otherwise generate more cytotoxic
oligomers. Recent work has shown that, by binding to fibrils formed by apo-CII, αB-c
prevents their dilution-induced fragmentation (Binger et al. 2013). Thus, future work could
explore whether, by binding to α-syn fibrils, sHsps stabilises them in order to prevent
fragmentation. Determining whether the ability of sHsps to stabilise fibrillar forms of
proteins is a generic property of the sHsps or specific to particular sHsps and fibrils, would
represent a significant avenue for further investigation.
Another potential area for future study would be investigating whether the α-syn fibrils must
be taken up by cells in order to exert their toxic effects or whether these effects are mediated
by them binding to the cell membrane. This would assist in understanding how the sHsps
inhibit the cytotoxicity associated with the addition of α-syn fibrils to cells, and guide the
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development of drugs that could mimic the binding of sHsps to α-syn fibrils. For example, if
the uptake of fibrils into cells is mediated by a specific surface receptor, it may be possible to
target this receptor by mimicking how sHsps bind to the fibrils. Alternatively, developing a
molecule to block the relevant receptor, and therefore prevent fibrils from binding to the
receptor, may also have therapeutic potential.
This work specifically considered intracellular ROS generation as a measure of fibrilassociated toxicity. However, many other toxic effects have been linked with amyloid fibrils
(Luk et al. 2009, Pieri et al. 2016). It therefore would be beneficial to examine whether, by
binding to fibrils, the sHsps inhibit other fibril-associated toxic effects, as this may provide
other promising avenues and pathways to target in the development of therapeutics to treat
diseases associated with protein aggregation.
6.3 sHsps prevent the aggregation of α-syn into inclusions in cells
The work presented in Chapter 5 aimed to develop a cell model of α-syn aggregation that
could subsequently be used to determine whether sHsps can prevent the aggregation of α-syn
into inclusions in cells. It was found that, when over-expressed in cells expressing
aggregation-prone α-syn, both Hsp27 and αB-c decrease the aggregation of α-syn into
inclusions in a neuronal cell line (N2a). This provides evidence that over-expression or
boosting the activity of sHsps may be a valid way to prevent amyloid fibril aggregation in
cells. However, the inability of the chaperones to prevent the intracellular aggregation of Htt
highlights the substrate specificity of the sHsp-target protein interaction in cells. Importantly,
the sHsps have previously been shown to prevent the cellular toxicity of Htt aggregates
without directly inhibiting aggregate formation (Wyttenbach et al. 2000). This again
highlights that the sHsps play a role in multiple protective pathways in cells in the context of
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amyloid aggregation. Elucidating each of these molecular mechanisms would significantly
enhance our understanding of the role sHsps have in cells.
One possible method for further developing a cell-based model of α-syn aggregation would
be the introduction of a functional fluorescent tagging system to allow real-time tracking of
α-syn in cells. The introduction of a C-terminal tag that replaces the truncated EGFP used in
this work, but still serves to destabilise the protein (and therefore enhance its aggregation
propensity), is a possibility. For example, the use of a series of self-labelling enzymes, known
as Halo or SNAP/CLIP tags, which are fused in frame with the protein of interest, enables the
introduction of small fluorescent ligands (Lin and Wang 2008). Alternatively, a tetracysteinebiarsenical approach, which requires the introduction of a short peptide sequence (Cys-CysX-X-Cys-Cys, where X is any amino acid other than cysteine) that reacts with a biarsenical
dye, most commonly fluorescein arsenical hairpin binder (FlAsH; emitting green
fluorescence) or resorufin arsenical hairpin binder (ReAsH; emitting red fluorescence),
enables specific labelling of proteins in cells with small fluorophores (Gaietta et al. 2002). In
fact, the latter approach has previously been used to investigate α-syn aggregation in cells,
however, only a small number of cells were found to contain inclusions (<10%,
corresponding to only 8 – 15 cells per treatment) (Bertoncini et al. 2007). Extending this
approach to encompass a larger population of cells may prove beneficial in the search for a
high-throughput model of intracellular α-syn aggregation.
6.4 A model of how sHsps interact with aggregation-prone α-syn
Based on the results presented in this thesis, it is clear that the sHsps target multiple
aggregation-prone species in order to inhibit amyloid accumulation and mediate its toxic
effects. These aspects of sHsp activity, in the context of the α-syn aggregation pathway, are
summarised in Figure 6.1. The sHsps prevent the aggregation of monomeric α-syn through
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transient interactions, without forming stable high molecular mass complexes (Chapter 3).
The sHsps also prevent the growth of small oligomeric nuclei, inhibiting the formation of
mature fibrils (Chapter 4). In addition, the sHsps form stable complexes with amyloid fibrils,
decreasing their surface hydrophobicity and inhibiting their toxicity (Chapter 5). Finally, by
inhibiting the aggregation of α-syn, the sHsps decrease the appearance of inclusions in a
neuronal cell model (Chapter 5).
A focus of future work should be defining the relative importance of the interactions of sHsps
with specific α-syn intermediates in a cellular context. This is because it is still unclear which
of the interactions observed in vitro (i.e. transient interactions with monomeric α-syn or
stable interactions with fibrillar α-syn) occur in cells. Studies utilising fluorescently labelled
Htt proteins (e.g. mCherry fusion proteins) coupled with the introduction of a tetracysteine
motif have enabled the subcellular localisation and oligomeric state of Htt to be monitored in
cells (Ramdzan et al. 2010). When the protein is monomeric, binding of the biarsenical dyes
is unperturbed and fluorescence from both the bound dye and fluorescent protein may be
detected; however, the formation of oligomers occludes the binding site of the biarsenical dye
and thus the loss of dye-associated fluorescence reports on the presence of oligomers. Cells
with large inclusions can be identified by the PulSA flow cytometry. Thus, together this work
has facilitated the distinction between monomeric, oligomeric and fibrillar forms of Htt in
cells and allows the presence of different conformations to be related to cellular outcomes
(Ormsby et al. 2013). Moreover, changes in the relative abundance of these forms were able
to be determined upon addition of aggregation modifiers such as chaperones. A similar
approach could be pursued in order to determine the forms of α-syn that exist within cells.
This would provide a method by which to address forms of α-syn that the sHsps interact with
in the cell.
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Figure 6.1: sHsps interact with various species formed during the fibrillar aggregation of α-syn.
Unfolded α-syn aggregates through a nucleation-dependent mechanism, in which prefibrillar nuclei
elongate via the addition of monomer to form amyloid fibrils. Fragmentation of mature fibrils can
generate additional oligomeric nuclei, further perpetuating aggregation. Fibrils may be sequestered
into inclusion bodies, or exert toxic effects on neighbouring cells following their release into the
extracellular environment. (1) The sHsps prevent the aggregation of monomeric α-syn via weak,
transient interactions, maintaining it in a monomeric state and preventing the growth of oligomeric
nuclei. (2) The interaction of sHsps with prefibrillar intermediates or fibril fragments prevents their
elongation into mature α-syn fibrils. sHsps can bind to fibrillar forms of α-syn with moderate (μM)
affinity. In doing so, they decrease the surface hydrophobicity of fibrils and inhibit the cytotoxicity
exogenous fibrils exert on neighbouring cells. Through these actions, sHsps are also able to inhibit the
aggregation and deposition of α-syn in cells. It is as yet unclear whether sHsps can inhibit the
fragmentation of α-syn fibrils, or inhibit the potential cytotoxicity of inclusion formation. Solid lines
represent pathways well supported by the literature and/or the work described in this thesis. Dotted
lines represent potential pathways that are yet to be fully characterised.

The results presented in this thesis contribute to a growing body of evidence that the term
‘holdase’ does not fully describe the molecular chaperone action of sHsps. Therefore, it is
proposed that the term ‘protein stabilisers’ is a more accurate description of the molecular
chaperone action of sHsps (Kulig and Ecroyd 2012). In this capacity, the sHsps monitor the
cellular environment and maintain potentially aggregation-prone proteins in a foldingcompetent state via transient interactions. Proteins at risk of catastrophic hydrophobic
collapse (commonly those destined for amorphous aggregation) are bound by the sHsps into a
stable high molecular mass complex to prevent their aggregation. In addition, should
aggregation-prone monomeric proteins (such as α-syn) escape interaction with the sHsps (e.g.

168

Chapter 6: Conclusions
through factors that act to increase the rate at which they aggregate), the sHsps are capable of
binding to oligomeric forms to prevent further aggregation. Finally, the sHsps are also able to
bind to mature aggregates and in doing so mitigate the toxicity of these species.
6.5 Concluding remarks
The amyloid fibrillar aggregation and deposition of α-syn is a pathological hallmark of many
neurodegenerative diseases, and represents a failure of the proteostasis network. It is
therefore imperative that we understand how the components of this pathway interact with αsyn to prevent its aggregation. A common theme evident in this work is the multi-faceted
nature of sHsp chaperone action. The results presented here significantly contribute to our
understanding of how the sHsps αB-c and Hsp27 interact with various species of α-syn
formed during its aggregation into amyloid fibrils. The biological relevance of these
interactions should now be pursued using more sophisticated cellular and animal-based
models of α-syn aggregation. Doing so will help to establish ways to boost the activity of the
sHsps and enable them to better protect against α-syn aggregation and the associated
cytotoxicity. In the context of the α-synucleinopathies, this may reveal potential avenues for
therapeutic intervention to treat these currently intractable and debilitating diseases.
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Appendix I:

Figure 8.1: sHsp variants inhibit α-syn aggregation. Recombinant α-synWT was incubated at

300 μM in 50 mM sodium phosphate buffer with 100 mM NaCl and 0.01% NaN3 (pH 7.4), in
the absence or presence of sHsp phosphomimicking (sHsp3D) or core domain (sHspcore)
variants. Fibril formation was monitored by the change in ThT fluorescence at 490 nm over
time. (A) A representative trace is shown for α-syn in the absence or presence of αB-c3D or
Hsp27core at a 1:10 molar ratio (sHsp:α-syn). Data were fitted with a Boltzmann sigmoidal
curve. (B) Values obtained for the maximum change in ThT fluorescence from these fits was
used to determine the percent protection afforded by the sHsp variants. Results are presented
as mean ± S.E.M.
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Appendix II:
The following script is for the analysis of SAVE images, and was written and executed
alongside Dr. Daniel Whiten using IgorPro v 6.3.4.1.
This script opens the source image stacks, thresholds these images to remove the background
and detects spots above background in each channel (ThT and 647). It then determines the
percentage of spots co-localised in the ThT and 647 channels. The script also calculates the
likelihood of spots being colocalised by chance, by randomly distributing the pixels of one
channel and determining the percentage of spots co-localised in the randomised and raw
channels.

#pragma rtGlobals=1
// Use modern global access method.
////////////////////////////////////////////////////////
//////////////THRESHOLD SECTION////////////////////////
////////////////////////////////////////////////////////
function setthresholds()
make/o/n=1 thtthreshold,redthreshold,savedpatchsize
wave thtfiltered
imagestats thtfiltered
thtthreshold[0]=v_avg + 5*v_sdev
// ThT threshold
wave af647filterd
imagestats af647Filtered
redthreshold[0]=v_avg+ 5*V_sdev
// Red threshold
savedpatchsize=8
// Patchsize
end
// Macro section:
// Run set from index:
macro multipleimages()
folder()
end
macro see(folder,image)
string folder="1"
Prompt folder, "Scan number to see "
// Set prompt for X param
variable image=0
prompt image,"Image to see"
setdatafolder root:$folder
seecoincident(image)
end
// Run set of 9 images in each folder defined by index- i.e. list of folder names as numbers:
function folder()
LoadWave/J/D/W/K=0/A
// Load index.
wave wave0
duplicate/o wave0,points
// Call the folder list points.
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killwaves wave0
string path=S_path
variable a,b,c,d
for(d=0;d<(dimsize(points,0));d+=1)
setdatafolder root:
string pathleveldown=S_path+num2str(points[d])
// This is the folder that the 3 sets of folders containing 9 images are stored in.
string foldername1=num2str(d+1)
newdatafolder/s $foldername1
// Make name of folderc=0
for(a=1;a<4;a+=1)
for(b=1;b<4;b+=1)
string filename=pathleveldown+":"+"Row"+num2str(a)+"Well"+num2str(b)+"_1_641andThT.tif"
// This may need changing depending on the name of the files.
string pathname=pathleveldown+":"
string leveldownagain=num2str(c)
// Name of folder that will contain each image
information.
//newdatafolder/s $leveldownagain
print filename
loadmulti(filename,c)
// Function for spot detection:
spots()
coincidentspots()
c+=1
endfor
endfor
setdatafolder root:
consolidate()
endfor
end
function load()
setdatafolder root:
// Load - will put up prompt to look for image:
ImageLoad/T=tiff/S=0 /C=-1 /O /N=image
ImageLoad/T=tiff/S=0 /C=-1 /O /N=imageforchance
// Function to extract ThT and AF647 images
averageimages()
// Need a function to remove backgrounds:
removebackground(0)
end
function loadmulti(filename,c)
string filename
variable c
ImageLoad/T=tiff/S=0 /C=-1 /O /N=image filename
// Function to extract ThT and AF647 images
averageimages()
removebackground(c)
end
// Function to extract averaged images from AF647 and ThT channels:
function averageimages()
wave image
duplicate/O/R=(10,480)(10,480)(4,6) image,AF647_pre
imagetransform averageimage AF647_pre
duplicate/o M_aveimage, AF647
duplicate/O/R=(10,480)(10,480)(101,200) image,tht
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imagetransform averageimage ThT
killwaves tht
killwaves image
killwaves m_stdvImage
duplicate/o m_aveImage,Tht
killwaves m_aveImage
killwaves AF647_pre
end
function removebackground(c)
variable c
wave tht,af647
variable a,b,d,e,f
duplicate/o ThT,ThTfiltered,ThTbackground
// Make various waves of same size
for(a=0;a<(dimsize(ThT,0));a+=1)
// Go through all of pixels
for(b=0;b<(dimsize(ThT,1));b+=1)
make/o temp=NAN
for(d=-2;d<2;d+=1)
for(f=-2;f<2;f+=1)
/
redimension/n=(e+1) temp
temp[e]=tht[a+d][b+f]
e+=1
endfor
endfor
e=0
wavestats/q temp
thtbackground[a][b]=V_min
// Minimum pixel value
thtfiltered[a][b]=tht[a][b]-V_min
// Remove background.
endfor
endfor
duplicate/o AF647,AF647filtered,Af647background
// Make various waves of same size
for(a=0;a<(dimsize(AF647,0));a+=1)
// Go through all of pixels
for(b=0;b<(dimsize(AF647,1));b+=1)
make/o temp=NAN
for(d=-2;d<2;d+=1)
for(f=-2;f<2;f+=1)
redimension/n=(e+1) temp
temp[e]=AF647[a+d][b+f]
e+=1
endfor
endfor
e=0
wavestats/q temp
AF647background[a][b]=V_min
// Minimum pixel vvalue
AF647filtered[a][b]=af647[a][b]-V_min
// Remove background.
endfor
endfor
string namertht="thtfiltered"+num2str(c)
string namerred="af647filtered"+num2str(c)
duplicate/o thtfiltered,$namertht
duplicate/o af647filtered,$namerred
killwaves thtfiltered
killwaves af647filtered
killwaves temp
killwaves ThTbackground
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killwaves AF647background
killwaves tht
killwaves af647
make/o/n=1 counter=c
end
function spots()
wave
counter,thtfiltered0,thtfiltered1,thtfiltered2,thtfiltered3,thtfiltered4,thtfiltered5,thtfiltered6,thtfiltered7,
thtfiltered8
wave
af647filtered0,af647filtered1,af647filtered2,af647filtered3,af647filtered4,af647filtered5,af647filtered
6,af647filtered7,af647filtered8
variable a=counter[a]+1
variable b
variable i,j,k,l,m
make/o/n=1
redintensityfromtht,thtcoincidentintensity,thtnoncoincidentintensity,ratiointensity,logratiointensity
Make/O ThTX,ThTY,ThTIntensity
Make/O redX,redY,redIntensity
for(b=0;b<a;b+=1)
string loadtht="thtfiltered"+num2str(b)
duplicate/o $loadtht,thtfiltered
string loadred="af647filtered"+num2str(b)
duplicate/o $loadred,af647filtered
imagestats ThTFiltered
setthresholds()
wave thtthreshold,redthreshold,savedpatchsize
variable thresholdtht = thtthreshold[0]
variable thresholdred=redthreshold[0]
variable patchsize=savedpatchsize[0]
duplicate/o ThTFiltered,thtworking
do
redimension/n=(i+1) ThTX,ThTY,ThTIntensity // Increase length of waves
ImageStats /M=1 thtworking
// Statistics of image
if(V_max>thtthreshold[0])
ThTX[i]=V_maxRowLoc
// Maximum intensity stored.
ThTY[i]=V_maxColLoc
ThTIntensity[i]=V_max
variable row=V_maxRowLoc
variable col=V_maxColLoc
for(j=0;j<=(2*patchsize);j+=1)
for(k=0;k<=2*patchsize;k+=1)
ThTworking[V_maxRowLoc-patchsize+j][V_maxColLoc-patchsize+k][]=0
endfor
endfor
if(ThTx[i]==ThTx[i-1]) // Control to prevent double counting of spots.
for(j=0;j<=(patchsize);j+=1)
for(k=0;k<=patchsize;k+=1)
ThTworking[row-patchsize+j][col-patchsize+k]=0
endfor
endfor
endif
i+=1
endif
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while (V_max>thtthreshold[0])
killwaves thtfiltered
killwaves thtworking
duplicate/o Af647Filtered,redworking
do
redimension/n=(l+1) redX,redY,redIntensity
// Increase length of waves for new data.
ImageStats /M=1 redworking
// Statistics of image
if(V_max>redthreshold[0])
redX[l]=V_maxRowLoc
// Maximum intensity stored.
redY[l]=V_maxColLoc
redIntensity[l]=V_max
row=V_maxRowLoc
col=V_maxColLoc
// This part is for straight-forward delete.
for(j=0;j<=(2*patchsize);j+=1)
for(k=0;k<=2*patchsize;k+=1)
redworking[V_maxRowLoc-patchsize+j][V_maxColLoc-patchsize+k][]=0
endfor
endfor
if(redx[l]==redx[l-1])
// Control to prevent double counting of spots.
for(j=0;j<=(patchsize);j+=1)
for(k=0;k<=patchsize;k+=1)
redworking[row-patchsize+j][col-patchsize+k]=0
endfor
endfor
endif
l+=1
endif
while (V_max>redthreshold[0])
endfor
end
function coincidentspots()
// Are there any coincident spots?
wave counter
variable number=8
variable a,b,c
variable u,q,h,x
make/o/n=(number+1) numberoftht,numberofcoincident,numberofchance,coincidence
make/o/n=1
coincidenttht,coincidentred,coincidentratio,noncoincidenttht,chancetht,chancered,chanceratio
for(a=0;a<(number+1);a+=1)
c=a-1
//Make files to work with
string thtname="thtfiltered"+num2str(a)
duplicate/o $thtname,workingtht
string redname="af647filtered"+num2str(a)
duplicate/o $redname,workingred
//For chance calculation:
if(a<8)
string redchance="af647filtered"+num2str(a+1)
else
redchance="af647filtered1"
endif
duplicate/o $redchance,workingredchance
// Need to look for all of spots in the ThT image now. Same code as previously:
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// Thresholding gubbings:
duplicate/o workingtht,thtfiltered
duplicate/o workingred,af647filtered
setthresholds()
wave thtthreshold,redthreshold,savedpatchsize
variable thresholdtht = thtthreshold[0]
variable thresholdred=redthreshold[0]
variable patchsize=savedpatchsize[0]
variable i=0,g=0
string thtx="ThTX"+num2str(a)
string thty="ThTY"+num2str(a)
string thtintensity="ThTIntensity"+num2str(a)
make/o/n=1 temp1=Nan,temp2=Nan,temp3=Nan,temp4=Nan,temp5=Nan,temp6=Nan
duplicate/o $thtname,thtworking
do
redimension/n=(i+1) temp1,temp2,temp3 // Increase length of waves for new data.
ImageStats /M=1 thtworking
// Statistics of image
if(V_max>thresholdtht)
temp1[i]=V_maxRowLoc
// Maximum intensity stored.
temp2[i]=V_maxColLoc
temp3[i]=V_max
variable row=V_maxRowLoc
variable col=V_maxColLoc
variable j,k
for(j=0;j<=(2*patchsize);j+=1)
for(k=0;k<=2*patchsize;k+=1)
ThTworking[V_maxRowLoc-patchsize+j][V_maxColLoc-patchsize+k][]=0
endfor
endfor
if(temp1[i]==temp1[i-1])
// Control to prevent double counting of spots.
for(j=0;j<=(patchsize);j+=1)
for(k=0;k<=patchsize;k+=1)
ThTworking[row-patchsize+j][col-patchsize+k]=0
endfor
endfor
endif
i+=1
endif
while (V_max>thresholdtht)
DeletePoints (dimsize(temp1,0)-1),1, temp1,temp2,temp3
duplicate/o temp1,$thtx
duplicate/o temp2,$thty
duplicate/o temp3,$thtintensity
numberoftht[a]=(dimsize(temp1,0))
// Check AF647 image just for spots:
string redx="redX"+num2str(a)
string redy="redY"+num2str(a)
string redintensity="redIntensity"+num2str(a)
make/o/n=1 temp7=Nan,temp8=Nan,temp9=Nan
duplicate/o $redname,redworking
do
redimension/n=(g+1) temp7,temp8,temp9 // Increase length of waves for new data.
ImageStats /M=1 redworking
// Statistics of image
if(V_max>thresholdred)
temp7[g]=V_maxRowLoc
// Maximum intensity stored.
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temp8[g]=V_maxColLoc
temp9[g]=V_max
row=V_maxRowLoc
col=V_maxColLoc
// This part is for straight-forward delete.
for(j=0;j<=(2*patchsize);j+=1)
for(k=0;k<=2*patchsize;k+=1)
redworking[V_maxRowLoc-patchsize+j][V_maxColLoc-patchsize+k][]=0
endfor
endfor
if(temp7[g]==temp7[g-1])
// Control to prevent double
counting of spots.
for(j=0;j<=(patchsize);j+=1)
for(k=0;k<=patchsize;k+=1)
redworking[row-patchsize+j][col-patchsize+k]=0
endfor
endfor
endif
g+=1
endif
while (V_max>thresholdred)
DeletePoints (dimsize(temp7,0)-1),1, temp7,temp8,temp9
duplicate/o temp7,$redx
duplicate/o temp8,$redy
duplicate/o temp9,$redintensity
// Check AF647 channel for coincident spots
j=0
k=0
make/o/n=(2*patchsize,2*patchsize) temp // temp for wavestats
i=0
variable p=0
for(i=0;i<(Dimsize(temp1,0));i+=1)
for(j=(-patchsize);j<=patchsize;j+=1)
for(k=(-patchsize);k<=patchsize;k+=1)
temp[j][k]=workingred[temp1[i]+j][temp2[i]+k]
endfor
endfor
wavestats/Q temp
if(V_max>thresholdred)
//Some stats on events.
redimension/n=(x+1) coincidenttht,coincidentred,coincidentratio
coincidentred[x]=V_max
coincidenttht[x]=temp1[i]
coincidentratio[x]=ln(V_max/temp1[i])
p+=1
x+=1
else
redimension/n=(q+1) noncoincidenttht
noncoincidenttht[q]=temp1[i]
q+=1
endif
endfor
numberofcoincident[a]=p
// Now for chance:
j=0
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k=0
make/o/n=(2*patchsize,2*patchsize) temp // temp for wavestats
i=0
variable t=0
for(i=0;i<(Dimsize(temp1,0));i+=1)
for(j=(-patchsize);j<=patchsize;j+=1)
for(k=(-patchsize);k<=patchsize;k+=1)
temp[j][k]=workingredchance[temp1[i]+j][temp2[i]+k]
endfor
endfor
wavestats/Q temp
wave redthreshold
// bring applied threshold.
if(V_max>thresholdred)
//Some stats on events.
redimension/n=(h+1) chancetht,chancered,chanceratio
chancered[h]=V_max
chancetht[h]=temp1[i]
chanceratio[h]=ln(V_max/temp1[i])
h+=1
t+=1
endif
endfor
numberofchance[a]=t
coincidence[a]=(numberofcoincident[a]-numberofchance[a])/(numberoftht[a]-numberofchance[a])
print coincidence[a]
//print coincidence[a]
endfor
end
function seecoincident(num)
variable num
wave savedpatchsize
variable patchsize=savedpatchsize[0]
string tht_x="thtx"+num2str(num)
string tht_y="thty"+num2str(num)
string red_x="redx"+num2str(num)
string red_y="redy"+num2str(num)
string tht_img="thtfiltered"+num2str(num)
string af647_img="af647filtered"+num2str(num)
duplicate/o $tht_x,thtx
duplicate/o $tht_y,thty
duplicate/o $red_x,redx
duplicate/o $red_y,redy
duplicate/o $tht_img,tht
duplicate/o $af647_img,af647filtered
duplicate/o tht,thtfiltered
setthresholds()
wave thtthreshold,redthreshold
variable redrange=redthreshold[0]*2
variable thtrange=thtthreshold[0]*2
wave redx,redy
// THT part
NewImage/K=0 tht
SetDrawLayer ProgFront
SetDrawEnv linefgc= (0,65535,0),fillpat= 0,xcoord= top,ycoord= left, save
// Part to draw rectangles:
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variable i
for(i=0;i<(Dimsize(thtx,0));i+=1)
DrawRect thtx[i]-patchsize,thtY[i]-patchsize,thtX[i]+patchsize,thtY[i]+patchsize
endfor
ModifyGraph tick=3,noLabel=2
variable numberoftht=(dimsize(thtx,0)
TextBox/C/N=text0/F=0/A=MT "\\K(65535,65535,65535)All spots in ThT image
("+num2str(numberoftht)+")"
TextBox/C/N=text0/B=1
ModifyImage tht ctab= {0,thtrange,Grays,0}
// Red Part
NewImage/K=0 af647filtered
SetDrawLayer ProgFront
SetDrawEnv linefgc= (65535,0,0),fillpat= 0,xcoord= top,ycoord= left, save
// Part to draw rectangles:
for(i=0;i<(Dimsize(redx,0));i+=1)
DrawRect redx[i]-patchsize,redY[i]-patchsize,redX[i]+patchsize,redY[i]+patchsize
endfor
ModifyGraph tick=3,noLabel=2
variable numberofred=(dimsize(redx,0))
TextBox/C/N=text0/F=0/A=MT "\\K(65535,65535,65535)All spots in AF647 image
("+num2str(numberofred)+")"
TextBox/C/N=text0/B=1
ModifyImage af647filtered ctab= {0,redrange,Grays,0}
//Coincident part
NewImage/K=0 tht
ModifyImage tht ctab= {*,*,Grays,0}
SetDrawLayer ProgFront
SetDrawEnv linefgc= (65535,65535,0),fillpat= 0,xcoord= top,ycoord= left, save // Draw yellow spots
in the tht image if the red is above threshold
// Part to draw rectangles:
make/o/n=(2*patchsize,2*patchsize) temp // temp for wavestats
variable j,k,t
for(i=0;i<(Dimsize(thtx,0));i+=1)
for(j=(-patchsize);j<=patchsize;j+=1)
for(k=(-patchsize);k<=patchsize;k+=1)
temp[j][k]=af647filtered[thtx[i]+j][thty[i]+k]
endfor
endfor
wavestats/Q temp
wave redthreshold
// bring applied threshold.
if(V_max>redthreshold[0])
DrawRect thtX[i]-patchsize,thtY[i]-patchsize,thtX[i]+patchsize,thtY[i]+patchsize
t+=1
endif
endfor
wave coincidence
variable percent=round(100*coincidence[num])
ModifyGraph tick=3,noLabel=2
ModifyGraph tick=3,noLabel=2
TextBox/C/N=text0/F=0/A=MT "\\K(65535,65535,65535)Coincident spots in ThT image
("+num2str(t)+", "+num2str(percent)+"% including chance)"
TextBox/C/N=text0/B=1
ModifyImage tht ctab= {0,thtrange,Grays,0}
end
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function consolidate()
wave points
setdatafolder root:
make/o/n=1
allcoincidence,allchance,allthtcounts,allfractioncoincident,thtintensities,redintensities,coincidentthtint
ensities,coincidentredintensities,coincidentratios,noncoincidentthtintensities
variable a,b,c=0,d=0,e=0,f=0,g=0
for(a=0;a<(dimsize(points,0));a+=1)
string folder=num2str(points[a])
setdatafolder root:$folder
wave coincidence,numberofchance,numberoftht,numberofcoincident
for(b=0;b<(dimsize(coincidence,0));b+=1)
redimension/n=(c+1) allcoincidence,allchance,allthtcounts,allfractioncoincident
allcoincidence[c]=numberofcoincident[b]
allchance[c]=numberofchance[b]
allthtcounts[c]=numberoftht[b]
allfractioncoincident[c]=coincidence[b]
c+=1
endfor
wave thtintensity
for(b=0;b<(dimsize(thtintensity,0));b+=1)
redimension/n=(d+1) thtintensities
thtintensities[d]=thtintensity[b]
d+=1
endfor
wave redintensity
for(b=0;b<(dimsize(redintensity,0));b+=1)
redimension/n=(e+1) redintensities
redintensities[e]=redintensity[b]
e+=1
endfor
wave coincidentred,coincidenttht,coincidentratio
for(b=0;b<(dimsize(coincidenttht,0));b+=1)
redimension/n=(f+1) coincidentthtintensities,coincidentredintensities,coincidentratios
coincidentthtintensities[f]=coincidenttht[b]
coincidentredintensities[f]=coincidentred[b]
coincidentratios[f]=coincidentratio[b]
f+=1
endfor
wave noncoincidenttht
for(b=0;b<(dimsize(noncoincidenttht,0));b+=1)
redimension/n=(g+1) noncoincidentthtintensities
noncoincidentthtintensities[g]=noncoincidenttht[b]
g+=1
endfor
endfor
setdatafolder root:
wavestats allfractioncoincident
make/o/n=1 coincident_average=V_avg
make/o/n=1 coincident_error=v_sdev
end
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Appendix III:
The following script is for the analysis of sPAINT images, and was written in Python 2.7 and
executed

using

Spyder

v2.3

(Spyder

developer

community,

available

from

github.com/spyder-ide/spyder).
This script opens the source images, thresholds these images to remove the background and
determines the pixels co-localised in the ThT and 647 channels. This script then collects the
localisation wavelength data from the original sPAINT render process, and bins the
localisations into low, medium and high ranges. These ranges are used to produce a colourmapped sPAINT image and a histogram of localisations according to the low, medium and
high ranges.
import
import
import
import
import
import
import

numpy as np
PIL as pil
Tkinter as tk
tkFileDialog
os
cv2
csv

def initialise():
global bin, threshold1, threshold2
bin = [100,50,3,2] #will create histogram data for these number of bins
frames_647 = 14 #images in tiff-stack to use
frames_tht = 100 #images in tiff-stack to use
threshold1 = 11 #change this for different thresholding
threshold2 = 5 #change this after trying the one above
image_opener(frames_647, frames_tht)
def image_opener(frames_647, frames_tht):
root = tk.Tk()
root.wm_attributes("-topmost", 1)
directory = tkFileDialog.askdirectory()
root.withdraw()
im647 = '/647.tif'
im647_path = directory + im647
imtht = '/ThT.tif'
imtht_path = directory + imtht
im = pil.Image.open(im647_path)
imtht = pil.Image.open(imtht_path)
ashape = np.shape(np.array(im.seek(1)))
max647_array = np.zeros(ashape)
maxtht_array = np.zeros(ashape)
avg647_array = np.zeros(ashape)
avgtht_array = np.zeros(ashape)
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frames = []
for frame in xrange(frames_647):
im.seek(frame)
im647_array = np.array(im)
frames.append(im647_array)
for array in frames:
max647_array = np.maximum(max647_array, array)
avg647_array = avg647_array + array
avg647_array = avg647_array/frames_647
deleter = []
for x in xrange(352):
deleter.append(x)
deleter = tuple(deleter)
max647_array = np.delete(max647_array,deleter,0)
avg647_array = np.delete(avg647_array,deleter,0)
frames = []
for frame in xrange(frames_tht):
imtht.seek(frame)
imtht_array = np.array(imtht)
frames.append(imtht_array)
for array in frames:
maxtht_array = np.maximum(maxtht_array, array)
avgtht_array = avgtht_array + array
avgtht_array = avgtht_array/frames_tht
maxtht_array = np.delete(maxtht_array,deleter,0)
avgtht_array = np.delete(avgtht_array,deleter,0)
folder = directory + '/Colocalisation analysis'
if not os.path.exists(folder):
os.makedirs(folder)
folder1 = directory + '/Colocalisation analysis/Histograms'
if not os.path.exists(folder1):
os.makedirs(folder1)
folder2 = directory + '/Colocalisation analysis/Binned images'
if not os.path.exists(folder2):
os.makedirs(folder2)
plots = []
plots.append(avgtht_array)
plots.append(avg647_array)
plots.append(maxtht_array)
plots.append(max647_array)
dirs = []
dirs.append((folder + '/avgtht.tif'))
dirs.append((folder + '/avg647.tif'))
dirs.append((folder + '/maxtht.tif'))
dirs.append((folder + '/max647.tif'))
count = 0
for plot in plots:
thresh(plot, dirs[count])
count += 1
colocalise(folder)
def thresh(arr, save_dir):
global threshold1, threshold2
arr = abs((arr/np.max(arr)*255)-255)
cv2.imwrite(save_dir, arr)
saver = save_dir[:-4]
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saver = saver + '_thresholded.tif'
img = cv2.imread(save_dir,0)
th1 = cv2.adaptiveThreshold(img,255,cv2.ADAPTIVE_THRESH_GAUSSIAN_C,\
cv2.THRESH_BINARY,threshold1,threshold2)
cv2.imwrite(saver, th1)
def colocalise(folder):
pm647 = folder + '/max647_thresholded.tif'
patht = folder + '/avgtht_thresholded.tif'
pa647 = folder + '/avg647_thresholded.tif'
pmtht = folder + '/maxtht_thresholded.tif'
im = pil.Image.open(pm647)
arrm647 = np.array(im)
im = pil.Image.open(pmtht)
arrmtht = np.array(im)
im = pil.Image.open(pa647)
arra647 = np.array(im)
im = pil.Image.open(patht)
arratht = np.array(im)
pos = 1
condition1 = ((arra647 < pos)
condition2 = ((arrm647 < pos)
condition3 = ((arra647 < pos)
condition4 = ((arrm647 < pos)
conditiona = (arra647 < pos)
conditionm = (arrm647 < pos)
conditionat = (arratht < pos)
conditionmt = (arrmtht < pos)

&
&
&
&

(arratht
(arratht
(arrmtht
(arrmtht

<
<
<
<

pos))
pos))
pos))
pos))

pos647a = len(arra647[conditiona])
pos647m = len(arrm647[conditionm])
posthta = len(arratht[conditionat])
posthtm = len(arrmtht[conditionmt])
coloc6ata = len(arra647[condition1])
coloc6atm = len(arra647[condition3])
coloc6mta = len(arrm647[condition2])
coloc6mtm = len(arrm647[condition4])
pix = str(arra647.size)
pix2 = str(arrm647.size)
results_path = folder + '/colocalisation results.txt'
with open(results_path, 'w+') as outfile:
outfile.write('Comparison\t\tPx\tThTpx\t647px\tCol px\t%647px col')
outfile.write('\navg647 & avgtht:\t' + pix + '\t' + str(posthta) +
'\t' + str(pos647a) + '\t' + str(coloc6ata) + '\t' +
str(round(coloc6ata/float(pos647a)*100, 2)))
outfile.write('\nmax647 & avgtht:\t' + pix2 + '\t' + str(posthta) +
'\t' + str(pos647m) + '\t' + str(coloc6mta) + '\t' +
str(round(coloc6mta/float(pos647m)*100, 2)))
outfile.write('\navg647 & maxtht:\t' + pix + '\t' + str(posthtm) +
'\t' + str(pos647a) + '\t' + str(coloc6atm) + '\t' +
str(round(coloc6atm/float(pos647a)*100, 2)))
outfile.write('\nmax647 & maxtht:\t' + pix2 + '\t' + str(posthtm) +
'\t' + str(pos647m) + '\t' + str(coloc6mtm) + '\t' +
str(round(coloc6mtm/float(pos647m)*100, 2)))
superres(folder)
def superres(folder):
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folder = folder[:-24]
nr = '/for_render.txt'
nr_path = folder + nr
diction = {}
with open(nr_path, 'rU') as tsv:
for column in zip(*[line for line in csv.reader(tsv,
dialect="excel-tab")]):
column = np.array(column)
label = column[0]
column = np.delete(column, [0])
column = column.astype(float)
diction[label] = column
use_true = (diction['use']==1)
xposi = diction['xposi'][use_true].astype(int)
yposi = diction['yposi'][use_true].astype(int)
wavelength = diction['wavelength'][use_true]
sr = np.zeros((512,512))
yx = zip(yposi, xposi)
count = 0
for ynx in yx:
sr[ynx] = wavelength[count]
count+=1
deleter = []
for x in xrange(352): #THIS CROPS THE OF THE IMAGE
deleter.append(x)
deleter = tuple(deleter)
sr = np.delete(sr,deleter,0)
srsave = np.copy(sr)
rdpath = folder+'/Colocalisation analysis/Histograms/raw data.csv'
np.savetxt(rdpath, sr, delimiter=",")
#Saving image with according to three colour bins
# These are ranges for wavelengths
short_range = 550
med_range = 600
med_range2 = 650
high_range = 700
binned_im = np.zeros((160,512))
short_ = ((sr > short_range) & (sr <= med_range))
medium = ((sr > med_range) & (sr <= med_range2))
long__ = ((sr > med_range2) & (sr <= high_range))
# Changing these numbers will shift colours up and down colourmaps
binned_im[short_] = 220
binned_im[medium] = 160
binned_im[long__] = 100
# Other colormaps here http://docs.opencv.org/2.4/modules/contrib/doc/facerec/colormaps.html
binned_im_HOT = cv2.applyColorMap(binned_im, cv2.COLORMAP_HOT)
binned_im_OCEAN = cv2.applyColorMap(binned_im, cv2.COLORMAP_OCEAN)
# Images are saved in "...\Colocalisation analysis\Binned images"
Var1 = folder + '/Colocalisation analysis/Binned
images/Wavelengths_blackwhite.tif'
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Var2 = folder + '/Colocalisation analysis/Binned
images/Wavelengths_hot.tif'
Var3 = folder + '/Colocalisation analysis/Binned
images/Wavelengths_ocean.tif'
cv2.imwrite(Var1, binned_im)
cv2.imwrite(Var2, binned_im_HOT)
cv2.imwrite(Var3, binned_im_OCEAN)
srsave = srsave/750*255
saver = folder + '/Colocalisation analysis/NRnew.tif'
cv2.imwrite(saver, srsave)
a647p = folder + '/Colocalisation analysis/avg647_thresholded.tif'
m647p = folder + '/Colocalisation analysis/max647_thresholded.tif'
m647
m647
a647
a647

=
=
=
=

cv2.imread(m647p)
cv2.cvtColor(m647, cv2.COLOR_BGR2GRAY)
cv2.imread(a647p)
cv2.cvtColor(a647, cv2.COLOR_BGR2GRAY)

allnr = (sr > 549)
acoloc = ((a647 < 255) & (sr > 549))
mcoloc = ((m647 < 255) & (sr > 549))
asepar = ((a647 == 255) & (sr > 549))
msepar = ((m647 == 255) & (sr > 549))
srall = sr[allnr]
srmxnc = sr[msepar]
srmxc = sr[mcoloc]
sravnc = sr[asepar]
sravc = sr[acoloc]
avgcolocalised_avg647 =
avgcolocalised_max647 =
avguncolocalised_avg647
avguncolocalised_max647

str(round(np.mean(sravc), 2))
str(round(np.mean(srmxc), 2))
= str(round(np.mean(sravnc), 2))
= str(round(np.mean(srmxnc), 2))

results_path = folder + '/Colocalisation analysis/Wavelength
summary.txt'
with open(results_path, 'w+') as outfile:
outfile.write('Avg wvlth uncoloc avg647\t\tAvg wvlth coloc
avg647\t\tAvg wvlth uncoloc max647\t\tAvg wvlth coloc max647\n')
outfile.write(avguncolocalised_avg647 + '\t\t\t\t\t' +
avgcolocalised_avg647 + '\t\t\t\t' + avguncolocalised_max647 + '\t\t\t\t\t'
+ avgcolocalised_max647)
global bin
readme = folder + '/Colocalisation analysis/Histograms/Read me.txt'
with open(readme, 'w+') as outfile:
outfile.write('Files are two rows, the histogram values (top) and
bin edges (bottom).')
outfile.write('\nThe last value in the histogram values should be
deleted (only added to make length even).')
for bins in bin:
histograms([srall,srmxnc,srmxc,sravnc,sravc],bins,count,folder)
print 'Done!'
def histograms(arrs,bin,count,folder):
count = 0
for arr in arrs:
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if count == 0:
array = 'All
elif count == 1:
array = 'Max
elif count == 2:
array = 'Max
elif count == 3:
array = 'Avg
elif count == 4:
array = 'Avg

pixels - '
647 - not colocalised - '
647 - colocalised - '
647 - not colocalised - '
647 - colocalised - '

rdpath = folder+'/Colocalisation analysis/Histograms/'+array+' raw
data.csv'
np.savetxt(rdpath, arr, delimiter=",")
path = folder+'/Colocalisation
analysis/Histograms/'+array+str(bin)+' bins.csv'
count+=1
histo, bin_edges = np.histogram(arr, bins=bin)
histo = np.append(histo,0.0)
data = np.concatenate((histo, bin_edges),axis=1)
data = np.reshape(data, (2,-1))
np.savetxt(path, data, delimiter=",")
initialise()
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Appendix IV:
The following script is for the analysis of DHE assay images, and was written in Python 2.7
and executed using Spyder v2.3 (Spyder developer community, available from
github.com/spyder-ide/spyder).
This script allows cells to be selected according to the red fluorescent image, such that the
mean fluorescence intensity for each of the cells can be determined from every image in the
series, in both the red and blue channels. The script then calculates the ratio of red to blue
fluorescence both before and after treatment, which is fit with linear regression. The
difference in the gradient of the line before and after treatment is then calculated for each
cell, and averaged over the population.
import PIL
import os
import numpy as np
import matplotlib.pyplot as pyplt
from matplotlib.widgets import RectangleSelector
#import Tkinter, tkFileDialog
from matplotlib.patches import Rectangle
import csv
def initialise():
global cells_to_analyse, start_coords, end_coords, images_per_channel,
images_to_discard_mid, images_to_discard_start
images_per_channel = 60
cells_to_analyse = 15
images_to_discard_mid = 2
images_to_discard_start = 2
start_coords = []
end_coords = []
opener()
def opener():
global files, directory
#Change path here
directory = 'E:/Path'
files = os.listdir(directory)
files.sort()
results_path = directory + '/Results'
if not os.path.exists(results_path): os.makedirs(results_path)
boxes()
def boxes():
global files, directory,images_per_channel
for f in files:
if 'ch02' in f:
x = 1
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y = 1
fig = pyplt.figure
ax = pyplt.subplot(111)
ax.plot(x,y)
red_image_path = os.path.join(directory, f)
img = PIL.Image.open(os.path.join(directory, f))#.convert('LA')
try:
img.seek(images_per_channel-1)
currentAxis = pyplt.gca()
for coord1, coord2 in zip(start_coords, end_coords):
x,y1 = coord1
x1,y = coord2
upper_left = (x,y1)
width = x1-x
height = y-y1
currentAxis.add_patch(Rectangle(upper_left, width, height,
facecolor="none", edgecolor='w'))
figManager = pyplt.get_current_fig_manager()
figManager.window.showMaximized()
pyplt.imshow(img)
toggle_selector.RS = RectangleSelector(ax, onselect,
drawtype='box')
def onselect(eclick, erelease):
global cells_to_analyse
'eclick and erelease are matplotlib events at press and release'
start = (eclick.xdata, eclick.ydata)
end = (erelease.xdata, erelease.ydata)
start_coords.append(start)
end_coords.append(end)
pyplt.close(1)
cells_to_analyse -= 1
if cells_to_analyse != 0:
boxes()
else:
analyse()
def toggle_selector(event):
if event.key in ['Q', 'q'] and toggle_selector.RS.active:
toggle_selector.RS.set_active(False)
if event.key in ['A', 'a'] and not toggle_selector.RS.active:
toggle_selector.RS.set_active(True)
def analyse():
global files, directory, images_per_channel
count = 1
uv_dict = {}
red_dict = {}
ratio_dict = {}
for coord1, coord2 in zip(start_coords, end_coords):
uv = []
red = []
x,y = coord1
x1,y1 = coord2
x = int(x)
x1 = int(x1)
y = int(y)
y1 = int(y1)
for f in files:
if 'ch02' in f:
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redimg2 = PIL.Image.open(os.path.join(directory, f))
for i in range(images_per_channel):
try:
redimg2.seek(i)
redarr2 = np.array(redimg2)
print 'running'
print '1', redarr2
redarr3 = redarr2[y:y1,x:x1]
print '2', redarr3
red.append(np.mean(redarr3))
except:
pass
red_dict[count] = red
if 'ch01' in f:
uvimg2 = PIL.Image.open(os.path.join(directory, f))
for i in range(images_per_channel):
try:
uvimg2.seek(i)
uvarr2 = np.array(uvimg2)
uvarr3 = uvarr2[y:y1,x:x1]
uv.append(np.mean(uvarr3))
except:
pass
uv_dict[count] = uv
count += 1
print 'Working...'
for key in red_dict:
ratio = []
for b,m in zip(red_dict[key], uv_dict[key]):
ratio.append(b/m)
ratio_dict[key] = ratio
before_treat = images_per_channel/2
x_ax = []
before_treat_slopes = []
for x in xrange(images_to_discard_start, before_treat):
x_ax.append(x)
for key, val in ratio_dict.iteritems():
print key, val
for key in ratio_dict:
y_ax = []
for x in xrange(images_to_discard_start, before_treat):
print key, x
val = ratio_dict[key][x]
y_ax.append(val)
slope, intercept = np.polyfit(x_ax, y_ax, 1)
before_treat_slopes.append(slope)
after_treat_start = images_per_channel/2+images_to_discard_mid
x_ax = []
after_treat_slopes = []
for x in xrange(after_treat_start, images_per_channel):
x_ax.append(x)
for key in ratio_dict:
y_ax = []
for x in xrange(after_treat_start, images_per_channel):
val = ratio_dict[key][x]
y_ax.append(val)
slope, intercept = np.polyfit(x_ax, y_ax, 1)
after_treat_slopes.append(slope)
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results_uv_path = directory + '/Results/uv_channel.csv'
results_red_path = directory + '/Results/red_channel.csv'
results_slopes_path = directory + '/Results/slopes.csv'
results_ratio_path = directory + '/Results/ratio.csv'
with open(results_uv_path, 'wb') as outfile:
writer = csv.writer(outfile)
writer.writerows(zip(*uv_dict.values()))
with open(results_red_path, 'wb') as outfile:
writer = csv.writer(outfile)
writer.writerows(zip(*red_dict.values()))
with open(results_slopes_path, 'wb') as outfile:
writer = csv.writer(outfile)
writer.writerow(['Before treatment','After treatment'])
writer.writerows(zip(before_treat_slopes, after_treat_slopes))
with open(results_ratio_path, 'wb') as outfile:
writer = csv.writer(outfile)
writer.writerows(zip(*ratio_dict.values()))
print 'Done!'
initialise()
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Appendix V:

Figure 8.2: Hsp27 interacts with α-syn fibril fragments. Recombinant monomeric α-syn was
incubated in 50 mM phosphate buffer and 0.01% NaN3 (pH 7.4) at 50 μM in the absence or presence
of Hsp27 at concentrations ranging from 0.1 – 10 μM. After equilibration at 37oC, α-syn seeds were
added at concentrations ranging from 0.5 – 5 μM (i.e. 1%-10% (w/w) when expressed as a percentage
of the soluble protein concentration) and elongation monitored via the change in ThT fluorescence at
490 nm over time. (A, C, E) Representative traces of the change in ThT fluorescence normalised to
the maximum value in the absence of Hsp27 are shown, in the presence of 1%, 2.5% and 10% seed.
(B, D, F) The linear portion (0 – 2.5 h) was fit with linear regression such that the rate of elongation
could be calculated. Data is representative of at least three independent experiments, consisting of
duplicate samples.
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Appendix VI:
The following script was written and executed using ImageJ’s internal macro editor.
This script utilises the GDSC PlugIn (University of Sussex, UK; available from
http://www.sussex.ac.uk/gdsc/intranet/microscopy/imagej/gdsc_plugins),

specifically

the

CellOutliner function, to produce a cell map based on a brightfield image. The script
measures the cell area, then determines the minimum, maximum, and average fluorescence
intensity of the cell. These parameters are assigned to each cell according to the cell map. The
user is then responsible for assigning which cells contain inclusion(s), using only the red
image (i.e. without information as to whether the cell also expresses the sHsp or control
protein in these experiments, which is done to minimise treatment-related bias).
macro "InclusionAnalyser [o]" {
var
var
var
var
var
var

path = File.openDialog("Select the merge image:");
dir = File.getParent(path);
name = File.getName(path);
merge = split(name,".");
simplefile = "Results"+File.separator
output = dir+File.separator+simplefile

channelRed = File.separator+merge[0]+"_ch02.jpg";
channelBright = File.separator+merge[0]+"_ch01.jpg";
redpath = dir+channelRed;
brightpath = dir+channelBright;
open(redpath);
run("Duplicate...", "title=OverlayRed");
run("Duplicate...", "title=Red");
run("32-bit");
open(brightpath);
run("Duplicate...", "title=DIC");
run("Add Image...", "image=[OverlayRed] x=0 y=0 opacity=20");
selectWindow("DIC");
setTool("multipoint");
waitForUser("Select centre of all displayed cells \n \nPress OK to
continue");
selectWindow("DIC");
run("Cell Outliner", "cell_radius=18 tolerance=1.0 kernel_width=13
dark_edge kernel_smoothing=1 polygon_smoothing=1 weighting_gamma=3
iterations=3 dilate=0");
selectWindow("DIC Cell Outline");
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setAutoThreshold("Default dark");
setThreshold(1, 255);
setOption("BlackBackground", true);
run("Convert to Mask");
run("Watershed");
selectWindow("DIC Cell Outline");
run("Set Measurements...", "area mean standard min limit display add
redirect=[Red] decimal=3");
run("Analyze Particles...", "size=100-Infinity show=Outlines display
clear");
selectWindow("Drawing of DIC Cell Outline");
run("Duplicate...", "title=CellOutline");
run("Add Image...", "image=[Red] x=0 y=0 opacity=60");
saveAs("Jpeg", output+merge[0]+"_CellOutline_Red.jpg");
close("Drawing of DIC Cell Outline");
saveAs("Results", output+merge[0]+"_Results_Red.txt");
print("Process Complete");
print("Results for "+merge[0]+" saved in directory: "+output);
selectWindow("Log");
}
macro "CloseAll [w]" {
run("Close All");
}

225

Appendices

Appendix VII:
The following script was written in Python 2.7 and executed using Spyder v2.3 (Spyder
developer community, available from github.com/spyder-ide/spyder).
This script collects output from Appendix VI and determines the following parameters: (1)
the cells which are co-transfected, (2) the percentage of co-transfected cells containing
inclusions, (3) the average fluorescence of co-transfected cells with and without inclusions.
import
import
import
import
import
import
import
import

Tkinter
# Allows closing of parent window
tkFileDialog
# Allows user input for getting directory
os
# Allows setting of default directory
glob
# Allows specification of filenames with wildcard characters
pandas as pd
# Allows parsing of files
numpy as np
re
csv

# Create a reference to parent window
root = Tkinter.Tk()
# Close parent window
root.withdraw()
# Get user input to select folder
directory = tkFileDialog.askdirectory()
# Set selected directory as active directory
os.chdir(str(directory))
# To hard-code constant thresholds
red_thresh = float(0.5)
green_thresh = float(3)
#To get the names of the treatments and directories
folderlist = glob.glob('*/')
treatmentfolderlist = []
for x in folderlist:
if 'Combined Results'not in x:
treatmentfolder = x
treatmentfolder = treatmentfolder[0:-1]
treatmentfolderlist.append(treatmentfolder)
treatment = treatmentfolder
outputdirectory = directory + '/' + '/Combined Results/'
# To go through each folder in the directory, that is not the combined
results folder
for dirName, subdirList, fileList in os.walk(directory):
if 'Combined Results' not in dirName:
if 'Results' in dirName:
#To set the working directory to each folder in turn
os.chdir(str(dirName))
#To adjust 'treatment' value according to each folder
resultsDir = re.split('\\\|/', dirName)
for x in treatmentfolderlist:
if x in resultsDir:
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treatment = x
print treatment
#Initalise empty lists - to clear lists that are appended to
appended_data_red = []
appended_data_green = []
cotrans_red = []
cotrans_green = []
appended_red = []
appended_green = []
rawdata_red = []
rawdata_green = []
for datafile in glob.glob("*Red.txt"):
# Add entire file to pandas data frame
data = pd.read_table(datafile)
# Create column showing where row came from
data['Filename'] = datafile
# Adds data frame to the list
appended_data_red.append(data)
# Append each data frame to a new data frame
appended_red = pd.concat(appended_data_red, ignore_index =
True)
# Save appended data frames to a new file
appended_red.to_csv("concatenated_data_red.txt")
for datafile in glob.glob("*Green.txt"):
# Add entire file to pandas data frame
data = pd.read_table(datafile)
# Create column showing where row came from
data['Filename'] = datafile
# Adds data frame to the list
appended_data_green.append(data)
# Append each data frame to a new data frame
appended_green = pd.concat(appended_data_green, ignore_index =
True)
# Save appended data frames to a new file
appended_green.to_csv("concatenated_data_green.txt")
rawdata_green = appended_green.rename(columns =
{'Area': 'Green Area',
'Filename':'Green
Filename',
'Label':'Green Label',
'Max':'Green Max',
'Min':'Green Min',
'Mean':'Green_Mean',
'StdDev':'Green StdDev',
})
rawdata_red = appended_red.rename(columns = {
'Area': 'Red Area',
'Filename':'Red Filename',
'Label':'Red Label',
'Max':'Red Max',
'Min':'Red Min',
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'Mean':'Red_Mean',
'StdDev':'Red StdDev',
})
#selects only rows with mean values that exceed the threshold
thresholded_green = rawdata_green[rawdata_green.Green_Mean >=
green_thresh]
thresholded_red = rawdata_red[rawdata_red.Red_Mean >=
red_thresh]
#collects indexes of the rows that passed the threshold
green_trans_indexer = thresholded_green.index.tolist()
red_trans_indexer = thresholded_red.index.tolist()
#finds co-transfected cells, copies into new list
cotrans_indexer=[]
for x in red_trans_indexer:
if x in green_trans_indexer:
cotrans_indexer.append(x)
else:
pass
#appends data common to both indexers
for x in cotrans_indexer:
cotrans_red.append(rawdata_red.xs(x))
cotrans_green.append(rawdata_green.xs(x))
#converts appended data to data frame
cotrans_red = pd.DataFrame(cotrans_red)
cotrans_green = pd.DataFrame(cotrans_green)
#Calculates the fluorescence load
cotrans_red['Red_load'] =
cotrans_red['Red_Mean']*cotrans_red['Red Area']
cotrans_green['Green_load'] =
cotrans_green['Green_Mean']*cotrans_green['Green Area']
#saves co-transfected data to excel files
cotrans_red.to_csv("cotransfected_Red.txt")
cotrans_green.to_csv("cotransfected_Green.txt")
#Separating data into with and without inclusions
cotrans_green_inclusions =
pd.DataFrame(cotrans_green[cotrans_red.Inclusions == 1])
cotrans_red_inclusions =
pd.DataFrame(cotrans_red[cotrans_red.Inclusions == 1])
cotrans_green_noinc =
pd.DataFrame(cotrans_green[cotrans_red.Inclusions != 1])
cotrans_red_noinc =
pd.DataFrame(cotrans_red[cotrans_red.Inclusions != 1])
#calculating info about cells with and without inclusions
num_inc = cotrans_red['Inclusions'].sum()
num_cells = len(cotrans_red.index)
num_ni = num_cells - num_inc
inc_percent = num_inc/num_cells*100
place_holder = 0
ct_total_red_load = cotrans_red['Red_load'].sum()
ct_av_red_load = ct_total_red_load / num_cells
ct_avmean_red = cotrans_red['Red_Mean'].sum() / num_cells
ct_total_green_load = cotrans_green['Green_load'].sum()
ct_av_green_load = ct_total_green_load / num_cells
ct_avmean_green = cotrans_green['Green_Mean'].sum() / num_cells
inc_total_red_load = cotrans_red_inclusions['Red_load'].sum()
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inc_av_red_load = inc_total_red_load / num_inc
inc_avmean_red = cotrans_red_inclusions['Red_Mean'].sum() /
num_inc
inc_total_green_load =
cotrans_green_inclusions['Green_load'].sum()
inc_av_green_load = inc_total_green_load / num_inc
inc_avmean_green = cotrans_green_inclusions['Green_Mean'].sum()
/ num_inc
ni_total_red_load = cotrans_red_noinc['Red_load'].sum()
ni_av_red_load = ni_total_red_load / num_ni
ni_avmean_red = cotrans_red_noinc['Red_Mean'].sum() / num_ni
ni_total_green_load = cotrans_green_noinc['Green_load'].sum()
ni_av_green_load = ni_total_green_load / num_ni
ni_avmean_green = cotrans_green_noinc['Green_Mean'].sum() /
num_ni
#creating series to store the calculated info
whole_treatment = (inc_percent, num_cells, ct_total_red_load,
ct_av_red_load, ct_avmean_red, ct_total_green_load,
av_green_load, ct_avmean_green)
inclusions_only = (place_holder, num_inc, inc_total_red_load,
inc_av_red_load, inc_avmean_red, inc_total_green_load,
inc_av_green_load, inc_avmean_green)
no_inclusions = (place_holder, num_ni, ni_total_red_load,
ni_av_red_load, ni_avmean_red, ni_total_green_load,
ni_av_green_load, ni_avmean_green)
#list to store the index label for each row of stats
row_labels = ('% cells w Inclusions', 'Number of cells',
'Red Load (Total)', 'Red Load (per cell)', 'Average
Intensity',
'Green Load (Total)', 'Green
Load (per cell)', 'Average Intensity')
#creates the dictionaries to link calculated values with row
labels
summary_stats_whole = {'Whole Treatment':
pd.Series(whole_treatment,
index=row_labels)}
summary_stats_inclusions = {'Inclusions':
pd.Series(inclusions_only,
index=row_labels)}
summary_stats_noinc = {'No Inclusions':
pd.Series(no_inclusions,
index=row_labels)}
summary_stats = {
'Whole Treatment': pd.Series(whole_treatment,
index=row_labels),
'Inclusions': pd.Series(inclusions_only,
index=row_labels),
'No Inclusions': pd.Series(no_inclusions,
index=row_labels),
}
#turns series into dataframes
summary_stats_whole =
np.round(pd.DataFrame(summary_stats_whole),
decimals=2)
summary_stats_inclusions =
np.round(pd.DataFrame(summary_stats_inclusions), decimals=2)
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summary_stats_noinc =
np.round(pd.DataFrame(summary_stats_noinc),
decimals=2)
summary_stats = np.round(pd.DataFrame(summary_stats),
decimals=2)
#saves outputs to excel files:
summary_stats.to_csv("Stats.txt")
summary_stats.to_csv(outputdirectory+treatment+"_Stats.txt")
summary_stats_whole.to_csv(outputdirectory+treatment+"_Stats_Wh
ole.txt")
summary_stats_inclusions.to_csv(outputdirectory+treatment+"_Sta
ts_Inclusions.txt")
summary_stats_noinc.to_csv(outputdirectory+treatment+"_Stats_No
Inc.txt")
#Renaming columns to allow joining Red and Green data
co_green = cotrans_green.rename(columns = {'Area': 'Green
Area',
'Filename':'Green
Filename',
'Label':'Green Label',
'Max':'Green Max',
'Min':'Green Min',
'Mean':'Green Mean',
'StdDev':'Green StdDev',
})
co_green = co_green.drop(co_green.columns[[0]], axis=1)
co_red = cotrans_red.rename(columns = {'Area': 'Red Area',
'Filename':'Red
Filename',
'Label':'Red Label',
'Max':'Red Max',
'Min':'Red Min',
'Mean':'Red Mean',
'StdDev':'Red StdDev',
})
co_red = co_red.drop(co_red.columns[[0]], axis=1)
#joins cotransfected data, to save as excel file
cotrans = [co_green, co_red]
cotrans = pd.concat(cotrans, axis = 1)
cotrans.to_csv("cotrans.txt")
print treatment, 'Complete!'
os.chdir(str(outputdirectory))
# Initalise an empty list
appended_data_whole = []
appended_data_inclusions = []
appended_data_noinc = []
appended_data_stats = []
# Interate through each of the text files
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for datafile in glob.glob("*Whole.txt"):
# This does only 'whole' text
files
# Add entire file to pandas data frame, without the column header
data = pd.read_csv(datafile)
treatment = datafile.split('_')[0]
# Create row showing where row came from
data = data.rename(columns = {'Whole Treatment': treatment})
# Adds data frame to the list
appended_data_whole.append(data)
# Append each data frame to a new data frame
appended_whole = pd.concat(appended_data_whole, axis = 1)
# Save appended data frames to a new file
appended_whole.to_csv('Whole Treatment.txt')
# Interate through each of the text files
for datafile in glob.glob("*Inclusions.txt"):
# This does only
'Inclusion' text files
# Add entire file to pandas data frame, without the column header
data = pd.read_csv(datafile)
treatment = datafile.split('_')[0]
# Create row showing where row came from
data = data.rename(columns = {'Inclusions': treatment})
# Adds data frame to the list
appended_data_inclusions.append(data)
# Append each data frame to a new data frame
appended_inclusions = pd.concat(appended_data_inclusions, axis = 1)
# Save appended data frames to a new file
appended_inclusions.to_csv('Inclusions.txt')
# Interate through each of the text files
for datafile in glob.glob("*NoInc.xlsx"):
# This does only 'NoInc' text
files
# Add entire file to pandas data frame, without the column header
data = pd.read_csv(datafile)
treatment = datafile.split('_')[0]
# Create row showing where row came from
data = data.rename(columns = {'No Inclusions': treatment})
# Adds data frame to the list
appended_data_noinc.append(data)
# Append each data frame to a new data frame
appended_noinc = pd.concat(appended_data_noinc, axis = 1)
# Save appended data frames to a new file
appended_noinc.to_csv('No Inclusions.txt')
print 'Experimental Summary Complete. All files saved to: ',
outputdirectory
writer.save()
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Appendix VIII:
The concentration of α-syn detectable in cell extracts following transfection was determined
via dot blot. There was seen to be no significant difference in the intensity of detected
monomeric or fibrillar α-syn (Figure 8.3A), indicating the presence of aggregates in the cell
extract samples would not influence the detected concentration. Samples of known
recombinant monomeric α-syn concentration were therefore used to generate a standard curve
(Figure 8.3B). The concentration of α-syn was found to be 0.4 µM and 0.6 µM in the treated
and untreated cell extracts, respectively. This corresponds to ~ 0.009 µg/µL, or less than 1%
of the total protein extracted from cells.

Figure 8.3: Quantification of α-synA53T* expression in whole cell lysate. (A) Monomeric (1-8) or
fibrillar (9-10) recombinant α-syn was prepared at (1, 9) 50 µM, (2, 10) 25 µM, (3) 5 µM, (4) 1µM,
(5) 0.2 µM, (6) 0.04µM, (7) 0.008 µM or (8) 0.00016 µM in 50 mM phosphate buffer (pH 7.4).
Whole cell extracts were also prepared to a total concentration of 1 µg/µL from cells transfected with
the α-synA53T* construct incubated in the (11) absence or (12) presence of inhibitors (10 µM MG132
and 3 µM thapsigargin). Samples (5 µL) were blotted onto nitrocellulose membrane and detected
using a monoclonal mouse anti-α-syn followed by a HRP-conjugated secondary antibody. (B) The
relative intensity of each spot was determined using the ImageJ gel analysis tool, and fitted with onephase association.
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Appendix IX:
N2a cells were transfected with a range of Htt46Q-mCherry DNA concentrations (expressed
as a percentage of the standard 1 ug/mL) in the absence or presence of IRES constructs
expressing EGFP and either EGFPinv or LacZ. The proportion of live cells that were mCherry
positive was determined, and the proportion of these cells containing inclusions was
enumerated according to the PulSA gating strategy. Whilst decreasing the amount of Htt46Q
DNA used to transfect cells did not significantly influence the percentage of cells transfected
or the median fluorescence, it led to a decrease (by 22%) in the proportion of cells containing
inclusions.

Figure 8.4: The concentration of DNA used to transfect N2a cells influences the proportion of
transfected cells with Htt46Q inclusions. N2a cells were transiently transfected with Htt46QmCherry at various concentrations in the absence or presence of IRES constructs encoding EGFP and
EGFPinv or LacZ. Where necessary, in the absence of a second DNA construct the transfection volume
was equalised using serum free media (SFM). Cells were incubated for 36 h, then analysed via flow
cytometry. (A) The percentage of live cells which were mCherry-positive was quantified, and (B) the
median mCherry fluorescence of these cells determined. (C) The proportion of mCherry-positive cells
containing inclusions was determined using the PulSA gating strategy. DNA ratios are expressed as a
percentage of the standard (1 µg/ml), and data is presented as mean ± S.E.M. (n=2).
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